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To YOUR spoken WORD through Pastor John: 
 There is a great influence in the place He’s taking you. Lean on that influence as 
you continue to learn and grow.  You may have to risk everything that He has brought to 
you at this point.  As He leads you and guides you by His Spirit in your heart you will 
have peace.  When you make that step, you will see the treasure like you’ve never seen 
them before.  Progression by faith.  You are about to have to take another step.  Do what 
God asks you to do when He asks you to.  Step out; His hand will be there.  The 
Kingdom of God will be yours.  He will provide and make a way for you.  Opportunity 
will chase you.  He will cause those things that others chase after to chase you.  You will 
have an opportunity to speak, you will have opportunity to share, opportunity to 
enlighten.  You will have wisdom and knowledge beyond your years, ability, and it will 
all come from the Spirit and throne room of God, and He will pour it out to a vessel who 
says, “I will buy the whole field!” As you put your heart toward the Kingdom of God, He 
will unfold all those things for you in your life. (Pastor John 2/12/12) 
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Davies, Christopher W. Ph.D., Purdue University, December 2013.  Structural and 
Functional Characterization of the Endosome-Associated Deubiquitinating Enzyme 
AMSH.  Major Professor: Chittaranjan Das. 
 
The endosomal sorting complexes required for transport (ESCRT) machinery is a 
ubiquitin-dependent molecular mechanism made of up of four individual complexes: 
ESCRT-0, -I, -II, III, that is necessary for regulating the degradation of cell surface 
receptors directed towards the lysosome.  Not only are the ESCRTs implicated in 
endosomal sorting and trafficking of proteins, its members also have roles in other 
important biological processes such as: cytokinesis, HIV budding, transcriptional 
regulation, and autophagy. As a function of its involvement in several processes 
throughout the cell, the ESCRT machinery is implicated in a wide variety of diseases 
including cancer, neurological disease, bacterial infections, cardiovascular disease, and 
retroviral infection. Proteins marked for lysosomal degradation (cargo) are first 
ubiquitinated, and then, shuttled in a sequential mechanism through the complexes.  In 
the last step, ubiquitin is removed from the cargo, which is subsequently encapsulated 
into intralumenal vesicles (ILV) that will ultimately be transported to and fuse with 
lysosome, degrading and recycling its contents. Deubiquitination is the removal of 
xi 
ubiquitin, catalyzed by deubiquitinating enzymes (DUBs).  The human ESCRT 
machinery recruits two DUBs: AMSH (associated molecule with a Src homology 3 
(SH3) domain of signal transducing adaptor molecule (STAM) or simply, STAM-binding 
protein (STAMBP)), and UBPY/USP8 (ubiquitin specific protease 8).  Both AMSH and 
USP8 have the same ESCRT-recognition domains facilitating recruitment to ESCRT-0 
and ESCRT-III. The Saccharmyces cerevisiae (S. cerevisiae) version of the ESCRT 
complex employs only one DUB, Doa4 (degradation of alpha 4) that serves to recycle 
ubiquitin at ESCRT-III, just prior to ILV formation.  Therefore, it is not fully understood 
why the human ESCRT system requires the function of both AMSH and USP8.     
The focus of this thesis is to understand the role of AMSH recruitment at ESCRT-
0 with hopes of providing further insight into its role within the ESCRT complex.  In 
doing so, I crystallized and determined the structure of catalytic domain of AMSH. Using 
this structure, I structurally and thermodynamically compared AMSH to the homologous 
protein, AMSH-LP.  Secondly, I characterized AMSH kinetically by introducing 
individual point mutations within the catalytic domain and carried out a detailed kinetic 
analysis to understand the catalytic mechanism of AMSH.  Finally, using a combination 
of biophysical and biochemical experiments, I investigated how AMSH is recruited and 
recognized at ESCRT-0.  My studies show that AMSH is structurally identical to AMSH-
LP, however, thermodynamically less stable.  Also, AMSH has exquisite specificity for 
Lys63-linked ubiquitin chains because it recognizes a three-residue sequence within its 
proximal ubiquitin-binding site.  Furthermore, two residues within the distal ubiquitin-
binding site (Thr313 and Glu316) play significant roles within AMSH’s catalytic 
mechanism, one of which, Thr313, is mutated to Ile in children with microcephaly 
xii 
capillary malformation (MIC-CAP) syndrome.  Finally, I proposed a mechanism for how 
the activity of AMSH is stimulated at ESCRT-0 in which the proximal ubiquitin is held 
by the ubiquitin-interacting motif (UIM) from STAM (ESCRT-0), while the enzyme 
holds the distal ubiquitin, thus stabilizing the chain, enhancing the enzyme’s activity.  
From this mechanism, I assigned a role for AMSH at ESCRT-0 in which the enzyme 
facilitates the transfer of cargo from ESCRT-0 to the subsequent complexes.  These data 
taken together further supports that AMSH has an important, specific, and non-redundant 
function within the ESCRT machinery.
1 
CHAPTER 1: INTRODUCTION 
1.1 Ubiquitin and Ubiquitination 
 Ubiquitination is a highly dynamic post-translational modification within the cell 
that is conserved in eukaryotes. Ubiquitin is a small, basic protein, that is widely known 
to be used for directing proteins to the 26S proteasome for degradation (Figure 1.1).1 
Several studies now have shown that ubiquitin modification serve several other processes 
as well including: DNA repair, endosomal sorting, and protein signaling.2 Ubiquitination 
is an energy-dependent process occurring by the action of three classes of enzymes 
termed E1, E2, and E3 (Figure 1.2).3; 4; 5 E1s are ubiquitin-activating enzymes, E2s are 
ubiquitin-conjugating enzymes, and E3s are ubiquitin ligase enzymes.3; 4; 5 These three 
enzyme classes in tandem can form a single ubiquitin moiety attached directly to a 
protein via an isopeptide bond (lysine of the target protein is covalently attached to the C-
terminal glycine of ubiquitin), or polymeric chains of ubiquitin attached directly to 
protein targets.1 Polymeric chains of ubiquitin are formed from one of the seven lysine 
residues from ubiquitin (6, 11, 27, 29, 33, 48, and 63), or the N-terminal methionine 
amine group forming linear ubiquitin chains, all of which have been detected in cells 
(Figure 1.1).2; 6; 7 The complexity of ubiquitination has greatly increased in the recent 
years.  Ubiquitin chains can be in the form of monoubiquitin, multi-monoubiquitination, 
homogenous linkages, mixed ubiquitin linkages, and finally, branched ubiquitin chains.2 
2 
Increasing complexity occurs with the different linkages and their roles within the cell.  
Lys48 is the most abundant ubiquitin linkage found in cells,6; 7 and it is known as a 
degradation signal by the 26S proteasome.1 Lys63 is the next most characterized 
ubiquitin linkage, directing cell surface receptors for degradation by the lysosome.8 Other 
roles for Lys63 chains include DNA damage repair9; 10; 11 and proteasomal degradation.12; 
13 Lys11 linkages have emerging roles as a proteasomal target, largely because Lys11 
linked ubiquitin have been shown to bind proteasomal receptors and causes cell cycle 
regulators to be degraded during mitosis.14; 15; 16 Lys29 is implicated in substrate turnover 
within the ubiquitin-fusion degradation pathway.2 Linear ubiquitin chains are involved in 
regulation of protein activity as done by LUBAC (linear ubiquitin chain assembly 
complex).17 Little is known about the physiological relevance of the four remaining 
ubiquitin linkages: Lys6, Lys27, Lys29, and Lys33. 
1.2 Deubiquitination and Deubiquitinating Enzymes 
 Deubiquitination, carried out by deubiquitinating enzymes (DUBs), opposes the 
activity of E3 ligases (Figure 1.2).18 The human genome codes for ~90 DUBs, of which, 
79 are predicted to be active.18; 19; 20; 21 DUB activity is categorized into three functions: 
(1) to generate free ubiquitin from the linear fusion of multiple ubiquitin moieties after 
translation, (2) to reverse the post-translational modification of proteins by ubiquitin, 
promoting protein stability or to recycle ubiquitin, maintaining the cellular pool of 
ubiquitin, and (3) to edit the form of ubiquitin modification by trimming ubiquitin 
chains.19 DUBs have an important role in ubiquitin regulation because de-regulation of 
DUB activity is implicated in hereditary cancer, inflammation, immune response, and 
3 
neurodegenerative disorders; the current trend is to regulate DUB activity by targeted 
design of pharmacological therapeutics.18; 21  
 There are five subclasses of DUBs: Ubiquitin C-terminal Hydrolases (UCH), 
Ubiquitin Specific Proteases (USPs), Machado-Joseph Disease Domain Proteases 
(MJDs), Ovarian Tumor Proteases (OTUs), and JAB1/MPN/Mov34 metalloproteases 
(JAMM).18  Of the five classes of DUBs, all are cysteine proteases except the JAMM 
family, which are zinc metalloproteases.18  The USP family is the largest with 56 
individual members, with another 11 from the UPS17 multigene family,22 OTU family 
has 15 members, the JAMM family has 8 members, and then, the UCH and MJD families 
each have 4 members.18; 19; 21   
 Just as ubiquitination is implicated in a wide variety of roles throughout the cell, 
deubiquitination is just as complex.  The specificity of DUBs can be determined by sub-
cellular localization, specific binding interactions, or the preference for a specific 
ubiquitin chain linkage.20 Increasing functions for DUBs have been found throughout the 
cell; cytosolic functions such as endosomal trafficking, organelle-specific functions as 
seen in the mitochondria, Golgi, and endoplasmic reticulum (ER), and the nucleus.20  
DUBs bind E3 ligases, regulating E3 autoubiquitination, allowing the E3 to regulate the 
target and its DUB simultaneously, or confering specificity to the DUB.18 The diversity 
in the ubiquitin linkages bring about the diversity in DUB linkage specificities, anywhere 
from recognition of a specific type of isopeptide bond to linkage promiscuity, all of 
which has been extensively reviewed previously.21 
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1.3 ESCRT Complex 
 The endosomal sorting complexes required for transport (ESCRT) is a multi-
subunit machinery that is an essential part of the multivesicular body (MVB) pathway in 
which cargo is sequestered and sorted into endosomal membranes to create MVBs 
(Figure 1.3).23; 24 The ESCRT complex was initially discovered in yeast as a part of the 
vacuolar protein-sorting (vps) mutants, which were unable to deliver proteins to the 
vacuole.23 13 of 46 vps mutants (class E) lacked the ability to deliver membrane proteins 
to the vacuole, giving rise to the discovery in 2001 of ESCRT-I (the second ESCRT 
complex) resulting from biochemical characterization of those vps mutants.23; 24 The 
ESCRT machinery is a ubiquitin-dependent entity that is involved in several cellular 
processes including endosomal sorting, endosomal trafficking, viral budding, cytokinesis, 
transcriptional regulation, and autophagy.25 As a function of its involvement in several 
processes throughout the cell, the ESCRT machinery is implicated in a wide variety of 
diseases including cancer, neurological disease, bacterial infections, cardiovascular 
disease, and retroviral infection.26; 27 The ESCRT machinery is subdivided into four 
complexes: ESCRT-0, -I, -II, -III, that work in a sequential mechanism to sort membrane 
proteins to the lysosome (vacuole in yeast),24 other cellular process do not require all four 
of the complexes to carry out its function. 
1.3.1 ESCRT-0 
 ESCRT-0, the initial ESCRT complex, was not originally classified as a member 
of the ESCRT complexes; studies later showed that it should be considered apart of the 
ESCRT machinery.8; 28; 29; 30 Of all the ESCRTs, ESCRT-0 is the least conserved, not 
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found in plants and protists, but yet, the ESCRT-dependent MVB pathway for protein 
degradation is still functional.8; 23 ESCRT-0 consists of two subunits, hepatocyte growth 
factor-regulated tyrosine kinase substrate (Hrs) and signal transducing adaptor molecule 
(STAM) (Vps27 and Hse1 in yeast respectively) (Figure 1.4).8; 23; 24; 31 Hrs/STAM form a 
1:1 heterodimer that localizes to the endosomal membrane via the Hrs 
Fab1/YOTB/Vac1/EEA1 (FYVE) domain that specifically recognizes 
phosphatidylinositol 3-phosphate (PI3P).8; 24; 31; 32; 33 In vivo, Hrs/STAM aggregate at the 
endosomal membrane, forming a stable 2:2 heterotetramer.32 Giant unilamellar vesicles 
followed by fluorescent probes showed that ESCRT-0 serves to cluster ubiquitinated 
cargo at the membrane, supporting the aggregation event seen previously.34 The 
stoichiometry of ESCRT-0 becomes important in its ubiquitin binding capabilities.  Hrs 
alone has a VHS (Vps27/Hrs/STAM) domain and a double-sided ubiquitin-interacting 
motif (DUIM); STAM has its own VHS domain and a UIM, thus, the complete ESCRT-0 
has five ubiquitin binding domains (UBDs).23; 31; 32; 35 Therefore, if ESCRT-0 has five 
UBDs, the heterotetramer that forms on the endosomal membrane should theoretically 
bind up to ten ubiquitin moieties simultaneously, especially since it has been shown that 
ubiquitin chains bind cooperatively at ESCRT-0.35 However, there are discrepancies in 
literature over the accepted amount of ubiquitin moieties that bind at ESCRT-0.  Mayers 
et al. stated that the ESCRT-0 heterodimer has the capacity to bind four ubiquitin 
molecules, and their model suggests that the heterotetramer will bind eight ubiquitin 
molecules once localized to the membrane.32 Ren et al. did detect ubiquitin binding by 
the VHS domain of Hrs, but, were surprised by its low affinity.35 Now adding the VHS 
domain from Hrs, ESCRT-0 will cooperatively bind 10 ubiquitin moieties at the 
6 
membrane as first hypothesized.  Recently, Lange et al. found that the SH3 domain of 
STAM specifically and independently binds ubiquitin.36 With the addition of these new 
data, ESCRT-0 would have six UBDs, which when localizes to the membrane, forming 
the heterotetramer, would simultaneously bind 12 ubiquitin moieties. 
 
1.3.2 ESCRT-I 
 ESCRT-I is recruited to the membrane by direct interaction with ESCRT-0 via the 
PSAP-like motif from Hrs to ubiquitin E2 variant (UEV) domain of ESCRT-I member, 
Tsg101 (Vps23 in yeast).8; 23; 24 The ESCRT-I core is made up of a heterotetrameric 
complex in a 1:1:1:1 ratio of Tsg101, Vps28, Vps37 (A, B, C), and Mvb12 (A, B) or 
ubiquitin-associated protein 1 (UBAP1) (Vps23, Vps28, Vps37, and Mvb12 in yeast).8; 23; 
24; 37; 38 The x-ray crystal structure of the core ESCRT-I has been determined, revealing an 
asymmetric complex that spans 18 nm in length and consists of a headpiece attached to a 
13 nm stalk (Figure 1.5).38 Further structural characterization of ESCRT-I using a 
combination of small angle X-ray scattering (SAXS) and double electron-electron 
resonance spectroscopy (DEER), circumventing the issues of crystallizing the entire 
ESCRT-I due to flexibility, showed that ESCRT-I adopts equal populations of a closed 
and open conformation in solution.37   
 Like ESCRT-0, ESCRT-I binds ubiquitin using the UEV domain of Tsg101, thus 
facilitating the passage of ubiquitinated cargo from ESCRT-0 to ESCRT-I.37 Structural 
characterization of UBAP1 revealed another ESCRT-I UBD.39 The ubiquitin-association 
(UBA) domain within UBAP1 binds ubiquitin with a KD of 70 M; an intact ESCRT-I 
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with full-length UBAP1 and Tsg101 (UEV domain deleted to measure ubiquitin binding 
by simply the UBA domain of UBAP1) showed an apparent KD of 140 M.39 Lys63-
linked diubiquitin binds to the UBA domain with a similar affinity as ubiquitin.39 Taken 
together, ESCRT-I can bind a minimum of two ubiquitin moieties. 23 No data has shown 
if ubiquitin binds cooperatively as was seen at ESCRT-0.35 ESCRT-I works in tandem 
with ESCRT-II to induce bud formation, confining the cargo within the nascent bud.34 
Not only is ESCRT-I necessary for MVB biogenesis, it adopts important roles in HIV-1 
budding from infected cells and midbody localization in cytokinesis.40; 41; 42; 43; 44; 45 
 
1.3.3 ESCRT-II 
 ESCRT-II is composed of EAP30 (ELL-associated protein of 30kDa), EAP45, 
and two molecules of EAP20 (Vps22, Vps36, and Vps25 in yeast, respectively) forming a 
‘Y’ shaped complex where EAP30 and EAP45 form the base, each bound by one copy of 
EAP20, which are the branches (Figure 1.6).46; 47 ESCRT-II recruitment to the membrane 
is a result of ESCRT-I; recruitment of ESCRT-II by ESCRT-I is well characterized in 
yeast, but poorly understood in mammals.  In yeast, the GLUE (GRAM-like ubiquitin-
binding in EAP45) domain of Vps36 binds with nanomolar affinity to the C-terminus of 
Vps28.24; 48 The yeast Vps36 GLUE domain has two Npl4 type zinc finger (NZF) 
domains, one binds to Vps28 (ESCRT-I), and the other binds ubiquitin.48 Human EAP45 
retains the GLUE domain, without the NZF domains. Therefore, the GLUE domain has 
the ability to bind ubiquitin, but not much is understood about the ESCRT-I binding.24 A 
study probed ESCRT-I-II binding in humans and found that residues 149-169 within 
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EAP45 (VPS36, nomenclature used in publication) is necessary, but not sufficient for 
binding to Vps28 (ESCRT-I), suggesting that there maybe more than one point of contact 
between ESCRT-I and II.49  
 As stated previously, ESCRT-I and II work together to deform and stabilize bud 
necks in which cargo is confined.34 This localization and deformation of the membrane is 
further supported by the ability of ESCRT-II to bind with high affinity to PI3P via the 
GLUE domain, similar to the FYVE domain of ESCRT-0.24 Structural insight into this 
mechanism of how ESCRT-I and II working together to deform membranes was provided 
in a study that combined solution data from SAXS, DEER, and small-molecule Forster 
resonance energy transfer (smFRET).50 It was found that the ESCRT-I-II supercomplex 
forms a crescent shape, which is common for proteins that work at the membrane to 
induce curvature.50; 51 This study has provided a structural basis for the mechanism of 
cargo transfer within MVB biogenesis.50 
 
1.3.4 ESCRT-III 
 ESCRT-III, the final ESCRT member, catalyzes the scission of the bud necks 
created by ESCRT-I and II, creating intralumenal vesicles (ILVs) that will ultimately fuse 
with the lysosome (vacuole in yeast) for degradation.52 Unlike the previous three ESCRT 
complexes, ESCRT-III does not exist as a pre-formed complex in the cytosol; its 
members exist in an autoinhibited form prior to its polymerization on the endosomal 
membrane.23; 24; 53; 54 ESCRT-II member, Vps25, binds directly to Vps20, initiating 
recruitment of ESCRT-III proteins in yeast.8; 24 Subsequently, Vps20 promotes the 
9 
sequential recruitment of Snf7, building the main polymer consisting of Vps24 and Vps2, 
which together cap the polymer and control disassembly.55; 56; 57 Snf7 is the component 
with the highest stoichiometry of all the ESCRT-III proteins, and has been found to be 
absolutely necessary for membrane severing.58 Recently, a study elucidated Snf7 
mechanism of activation in which it exists in its inactive “closed” state in solution, and 
then, Vps20 gets activated, causing a movement of helix 5 and linker region away from 
the core domain of Snf7, facilitating interaction with the membrane and downstream 
ESCRT-III subunits.59 In humans however, the ESCRT-III complex expands to include 
12 members, termed charged multivesicular body proteins (CHMPs).57; 58; 60 CHMPs 
have the potential to form analogous complexes to that of yeast using CHMP6 (Vps20), 
one of three isoforms of Snf7 (CHMP4 A, B, or C), CHMP3 (Vps24) (Figure 1.7), and 
finally, one of two isoforms of Vps2 (CHMP2 A or B).58; 60 There are also other CHMPs 
that serve regulatory roles within ESCRT-III including: two isoforms of CHMP1 (A and 
B, Vps46 in yeast), CHMP5 (Vps60 in yeast), CHMP7 (no yeast homologue), and 
increased sodium tolerance-1 (IST-1, Ist-1 in yeast).58; 60 
 Research has been done and models have been proposed attempting to elucidate 
how ESCRT-III catalyzes membrane scission, forming ILVs.  When the four yeast 
ESCRT-III subunits were added at submicromolar levels in their correct order, ILV 
formation was observed. However, the activity was less active compared to when a 
mutant of Vps20 was added in which the C-terminus was deleted, supporting the 
autoinhibited nature of the subunits prior to membrane localization.52 Further studies 
showed that efficient ILV formation and detachment requires the activated from of 
Vps20, Snf7, and Vps24, but also, lipid composition has some importance to ILV 
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formation.52 Several models were proposed as a result of these studies. One model 
suggests that the ESCRT-III proteins make filaments that form an inward-directed 
curvature, resulting in its constrictive force.56 Another model speculates that the ATPase 
Vps4 plays an important role by remodeling the ESCRT-III components once filament 
spirals are formed.56 A third possibility for membrane cleavage could be due to the lipid 
composition, stabilized by the ESCRT-III polymers.56 Finally, a dome-like structure has 
been proposed in which ESCRT-III polymers acquired a dome-like configuration, 
exposing membrane-binding interfaces, which theoretically has a higher binding energy 
than required for the membrane to wrap around the dome, thus causing membrane 
scission.56   
 Upon membrane constriction, the ESCRT-III subunits have to be recycled to carry 
out multiple rounds of ILV detachment.52 Vps4 is an ATPase associated with various 
cellular activities (AAA) ATPase that requires ATP hydrolysis to completely recycle 
ESCRT-III subunits.24 Vps4 is a dodecamer of two hexameric rings that has an N-
terminal microtubule interacting and trafficking (MIT) domain that interacts with the C-
terminal microtubule interacting motifs (MIMs) of ESCRT-III members.24; 58 Vps4 works 
in tandem with Vta1, for which a structural basis has been determined, causing an 
enhancement of ATPase activity, promoting oligomerization, and helping in ESCRT-III 
disassembly.61 Formation of this complex is thought to facilitate disassembly of subunits 
by threading them through the central pore of the ATPase, however, this model is only 




1.4 Deubiquitination Within the ESCRT Complex 
 Since the ESCRT machinery is a ubiquitin-dependent process, deubiquitination 
and DUBs become regulators of this entire machinery.  The model ESCRT system within 
Saccharmyces cerevisiae (S. cerevisiae) uses the DUB, Degradation of alpha 4 (Doa4), to 
recycle ubiquitin from ubiquitinated cargo that has been shuttled through the upstream 
ESCRT complexes and are committed to ILVs.62 Doa4 has also been shown to interact 
directly with ESCRT-III subunit, Snf7, thus promoting its localization to the last 
complex, further supporting its DUB role, however, direct deubiquitination of cargo is 
not required for MVB sorting in yeast.62; 63; 64   
 Similarly, the human ESCRT system requires DUBs. In humans, there are two 
DUBs employed, associated molecule with a Src homology 3 (SH3) domain of STAM 
(or STAM-binding protein (STAMBP) or simply AMSH), and ubiquitin-specific protease 
Y (UBPY or ubiquitin-specific protease 8 (USP8)).62; 65; 66; 67; 68 Both AMSH and UBPY 
have functional SH3-binding motifs (SBMs) that facilitate recruitment to ESCRT-0 via 
STAM’s SH3 domain, and functional MIT domains that allow for recruitment to various 
CHMPs of ESCRT-III.62; 67; 69; 70; 71 ESCRT-0 SH3 recruitment is carried out using a 
conserved consensus sequence, PX(V/I)(D/N)RXXKP (X is any residue).62; 67 Linking 
the S. cerevisiae and human ESCRTs, there are three yeast proteins with similar domain 
structures to UBPY, Doa4, Ubp7, and Ubp5, and of the three, Doa4 has a seemingly 
analogous role to UBPY at ESCRT-III. Interestingly, Ubp7 interacts with Hse1, 
mimicking UBPY binding to ESCRT-0.62 There is no direct AMSH homolog within S. 




 AMSH is a 424-amino acid member of the JAMM family of DUBs that binds 
Zn2+ at the active site coordinated by two histidines, an aspartate, and a glutamate bridged 
by the catalytic water molecule; a second Zn2+ is bound ~14Å away from the active-site 
zinc for structural integrity.72; 73 AMSH is involved in the regulation of several receptors 
including: epidermal growth factor (EGFR) receptor, calcium-sensing receptor, -opioid 
receptor, protease-activated receptor (PAR), and the chemokine receptor CXCR4.65; 74; 75; 
76; 77; 78; 79; 80 Not only is AMSH implicated in receptor down-regulation, but also has roles 
within mitosis, cytokinesis, and HIV budding.44; 45; 81; 82 More recently, whole-exome 
sequencing analysis has shown that recessive mutations in AMSH lead to microcephaly-
capillary malformation (MIC-CAP) syndrome.83 MIC-CAP is discovered at or shortly 
after birth in which children diagnosed with the disease have severe microcephaly with 
progressive cortical atrophy, intractable epilepsy, profound developmental delay and 
multiple small capillary malformations on the skin.83; 84; 85; 86 Out of the ten patients that 
were screened, six had missense mutations, two had nonsense mutations, two 
translational frameshift mutations, and three intronic mutations.83 Interestingly, five out 
of the six missense mutations were found within AMSH’s MIT domain, and the sixth, 
Thr313Ile, found within the JAMM domain.83  
 AMSH has exquisite specificity for Lys63-linked polyubiquitin chains.65 The 
structural basis for specifically recognizing Lys63-linked polyubiquitin chains by the 
AMSH family of DUBs has been elucidated with the x-ray crystal structure of AMSH-LP 
bound to a Lys63 ubiquitin dimer.87 The structure revealed that specificity arises from 
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recognition of a tripeptide sequence (Gln62-Lys63-Glu64) within the proximal ubiquitin 
by four residues within the enzyme (Thr, Phe, Ser, and Phe).87 
 AMSH localization to ESCRT-0 is facilitated by the SH3 domain of STAM 
binding to the SBM of AMSH.62 Previous work has shown that clathrin, not the SH3 
domain of STAM is required for AMSH to be localized to the endosome, suggesting that 
binding clathrin allows AMSH to be in close proximity to bind the SH3 domain of 
STAM.88 Similarly, ESCRT-0 localizes to the endosome because of its interaction with 
clathrin via the C-terminal domain of Hrs.89 Furthermore, the recruitment of AMSH to 
ESCRT-0 enhances the enzyme’s activity.  One study showed that in the presence of 
STAM, AMSH processed Lys63 ubiquitin chains better than without STAM, or with 
mutations disrupting the enzyme’s ability to bind STAM.66 Also, it was found that 
mutations within the UIM domain of STAM greatly reduced this enhancement of 
activity, suggesting the UIM has a KM effect.66 Another study showed that when Lys63-
linked diubiquitin was bound to STAM, the enzyme processed the chains better than 
when not bound to STAM; AMSH mutants lacking the SBM showed no activity towards 
diubiquitin bound STAM.90  
 AMSH recruitment to ESCRT-III is facilitated through direct interaction with 
CHMPs.69; 70; 71 A yeast-two hybrid system found that AMSH interacts with several 
CHMP members: CHMP1A, CHMP1B, CHMP2A, and CHMP3; all of these CHMPs did 
not interact with AMSH-LP, suggesting specific AMSH-CHMP interactions.71 A more 
detailed study of AMSH-ESCRT-III binding using a glutathione S-transferase (GST)-pull 
down assay suggests that AMSH interacts most prominently with CHMP1A, followed by 
CHMP3 and then, CHMP4C. However, CHMP1A only plays a regulatory role, whereas 
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CHMP3 is one of the proteins necessary for capping the ESCRT-III polymer in the 
scission process.60; 69 Further structural and biophysical studies have been done on the 
AMSH-CHMP3 interaction.  Some initial studies using SAXS found that CHMP3 existed 
in multiple conformations ranging from a closed conformation in a no-salt buffer to an 
open conformation in a high-salt condition.53 This study also determined using isothermal 
titration calorimetry (ITC) that the AMSH-CHMP3 binding affinity changes as a function 
of salt concentration ranging from 5.6 nM in no salt to 392 nM in 500 mM NaCl.53   
 More recently, the structural basis of AMSH recruitment by CHMP3 was 
elucidated with the X-ray crystal structure of a complex including the MIT domain of 
AMSH (residues 1-146) and a C-terminal fragment of CHMP3 (residues 183-22) (Figure 
1.9).91 In great agreement with the previous study, the KD of the MIT-MIM interaction 
was found to be 60 nM using ITC and 113 nM using Surface Plasmon Resonance 
(SPR).91 The extraordinarily tight complex is mainly stabilized by polar interactions, 
which is novel compared to previous crystal structures of MIT-MIM interactions, which 
showed the importance of hydrophobic interactions.91 Furthermore, the interaction of 
AMSH and CHMP1A was analyzed by SPR revealing a KD of 1.49 mM, suggesting a 
different mode of interaction between the two subunits and AMSH.53; 91 Since ESCRT-III 
is necessary for the final scission step in MVB biogenesis, it is important to comment on 
how AMSH relates to the role of Vps4 disassembly.  Overexpression of Vps4 resulted in 
weakened affinity of CHMP1B for AMSH, suggesting that the MIT domain of Vps4 
competes for the same binding spot on CHMPs.71 Though Vps4 competed off AMSH 
from CHMP1B, it is not well understood how Vps4 would compete of CHMP3 because 
of the low nanomolar affinity that AMSH-CHMP3 has, whereas Vps4-CHMP 
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interactions have micromolar affinities.91; 92 Further studies need to be done to elucidate 
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Figure 1.3. Cartoon representation of the ESCRT complexes taken from Railborg, C., et 























Figure 1.4. X-ray crystal structure of the human core ESCRT-0 heterodimer determined 
















Figure 1.5. X-ray crystal structure of the yeast heterotetrameric ESCRT-I complex. (PDB 
ID: 2P22) Vps23 is shown as blue ribbon, vps28 as cyan ribbon, vps37 as red ribbon, and 












Figure 1.6. X-ray crystal structure of human ESCRT-II.  The structure is the complex 
ESCRT-II lacking the GLUE domain (PDB ID: 3CUQ). VPS36 is shown as green 













































Figure 1.9.  X-ray crystal structure of the AMSH MIT domain bound to CHMP3 
(PDB ID: 2XZE).  The MIT domain of AMSH is shown in cyan ribbon and 










CHAPTER 2: STRUCTURAL AND THERMODYNAMIC COMPARISON OF  
AMSH AND AMSH-LP 
2.1 Introduction 
 This chapter describes the structural and thermodynamic comparison of the 
catalytic domains of AMSH and AMSH-LP. I have determined x-ray crystal structures of 
two constructs representing the catalytic domain of AMSH: AMSH244-424, the JAMM-
domain-containing polypeptide segment from residues 244 to 424 (hereafter referred to 
simply as AMSH244) and AMSH219E280A, an active-site mutant, Glu280 to Ala, of the 
segment 219-424, which, in addition to the JAMM domain, also features the SH3-
domain-binding motif (SBM) at its N-terminus. When comparing the x-ray crystal 
structures of AMSH and AMSH-LP, we see that while the overall folds of the two 
proteins are nearly identical, as expected, the catalytic domain of AMSH is 
thermodynamically less stable than of AMSH-LP under guanidine hydrochloride 
(GdHCl)-induced unfolding.  Moreover, to further understand the disease basis of MIC-
CAP syndrome, the disease-associated mutation, Thr313Ile, was analyzed for its 
thermodynamic stability.  It was determined that the mutation does not significantly alter 
AMSH’s thermodynamic stability, suggesting that the basis of the disease lies elsewhere. 
Together, these results suggest that the catalytic domain of AMSH is structurally more 
plastic than AMSH-LP, a property that may endow specific advantage to AMSH enabling 
it to adapt to a variety of working environments within the context of ESCRT machinery. 
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2.2 Materials and Methods 
 
2.2.1 Cloning, Expression, and Purification  
AMSH244 was subcloned from the full-length plasmid following standard PCR 
protocols.  The resulting gene encoding the catalytic domain was subcloned into pGEX-
6p1 (GE Biosciences) by using standard cloning protocols. The resulting N-terminally 
fused glutathione S-transferase (GST)-tagged protein was expressed in Escherichia coli 
Rosetta cells (Novagen) and purified with a glutathione-Sepharose column (GE 
Biosciences) following manufacturer’s instructions.  
 AMSH219 was subcloned into a pGEX-6p1 expression vector as before.  The 
Glu280Ala and Thre313Ile mutations was introduced into the gene by site-directed 
mutagenesis using QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the 
manufacturer’s protocol.  DNA sequencing confirmed the presence of the mutation. 
AMSH219E280A and AMSH219T313I were purified using standard GST affinity 
chromatography. The DUB domain of AMSH-LP (a kind gift from Prof. Shuya Fukai, 
The University of Tokyo, Japan) was purified as described before.1 
2.2.2 Crystallization and Structure Determination 
Crystals of AMSH244 were grown at room temperature by the sitting drop vapor 
diffusion method from a mother liquor containing 0.2M sodium malonate pH 7.0, 20% 
PEG 3350, and 5% PEG 400.  Crystals of AMSH219E280A were grown at room 
temperature by the sitting drop vapor diffusion method from a mother liquor containing 
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0.1M 2-(N-morpholino)ethanesulfonic acid (MES) pH 6.5, 15% PEG 6000, and 5% 2-
methyl-2,4-pentanediol (MPD).  Crystals were briefly soaked in cryoprotectant solution 
(20% ethylene glycol) and then plunged into liquid nitrogen for flash cooling.  X-ray 
diffraction data were collected at 100 K on a Mar300 CCD detector (Mar USA) at the 
beamline 23-ID-D at the Advanced Photon Source at Argonne National Laboratory.  The 
data were processed using HKL2000. 
  AMSH244 was determined by molecular replacement using a homology modeled 
catalytic domain of AMSH based on the catalytic domain of AMSH-LP, from SWISS-
MODEL homology modeling server,2 as a search model.  Refinement and multiple 
rounds of model building were carried out using Phenix3 and Coot,4 respectively, yielding 
a final model with a crystallographic Rfac of 19.3% and free R of 22.9%. Residues Thr250 
of chain C, Ile251 of chain D, Pro402 of chain E, and Glu314, Asn315, and Glu316 of 
chain G are within disallowed regions of the Ramachandran plot.  All of these residues 
were in weak or no density at 1 except Glu314 and Thr250.  The structure of 
AMSH219E280A was also determined by molecular replacement using the previous 
structure as a search model.  Refinement and model building were carried out in the same 
method yielding a crystallographic Rfac of 18.0% and free R of 20.5% (Table 1).  
Graphical analysis was carried out using PyMOL (DeLano Scientific). 
2.2.3 Analytical Ultracentrifugation 
 To characterize the oligomeric state of AMSH and AMSH-LP, sedimentation 
velocity experiments were conducted at 50,000 rpm using both the Beckman-Coulter XLI 
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and XLA (Beckman-Coulter, Fullerton, CA, USA). The samples were monitored by both 
absorbance and interference optics at 280 and 675 nm, respectively. The proteins were 
dialyzed in 50 mM TRIS-HCl pH 7.6, 50 mM NaCl and 1 mM DTT.  Three 
concentration series were conducted to evaluate the formation of higher order species, 
AMSH244 at 30, 60, and 120 M, AMSH-LP at 25, 47, and 94 M. The sedimentation 
coefficients and apparent molecular weights were calculated from size distribution 
analyses (c(s)) using SEDFIT v. 12.0.5; 6 The solvent density, viscosity and partial 
specific volume of the proteins were calculated using SEDNTERP v. 1.09 
(http://www.rasmb.bbri.org/rasmb/windows/sednterp-philo). 
 
2.2.4 Guanidine Melt Using Circular Dichroism Spectroscopy 
The stability of the folded state of AMSH244, AMSH219T313I, and AMSH-LP 
towards GdHCl was determined using 8M stock concentrations of GdHCl (Sigma).  
Varying concentrations of GdHCl were added to the protein (0.2 mg.mL-1) diluted in 100 
mM phosphate buffer pH 7.4 and allowed to sit at room temperature overnight to allow 
for complete equilibration. Changes in the folded state of the proteins were monitored 
using circular dichroism by following changes in ellipticity at 220 nm. CD spectra were 
recorded in a Jasco J-810 Spectropolarimeter in the far UV region (195-260 nm) in a 0.1 
cm path length cuvette.  Each spectrum was averaged over 4 scans (50 nm.min-1 scan 
speed, with a 8 second time constant) and corrected by subtraction of a spectrum of the 





  [] =         100  M     (EQN 1) 
C  l  n 
 
Where  is the ellipticity in degrees, l is the optical path in cm, C is the concentration in 
mg/ml, M is the molecular mass and n is in the number of residues in the protein. 
The mean residue molar ellipticity [] is given in deg.cm2.dmol-1.  Unfolding curves were 
analyzed using a two-state unfolding model, using linear extrapolation to obtain the G 




2.3.1 Structure of the Catalytic Domain of AMSH 
AMSH244 crystallized in the C2 space group, with seven monomers in the 
asymmetric unit (Figure 2.1). The structure was solved by molecular replacement (MR) 
with the catalytic domain of AMSH-LP as the search model.1 The MR search identified a 
model with seven subunits in the asymmetric unit. Rigid-body followed by restrained 
refinement of this model yielded a crystallographic R factor (Rcrys) and free R factor 
(Rfree) of 25.4 and 34.8 %, respectively. Electron density map at this stage was 
interpretable and showed clear density for the two Zn2+ ions where they should be 
located, indicating that the MR search was successful. Refinement using Phenix3 after 
rounds of model building yielded a final Rcrys and Rfree of 19.3 and 22.9 %, respectively 
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(Table 2.1). The structure of the polypeptide in different subunits is nearly identical 
except for the N-terminal residues, Asn244 to Asp252, which were ordered to different 
extent in different subunits. 
 The observation of seven monomers in the asymmetric unit prompted us to 
investigate the oligomeric state of the catalytic domain of AMSH in solution.  AMSH244 
was subjected to analytical ultracentrifugation (AUC) experiments, along with the 
catalytic domain of AMSH-LP for comparison. The AUC data indicate that in solution, 
the catalytic domains of both AMSH and AMSH-LP exist as predominantly globular, 
monomeric proteins with a sedimentation coefficient (s20) value of 2.1 and 2.03, 
respectively (Figure 2.2). However, this data does not rule out the possibility that the full-
length protein can exist as a multimer in solution, through self-association of the part 
missing in our construct.  
Like the DUB domain of AMSH-LP, the structure of AMSH244 consists of the 
JAMM core with two characteristic insertions, insertion 1 (Ins-1, residues 302-327) and 
insertion 2 (Ins-2, residues 381-403). The JAMM core comprises a mixed -sheet in the 
shape of a partially unfurled -barrel sandwiched by two -helices, one on top (1) and 
one on the bottom (3) (Figure 2.3), a feature found in other JAMM domain proteins, 
such as AfJAMM and Prp8.8; 9; 10; 11 As seen in AMSH-LP, the catalytic site is lined 
mostly by residues from the JAMM core, from the loop between 1 and 2, 3, 6 and 
the loop following it (Figure 2.3a). Residues from the -hairpin turn segment in Ins-1 
also contribute to the catalytic site. The catalytic zinc is coordinated by His335, His337 
(located on 6 and immediately following it), Asp348 (located on 3) and a water 
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molecule that is hydrogen bonded to Glu280 (located on the loop following 1) (Figure 
2.3b). In addition to these zinc-coordinating residues, the oxyanion-stabilizing side chain 
from Ser345 (on 3) completes the set of catalytic residues required for peptide bond 
hydrolysis by a thermolysin-type, mechanistically speaking, zinc metalloprotease.12; 13 
We confirmed the presence of a second zinc ion, 14Å away from the active site, by the 
presence of strong electron density in the 2fo-fc map in the area coordinated by the 
residues His350 from the JAMM core, and His396, His398, and Cys390 from Ins-2 
(Figure 2.3c), the same set of residues that coordinate the second zinc ion in AMSH-LP.24  
As seen in the structure of the DUB domain of AMSH-LP, the active-site of 
AMSH is in a closed configuration, covered by two side chains, that of an asparate 
(Asp309) in Ins-1 and a phenylalanine (Phe395) in Ins-2, with their van der Waals 
surface touching each other (Figure 2.3a). The side chains of these two residues have to 
move away from each other to let the scissile isopeptide bond on the substrate access the 
active site, suggesting that there is considerable flexibility either in these side chains or in 
the polypeptide backbone bearing them. Interestingly, in the structure of AMSH-LP DUB 
domain bound to Lys63-linked ubiquitin dimer, the corresponding residue pair is still 
seen in a similar position as the substrate-free form,1 suggesting that these residues close 
the active site during catalysis as well, perhaps to help position the scissile peptide bond 
or stabilize the transition state or both. Both these residues are absolutely conserved in all 
AMSH sequences analyzed so far (data not shown) and in AMSH-LP as well suggesting 
a functional role.  
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 In our efforts to structurally characterize AMSH’s recruitment to the ESCRT-0 
complex, we generated an N-terminally longer construct of the catalytic domain that has, 
in addition to AMSH’s DUB domain, the peptide sequence which AMSH uses to bind to 
STAM’s SH3 domain.14 An active-site mutant of this construct, AMSH219E280A, in which 
Glu280 is mutated to alanine, crystallized in the tetragonal space group, P43212, with a 
single molecule in the asymmetric unit, consistent with the monomeric state of 
AMSH244 found in solution. The structure of this mutant was solved by MR using the 
structure of AMSH244 as the search probe (Table 1). The overall fold of the two 
structures is very similar with a root mean square deviation (rmsd) between C atoms of 
0.84Å. The N-terminal SH3-binding peptide segment was not visualized in the structure 
perhaps because of disorder in the crystal, suggesting that this peptide segment is flexible 
and is easily accessible for binding to the SH3 domain of STAM. We speculate that the 
flexibility of this segment may allow it to serve as apart of a linker that connects the 
JAMM domain to the N-terminal portion of the protein. The structure of the mutant does 
confirm the presence of the E280A mutation; however, clear density in the vicinity of the 
active-site metal-coordinating residues was still observed, which was interpreted as the 
density corresponding to a Zn2+ ion (Figure 2.4). Thus, despite having lost the catalytic 
glutamate, and consequently the water molecule bound to it, the active-site Zn2+ is still 
present. Further inspection reveals that the side chain of a nearby aspartate, Asp309, has 
swung by nearly 120 degrees from its position in the wild-type structure positioning itself 
such that one of its O atoms can coordinate to the zinc, thereby restoring the tetrahedral 
coordination around it (Figure 2.4).  
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2.3.2 A Potential Disulfide Bond in the Catalytic Domain of AMSH 
 The overall structure of AMSH244 and AMSH219E280A are nearly identical, 
however, further inspection during model building revealed the presence of a potential 
disulfide bond 7.4Å away from the catalytic zinc in the latter.  Rounds of refinement 
showed positive density around Cys282 within which we modeled in three alternate 
conformations, one of which placed this cysteine side chain within disulfide-bonding 
distance from Cys311 (S-S distance of 2.0Å) (Figure 2.5).  The presence of 
dithiothreitol (DTT) throughout purification and in the crystallization buffer presents a 
possible reason for the multiple conformations observed in the crystals, preventing the 
cysteine pair from achieving 100% occupancy in its oxidized form (Figure 2.5). It is 
possible that this disulfide may exist in AMSH244 as well, but its observation is 
precluded because of DTT, whose reducing effect is perhaps more in this construct than 
in AMSH219E280A. Interestingly, sequence alignment analysis shows that these cysteines 
are conserved between AMSH and AMSH-LP;1 however, we do not see the equivalent 
cysteine pair within disulfide-bonding distance in AMSH-LP (S-S distance is 4.2Å in 
this case).  
 
2.3.3 Comparison of Thermodynamic Stability of the Catalytic Domains of  
AMSH and AMSH-LP 
 The overall three-dimensional fold of the catalytic domain of AMSH is very 
similar to the previously determined DUB domain of AMSH-LP (PDB code: 2ZNR) 1 
with a rmsd of 1.49Å of C atoms as determined by the superposition program 
SuperPose.15 The architecture of both the active site and the second zinc-binding site of 
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both the proteins are nearly identical (Figure 2.6). To explore further the similarity or the 
lack thereof between the catalytic domains of AMSH and AMSH-LP, we wondered if 
there would be any difference in thermodynamic stability between the two proteins. The 
unfolding of the catalytic constructs of both AMSH (AMSH244) and AMSH-LP was 
induced by guanidine hydrochloride (GdHCl) and monitored at 220 nm using circular 
dichroism spectroscopy (CD).  Both proteins reveal a loss in secondary structure with 
increasing concentration of GdHCl (Figure 2.7); however, it was observed that 
AMSH244 is less stable towards GdHCl than AMSH-LP, with a midpoint of transition at 
2.7 and 3.5 M GdHCl for AMSH and AMSH-LP, respectively (Table 2.2).  Using the 
linear extrapolation method described previously,7 GH2O of AMSH244 was found to be  
1.2 kcal.mol-1 less than that of the DUB domain of AMSH-LP, indicating the former is 
thermodynamically less stable than the latter (Figure 2.8 and Table 2).  
 To assess the thermodynamic stability of the MIC-CAP-associated mutation, 
Thr313Ile, in hopes to understand the basis of the disease, another GdHCl-induced 
melting experiment was done. It was determined that the MIC-CAP-associated mutation 
has similar thermodynamic stability to the wild type AMSH219 with a GH2O of 2.9 
kcal.mol-1 compared to the wild type construct at 3.6 kcal.mol-1, with both having similar 
midpoints of transition at 2.7 and 2.5 M GdHCl respectively (Figure 2.8 and Table 2).  
 
2.4 Discussion 
 We have determined the structure of two constructs representing the catalytic 
domain of AMSH, AMSH244 and AMSH219E280A. The structure of AMSH244 confirms 
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that AMSH is indeed a zinc metalloprotease of the JAMM family of DUBs with two Zn2+ 
ions, one at active site and the other playing a structural role in supporting the placement 
of ubiquitin-binding residues in Ins-2 in a position appropriate for isopeptide bond 
recognition. The structure of AMSH219E280A provided a surprising observation.  We 
anticipated the loss of the active-site zinc due to the E280A mutation, because Glu280, 
according to the known mechanism of thermolysin-type zinc-dependent-
metalloproteases, is responsible for holding a water molecule, the one that functions as 
the nucleophile, at a position such that it is able to serve as the fourth ligand in the 
coordination sphere of the catalytic zinc. Instead, we see clear density for the zinc.  
Asp309, on an adjacent loop (from Ins-1), has moved in place to become the fourth 
residue to coordinate the zinc. The observation that Asp309 moves in the mutant to 
coordinate zinc is suggestive of the dynamic nature of the hairpin loop in Ins-1.  The 
ability of the enzyme to counteract the loss of the glutamate by still retaining its zinc 
suggests a form of structural plasticity, allowing for conformational freedom. A similar 
mutation was incorporated in AMSH-LP for the purpose of co-crystallization with 
diubiquitin, and the authors stated that they do not see any electron density corresponding 
to the active site zinc.1 Interestingly, Asp309 and its equivalent residue in AMSH-LP 
have to have a certain amount of flexibility; otherwise, the active site will not be 
accessible for the diubiquitin substrate. The question that if the observation pertaining to 
Aps309 in AMSH219E280A is due to more flexibility of Ins-1 in AMSH than in AMSH-LP 
cannot be answered from the data presented here. It is possible that the same 
rearrangement of the equivalent asparate in AMSH-LP might have been observed in the 
structure of ubiquitin-free AMSHE292A.  
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Another interesting finding we see from the structure of AMSH219E280A is the 
presence of a potential disulfide bond adjacent to the active site. It should be noted that a 
disulfide bond next to the putative active-site zinc was also observed in the structure the 
JAMM-domain protein AfJAMM, a cytosolic protein from Archaeoglobus fulgidus.10 
The possibility that the cysteine pair in AMSH is capable of existing in reduced and 
oxidized forms, reduced when in cytosol and oxidized when associated with endosomes, 
cannot be ruled out. This feature may contribute to or result from the structural plasticity 
of the enzyme. However, we cannot say with any degree of certainty if this reversible 
disulfide bridge is unique to AMSH, and if it is, whether it contributes to the biological 
difference between AMSH and AMSH-LP, two very similar proteins. It is not clear why 
the DUB domain of AMSH not AMSH-LP should have a disulfide, or is it common to 
both of them (DTT was also present in the crystallization buffer and throughout 
purification in the case of the AMSH-LP DUB domain). If it happens to be unique to 
AMSH, it could perhaps be linked to its association with endosomes, which have been 
shown to be oxidizing.16  
Lastly, we sought to compare the structural and thermodynamic properties of the 
catalytic domains of AMSH and AMSH-LP.  It is expected that homologous proteins that 
share 75% sequence similarity to have a similar fold and overall architecture.  On par 
with this expectation, the catalytic domains of AMSH and AMSH-LP have a nearly 
identical fold and superimposable zinc coordination sites.  Furthermore, AUC 
experiments confirmed that both the proteins are globular and monomeric in solution. 
Thus, structurally, we cannot separate the two proteins from one another. 
Thermodynamically, however, we see a difference between the two. Chaotrope-induced 
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unfolding with GdHCl indicates that the catalytic domain of AMSH is 
thermodynamically less stable than that of AMSH-LP. Analysis of primary sequences of 
the proteins does reveal some differences in certain key positions, such as in the 
hydrophobic core (residues Val259, Val363, and Phe376 in AMSH are substituted by 
residues Leu271, Ile375, Ile388 in AMSH-LP, respectively), which could contribute to 
the difference in thermodynamic stability; however, this needs to be investigated in 
future. 
Furthermore, to understand the basis for the onset of MIC-CAP syndrome in 
children, we further assessed stability using GdHCl.  Surprisingly, we do not see a 
significant difference in thermodynamic stability between the T313I mutant and the wild 
type, amounting to a minimal 0.4 kcal.mol-1 difference.  This data suggests that the onset 
of the disease lies beyond protein folding, perhaps because the original threonine residue 
is surface-exposed, therefore, a substitution to isoleucine would present minimal changes 
to the overall three-dimensional structure.    
   Overall, we propose that the difference in thermodynamic stability between 
AMSH and AMSH-LP implies more plasticity in case of AMSH, a property that is 
consistent with its ability to function in the context of diverse environments such as 
within ESCRT-0 and ESCRT-III. We propose that this difference in stability implies a 
difference in flexibility between the catalytic domains of the AMSH and AMSH-LP. A 
more stable protein is likely to have better close packing of side chains making it more 
rigid, whereas a less stable protein, presumably because it has lesser amount of close 
packing, can tend to be more plastic, a property that may make AMSH more suitable for 
working in the context of a number different type of protein-protein complexes, such as 
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ESCRT-0 and ESCRT-III. Whether this has anything to do with the biological 
differences between the two proteins is worth investigating in future. 
This chapter presents structurally and thermodynamic evidence that further 
separates the functional significance of AMSH and AMSH-LP.  The two x-ray crystal 
structures of the catalytic domain of AMSH reveal an identical fold to AMSH-LP, 
however, two differences were discovered: (1) the E280A mutation did not lose Zn2+ at 
the active site, but instead had Asp309 complete the tetrahedron around Zn2+, and (2) 
there are two cysteines at the peripheral of the active site in which one orientation formed 
a disulfide bridge.  Finally, the most significant difference between AMSH and AMSH-
LP was in their thermodynamic stability, where AMSH was significantly less stable than 
AMSH-LP.  These data together suggest that AMSH has a clear, yet undefined, role 
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Figure 2.1. Asymmetric unit of AMSH244.  The crystallographic heptamer present in the 
asymmetric unit of AMSH244 crystal structure.  Each of the seven monomers of 















Table 2.1. Crystallographic data and refinement statistics 
 
 
*Rsym =  I hkl – I hkl(j)  /  I hkl , where Ihkl(j) is the observed intensity and Ihkl is the final 
average intensity. 
1Rcrys =  Fobs - Fcalc  /  Fobs and Rfree =  Fobs - Fcalc /  Fobs, where Rfree and Rcrys 
are calculated using a randomly selected test set of 5% of the data and all reflections 











Figure 2.2. c(s) distribution plots of the DUB domains of AMSH244 and AMSH-LP as 
determined by AUC.  (a) c(s) distribution plot of AMSH244 using interference optics 
shows that the majority discrete species at 2.1S is a globular, monomeric protein.  The 
protein concentrations used were 30M (large dashes), 60M (solid line), and 120M 
(small dashes).  (b) c(s) distribution plot of AMSH-LP using absorbance at 280nm shows 
that the majority discrete species at 2.03S is a globular, monomeric protein.  The protein 














Figure 2.3. The structure of the catalytic domain of AMSH. (a) Ribbon representation of 
the X-ray structure of AMSH244. (b) Expanded view of the active-site zinc coordination. 
(c) Expanded view of the second zinc coordination site.  The coordinating residues are 
shown as sticks, with carbon shown in green, oxygen in red, nitrogen in blue and sulfur in 















Figure 2.4. Superposition of the active sites of AMSH244 and AMSH219E280A.  
AMSH244 is shown in green and AMSH219E280A in pink.  The zinc-coordinating 















Figure 2.5. A potential disulfide bond in AMSH219E280A.  Expanded view of Cys282 
modeled in three alternate conformations, one of which makes a disulfide bond with 






















Figure 2.6. Structural comparison of the catalytic domains of AMSH and AMSH-LP.  (a) 
Backbone superposition of AMSH (shown in green) and AMSH-LP (shown in cyan).  (b) 
Expanded view of the zinc-coordinating residues in the active site.  (c) Expanded view of 
the residues coordinating the second zinc. The coordinating residues are shown as sticks, 
with carbon shown in green and cyan, oxygen in red, nitrogen in blue and sulfur in 
















Figure 2.7. Circular dichroism spectra of guanidine hydrochloride induced melting.  Raw 
data of the guanindine hydrochloride induced melting experiment for (a) AMSH and (b) 
AMSH-LP.  Both spectra show a decrease in signal with increasing concentration of 














































Figure 2.8. Fraction unfolded curves comparing the stability of two wild-type AMSH 
catalytic domain segments: AMSH244 (black diamonds) and AMSH219 (blue squares), 
the DUB domain of AMSH-LP (green circles), and the MIC-CAP mutants, T313I (red 
triangles) with increasing concentrations of GdHCl followed by circular dichroism 









CHAPTER 3: COMPARISON OF KINETIC PROPERTIES OF  
AMSH AND AMSH-LP 
 
3.1 Introduction 
 This chapter’s aim is to provide further insight into the differences between 
AMSH and AMSH-LP by comparing their kinetic properties.  We have carried out a 
DUB diubiquitin cleavage assay in which we have determined the Michaelis-Menten 
kinetic parameters.  We see that AMSH-LP is ~4-fold more active compared to AMSH 
mainly due to a 10-fold increase in kcat.  To help understand this difference in catalytic 
activity, we modeled the structure of the catalytic domain of AMSH onto the previously 
determined co-crystal structure of AMSH-LP bound to a Lys63-linked ubiquitin dimer.1  
We see that the proximal ubiquitin recognition between the two enzymes is completely 
conserved, however, the distal ubiquitin recognition is the main difference between the 
two enzymes, arising from three residue substitutions, one of which (Thr313) is mutated 
in microcephaly capillary malformation (MIC-CAP) syndrome.2  To assess the role of 
these residues within AMSH, we carried out extensive mutational and kinetic analyses 
introducing individual point mutations within the active site, proximal, and distal 
ubiquitin binding sites to determine their individual kinetic parameters.  Our results 
confirm that AMSH’s proximal ubiquitin recognition reveals similar effects as was seen 
in AMSH-LP, but much to our surprise, the distal ubiquitin site differed from AMSH-LP 
with the most significant effects seen when residues Thr313 and Glu316 were modified.  
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These data further separate the catalytic mechanisms of AMSH and AMSH-LP, which 
could correlate to AMSH, not AMSH-LP, recruitment to regulate the ESCRT machinery.      
3.2 Materials and Methods 
 
3.2.1 Cloning, Expression, and Purification 
 The DNA encoding the catalytic domain of AMSH was amplified by PCR using a 
plasmid that contained full-length DNA as the template (pGEX-6p1-AMSH, a kind gift 
from Sylvie Urbe, University of Liverpool, UK) and was subcloned into pGEX-6p1 (GE 
Biosciences) by using standard cloning protocols.  The resulting N-terminally fused 
glutathione S-transferase (GST)-tagged protein was expressed in Escherichia coli Rosetta 
cells (Novagen) and purified with a glutathione-Sepharose column (GE Biosciences) 
following manufacturer’s instructions.  After removal of the tag by PreScission protease 
(GE Biosciences), the protein was further purified by size-exclusion chromatography 
(SEC) using Superdex S75 column (GE Biosciences).   
 The series of individual point mutations were introduced into the AMSH catalytic 
domain gene by site-directed mutagenesis using QuikChange Site-Directed Mutagenesis 
Kit (Stratagene) following manufacturer’s protocol.  DNA sequencing confirmed the 
presence of the mutations.  The resulting proteins were purified using standard GST-
affinity chromatography followed by SEC (Superdex S75 column).  
  Human ubiquitin (residues 1-75) was subcloned into pGEX-6p1 and purified 
using GST affinity chromatography, and the GST tag was removed by PreScission 
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Protease.  The protein was further purified using SEC (Superdex S75 column).  Lys63-
diubiquitin was enzymatically synthesized from ubiquitin using ATP, human E1, and the 
E2 complex (Ubc13 and Uev1a) following previously reported procedures.1  The reaction 
was incubated at 37C for 2 h and then quenched by dilution with buffer A (50 mM 
sodium acetate, pH 4.5).  The quenched reaction mixture was subjected to ion-exchange 
chromatography on a Mono-S column (GE Biosciences) to obtain Lys63-diubiquitin. 
 
3.2.2 Determination of Kinetic Parameters 
 The qualitative in vitro DUB assay was carried out by incubating wild-type 
AMSH244, wild-type AMSH219, wild-type AMSH219 (expressed and purified in the 
absence of DTT) (AMSH219-DTT), AMSH219C282A (expressed and purified in the absence 
of DTT), and AMSH219E280A to a final enzyme concentration of 100 nM with 20 M 
K63-linked diubiquitin in a total reaction volume of 20 L.  All reactions were carried 
out in reaction buffer (50 mM TRIS-HCl pH 7.0, 25 mM KCl, 5 mM MgCl2, and 1 mM 
DTT) for one hour at 20C, except AMSH219-DTT and AMSH219C282A were incubated in 
the same reaction buffer without the 1 mM DTT. The reaction was quenched by the 
addition of 5X SDS-PAGE sample buffer followed by boiling, and then analyzed by 
SDS-PAGE.    
 The kinetic parameters of AMSH244 were determined by incubating 100 nM of 
enzyme with four concentrations of diubiquitin ranging from 20-100 M in reaction 
buffer (50 mM TRIS-HCl pH 7.0, 25 mM KCl, 5 mM MgCl2, and 1 mM DTT) along with 
ubiquitin standards ranging from 4-12.3 g.  The reaction was carried out at 20C for 15 
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minutes for initial velocity measurements.  Reaction tubes were quenched by the addition 
of 5X SDS-PAGE sample Buffer followed by boiling.  The reaction mixtures were 
visualized by SDS-PAGE gels and scanned.  Bands corresponding to ubiquitin were 
integrated using ImageJ software (http://rsb.info.nih.gov/ij/).  Kinetic parameters were 
calculated by fitting the data in SigmaPlot. 
 The kinetic parameters were determined by incubating the enzymes (25 nM 
T313A, 100 nM C282A, N312A, T313I, E317A, and F320A, 2 M E316A and F395A, 3 
M T341A and S346A, and 10 M F343A and S345A) with four concentrations of 
diubiquitin, ranging from 20 to 177M, in reaction buffer (50 mM TRIS-HCl (pH 7.0), 
20 mM KCl, 5 mM MgCl2 and 1 mM DTT).  The reaction was carried out at 20C for 10-
75 min depending on activity for initial velocity measurements.  Reaction tubes were 
quenched as described above. Ubiquitin quantification and kinetic parameters were 




3.3.1 Qualitative Analysis of the Kinetic Activity of AMSH  
 The previous chapter discusses the crystal structures of two constructs of the 
catalytic domain of AMSH, AMSH244 and AMSH219E280A.  Within the AMSH219E280A 
structure we found a potential disulfide bridge between Cys282 and Cys311 that is 7.4Å 
away from the active-site Zn2+.  In order to understand if the varying lengths of AMSH 
and if Cys282 has any effect on the activity of the enzyme, we carried out a qualitative 
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Lys63-linked diubiquitin cleavage assay.  It was found that the catalytic activities of 
AMSH244 and AMSH219 are similar (Figure 3.1), suggesting that the SH3 domain-
binding peptide segment does not fold onto the catalytic domain, at least not in way to 
influence diubiquitin binding. As expected, the E280A mutant is still catalytically 
inactive despite having the zinc in place (Figure 3.1), as determined from the x-ray 
crystal structure. To probe if the oxidation state of Cys282 is important for the catalytic 
activity of the enzyme, a mutant that would lack the disulfide bond (the Cys282 to Ala 
mutant) was introduced and purified without DTT at all steps. The catalytic activity of 
the Cys282Ala mutant appears to be similar to the wild-type protein’s activity (the 
mutant retains ~80 % of activity seen with the wild type) (Figure 3.1).  
 
3.3.2 Comparison of the Kinetic Activities of AMSH and AMSH-LP  
 The overall three-dimensional fold of the catalytic domains of AMSH and 
AMSH-LP are structurally identical, having conserved active-site residues and 
architecture; we proceeded to understand if there are differences between the two 
enzymes kinetically. We found that AMSH244 is catalytically less efficient than the 
DUB domain of AMSH-LP, with most of the difference being contributed by a kcat that is 
10-fold less, but with a slightly better KM (2-fold lower) (Table 3.1 and Figure 3.2).  
 
3.3.3 Mutational and Kinetic Analysis of the Catalytic Domain of AMSH  
 To gain insight into how AMSH would recognize Lys63-linked diubiquitin, a 
model of AMSH244 bound to Lys63-linked ubiquitin dimer was generated by 
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superimposing AMSH244 onto the previously determined X-ray structure of the DUB 
domain of AMSH-LPE292A bound to Lys63-linked ubiquitin dimer (PDB code: 2ZNV) 
(Figure 3.3).1 The overall structure of AMSH244 is similar to ubiquitin-bound DUB 
domain of AMSH-LP with an rmsd (root mean square deviation) of 0.93Å of C atoms. 
This level of structural similarity suggests that the mode of diubiquitin binding seen in 
the model would be preserved in the actual structure of AMSH244 bound to Lys63-
linked diubiquitin. To further validate that AMSH does indeed have a very different 
catalytic mechanism compared to AMSH-LP based on the difference in catalytic activity, 
we introduced individual point mutations within the AMSH catalytic domain gene and 
carried out an extensive kinetic analysis. 
 
3.3.3.1 Active Site 
 The active site of AMSH consists of a Zn2+ ion, coordinated directly by three 
residues (Asp348, His 335, and His337) and a water molecule that is hydrogen bonded to 
Glu280, and a putative oxy-anion stabilizing residue (Ser345) (Figure 3.4). In order to 
probe the roles of Asp348 and Glu280, we generated two aspartate mutants (D348A and 
D348N) and a glutamate mutant (E280A) and, as expected, found that there was no 
detectable activity in these mutants (Table 3.2), most likely due to the loss of Zn2+ for the 
aspartate mutations and the loss of the water molecule in the glutamate mutation.  
 Next, we probed the function of the putative oxy-anion hole-stabilizing residue, 
Ser345. Mutating serine to alanine resulted in a significantly impaired enzyme with a 
1000-fold reduction in kcat (Table 3.2). As described with other families of hydrolases, the 
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oxy-anion hole-stabilizing residue plays a critical role in donating a hydrogen bond to the 
negatively charged tetrahedral intermediate formed after the initial nucleophilic attack. 
Substantial reduction of kcat alone upon mutation to alanine, with KM remaining nearly the 
same, is consistent with Ser345 playing the role as the oxy-anion stabilizing residue in 
AMSH.  
 In our previous structural analysis, we noted a potential disulfide bridge between 
Cys282 and Cys311, 7.4Å away from the active-site Zn2+.3 Previous studies have shown 
that N-ethylmaleimide (NEM) inhibits AMSH activity (IC50 of 16.2 3.2 M),4; 5 
presumably by modifying one of these two cysteines, perhaps Cys282 because it is 
proximal to the active-site cleft. Its modification might introduce some steric hindrance 
for substrate binding thus explaining the inhibitory effect. We sought to determine if 
Cys282 has any role in the catalytic activity of the enzyme.  Previously, when Cys282 
was mutated to alanine, we noticed a loss of activity,3 however, a more detailed kinetic 
analysis of this mutant revealed a more significant reduction in activity, a 6-fold loss in 
kcat (Table 3.2), which would suggest that Cys282 does indeed have a role in catalysis. 
Cys282 is seen making a van der Waals contact with Leu73 of the distal ubiquitin, which 
may explain the reduction in activity observed here. 
 
3.3.3.2 Proximal Ubiquitin Site 
 Modeling of the catalytic domain of AMSH onto the structure of AMSH-LP 
bound to Lys63-linked diubiquitin revealed four residues within AMSH (Thr341, 
Phe343, Ser346, and Phe395) that could determine its specificity for Lys63-linked 
polyubiquitin chains by recognizing the tri-peptide sequence motif Gln62-Lys63-Glu64 
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within the proximal ubiquitin, which encompasses the acceptor Lys63 and its two 
immediate flanking residues.  Individual point mutants (to alanine) were generated and 
kinetic analysis was performed to probe the functional significance of these residues. 
Overall, the four resides within AMSH showed a drastic reduction in kcat with similar KM 
values compared to the wild-type enzyme, confirming their utmost importance to the 
enzyme’s catalytic mechanism (Figure 3.5 and Table 3.2), especially during the rate-
determining step of isopeptide bond hydrolysis. 
 
3.3.3.3 Distal Ubiquitin Site 
 The distal site is where AMSH significantly differs from AMSH-LP in diubiquitin 
recognition. Three substitutions are found going from AMSH-LP to AMSH: an aspartate 
to asparagine, a methionine to a threonine, and a valine to glutamate.  Two other 
important residues within the distal site are completely conserved between AMSH and 
AMSH-LP, a phenylalanine (Phe320, AMSH numbering) and a glutamate (Glu317) 
(Figure 3.6).  The conserved Phe320 when mutated to alanine exhibited a 4-fold 
reduction in kcat and 3-fold increase in KM, whereas, the Glu317Ala mutant exhibits 
somewhat similar activity to the wild type, with only a modest 2-fold reduction in kcat 
(Table 3.2).   
 Moving forward, individual point mutations of the three substitutions between 
AMSH and AMSH-LP revealed some interesting results.  Mutating Asn312 to alanine 
yielded only an approximate 3-fold reduction in kcat (Table 3.2).  Surprisingly, a 
qualitative diubiquitin cleavage assay revealed that Thr313Ala was apparently more 
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active than the wild type (Figure 3.7), however, detailed kinetic analysis showed simply 
an approximate 2-fold increase in kcat, with a ~3-fold loss in KM (Table 3.2).   
 Mutating the Glu316 to alanine proved to cause the most significant change in 
enzymatic activity amongst the distal site residues. Glu316Ala showed a substantial 74-
fold reduction in kcat (Table 3.2).  This kcat effect differs strikingly from the distal site 
residues from AMSH-LP whose mutation to Ala showed a loss primarily in KM.1 The 
effect of the glutamate mutation in AMSH mirrors that of residues from the proximal site.  
Inspection of the AMSH-diubiquitin model reveals that Glu316 is within hydrogen-
bonding distance from two distal ubiquitin residues: Arg42 is within 3.1Å (N of Arg42 
and O of Glu316), and Gln49 is within 2.8Å, if the side chain is flipped by 180 (Figure 
3.6).  A significant loss in kcat but not in KM is consistent with these hydrogen-bonding 
interactions contributing to the stabilization of the transition state, perhaps by playing a 
role in orienting the scissile peptide bond for nucleophilic attack.   
 
3.3.4 Kinetic Characterization of the Effect of the MIC-CAP-associated Mutation, 
Thr313Ile 
 
 To better understand the molecular basis of the MIC-CAP syndrome, the 
Thr313Ile (T313I) mutant was generated and analyzed for its catalytic activity towards 
Lys63-diubiquitin. In the absence of a structure, a modeled AMSH-diubiquitin structure 
suggests that the side-chain hydroxyl from threonine is hydrogen bonded to the backbone 
NH group of Leu73 in the distal ubiquitin (Figure 3.7). The T313I mutant was found to 
suffer a 6-fold reduction in kcat, with a comparable KM (Table 3.2). This result indicates 
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that the reduced catalytic activity of the mutant, with a similar thermodynamic stability, 
could lead to a loss of function of AMSH translating into the disease state.  
 
3.4 Discussion 
 Our kinetic analysis using site-directed mutants of conserved residues in the 
proximal ubiquitin binding site has shown that AMSH’s specificity for Lys63-linked 
polyubiquitin chains arises from its recognition of the proximal ubiquitin, similar to the 
case of AMSH-LP.1 Lys63-linked chain specificity for AMSH plays a significant role in 
understanding its function as an ESCRT-DUB.  Since Lys63-linked polyubiquitin chains 
are targeting signals for ESCRT-mediated degradation, the specific DUB activity of 
AMSH may play a central role in the persistent functionality of the ESCRT machinery. 
Mutation of the proximal ubiquitin binding residues causes drastic reduction in kcat, 
suggesting that recognition of the tri-peptide sequence motif Gln62-Lys63-Glu64 within 
the proximal ubiquitin plays a significant role AMSH’s ability to cleave Lys63-linked 
polyubiquitin chains.   Recognition of Lys63 isopeptide bond and its two flanking 
residues in the proximal ubiquitin would mean that AMSH could only efficiently 
hydrolyze bonds between successive ubiquitins in a polymeric chain, and not the last 
ubiquitin directly attached to a protein receptor (the cargo).  This impediment toward 
completely deubiquitinating a ubiquitinated receptor could have multiple functional 
implications. At the outset, it calls into question the functional role of AMSH when it is 
recruited to ESCRT-III, where complete deconjugation of a ubiquitinated cargo is the 
absolute desire, since ubiquitin will otherwise end up in intralumenal vesicles (ILVs) 
attached to the cargo and will be subsequently degraded in the lysosome. It seems 
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unlikely that AMSH can have a significant catalytic role with respect to hydrolyzing the 
last ubiquitin attached to the cargo, yet, AMSH binds to ESCRT-III component CHMP3 
with relatively high affinity.  
 Our data on mutational analysis of the distal ubiquitin binding residues offer some 
interesting insights. Of the three residues different between AMSH and AMSH-LP, two 
of them, Glu316 and Thr313, contribute significantly to catalysis playing different roles 
than the corresponding residues in AMSH-LP. The AMSH residue Glu316 contributes to 
stabilization of the transition state as indicated by the largely kcat effect when it is mutated 
to Ala, in contrast to mostly a KM effect observed when the corresponding residues Val in 
AMSH-LP mutated to Ala.1 Thr313 in our AMSH-diubiquitin model is seen making a 
hydrogen bonding contact with the backbone NH group of Leu73 of the distal ubiquitin 
using its side-chain hydroxyl group and its methyl group is engaged in van der Waals 
contact with the aliphatic side groups of Leu73 from ubiquitin. Its substitution with Ile as 
seen in children with the MIC-CAP syndrome is expected to preserve the van der Waals 
contact but loose the hydrogen bond. Our data show that the substitution of the Thr to an 
Ile has minimal effect on protein folding and stability, but results in a significantly 
reduced catalytic efficiency. Going from AMSH to AMSH-LP, the Thr residue is 
replaced by Met, which could contribute only van der Waals interaction with the 
substrate. Thus, it appears that the hydrogen-bonding interaction of Thr in AMSH has a 
unique role whose loss leads to a dramatic effect resulting in a loss of function substantial 
enough to cause the disease. Overall, these results indicate that subtle differences 
between very similar enzymes can have profound functional effect.6 Another important 
thing that our kinetic data has shown is that AMSH and AMSH-LP are more different 
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than initially thought.  Sharing very close homology and structural similarities usually 
allow for these two proteins to be used interchangeably.  Our distal site mutational and 
kinetic analysis reveals that the differences are on the scale of individual residue 
differences.  We saw three residue changes between AMSH and AMSH-LP and one of 
those, Thr313, is found in children with MIC-CAP syndrome.  It is interesting to see that 
a simple modification of the threonine to an isoleucine has minimal effect on protein 
folding and stability, but has significantly reduced catalytic properties.  Then again we 
see that Glu316 plays a surprisingly downstream catalytic role within AMSH as well.  
This shows that not only does AMSH-LP lack the functional domains required to be 
recruited to the ESCRT machinery, but also, that AMSH has inherent catalytic regulatory 
mechanism that lay within its amino acid sequence, that when modified proves to be very 
detrimental.  
  Overall, the kinetic analysis of AMSH reveals that even though AMSH has a 
similar structural makeup and sequence homology to AMSH-LP, AMSH is hardwired to 
function significantly different than AMSH-LP.  Beginning with the 10-fold difference in 
the activity of the wild type protein to the three residue differences in the distal ubiquitin 
binding site, AMSH has the necessary characteristics that promote its function within the 
ESCRT complex.  The most important thing these kinetic analyses have shown is that 
small residue level changes can translate into significant differences in protein function.  
These data provide further evidence that AMSH plays an exquisite and necessary 
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Figure 3.1. K63-linked AMSH Activity Assay.  Lane 1. Diubiquitin.  Lane 2.  
AMSH244. Lane 3.  AMSH219WT. Lane 4.  AMSH219-DTT. Lane 5. 




















*Kinetic parameters reported from Sato et al. Nature (2008). Differences in values 


















Figure 3.2. Michaelis-Menten curves for AMSH244 and AMSH-LP DUB.  Plots 
of initial velocity versus substrate concentration for which the kinetic parameters 















Figure 3.3. A model of AMSH244 bound to Lys63-linked ubiquitin dimer.  
Backbone superposition of AMSH244 (green), the DUB domain of AMSH-LP 
(cyan), and the DUB domain of AMSH-LP bound to Lys63-linked diubiquitin 
(gray).  The proximal ubiquitin and distal ubiquitin are shown in magenta and 


















Figure 3.4. A view of the active site of AMSH.  The active-site Zn2+ is shown as a 





























Figure 3.5. View of the residues involved in the proximal ubiquitin recognition. 
Superposition of AMSH244 (green ribbon), the DUB domain of AMSH-LP (cyan ribbon) 
and the DUB domain of AMSH-LP bound to Lys63-linked diubiquitin (gray ribbon). 

















Figure 3.6. View of the residues involved in the distal ubiquitin recognition. 
Superposition of AMSH244 (green ribbon) and the DUB domain of AMSH-LP 
bound to Lys63-linked diubiquitin (gray ribbon). The distal ubiquitin is shown in 
yellow.  Hydrogen bonding interactions are shown as black dashes and van der 









Figure 3.7.  Qualitative DUB Lys63-diubiquitin cleavage assay of the residues 
within AMSH’s catalytic domain that recognize the distal ubiquitin.  Lane 1: 
Lys63-diubiquitin. Lane 2: AMSH219WT. Lane 3: N312A. Lane 4: T313A. Lane 















Figure 3.8. Structural modeling of the interaction between Thr313 and the distal ubiquitin 







CHAPTER 4: MECHANISM OF AMSH RECRUITMENT AND ACTIVATION AT 
ESCRT-0 
4.1 Introduction 
 The aim of this chapter is to provide further evidence in support of the exquisite 
role of AMSH as an important regulator of the ESCRT machinery by revealing a 
mechanism for enzyme activation at ESCRT-0 and to assign a role for AMSH at ESCRT-
0.  I have employed a biophysical and biochemical approach to probe the function of 
AMSH at ESCRT-0. It was found that diubiquitin and ubiquitin bind with similar 
affinities to the catalytic domain of AMSH, suggesting only one binding site for 
ubiquitin, which sets up a mechanism for how the ESCRT-0 member, STAM, supports 
AMSH-diubiquitin binding.  Using the minimal domains of STAM, the UIM and SH3 
domains, both AMSH and ubiquitin binding to STAM were characterized, and then, the 
ternary complex of AMSH, the SH3 domain fused to its N-terminally adjacent UIM 
(UIM-SH3), and Lys63-linked diubiquitin were kinetically characterized. The AMSH-
SH3 interaction was confirmed by both isothermal titration calorimetry (ITC) and 
analytical ultracentrifugation (AUC). Furthermore, UIM-ubiquitin binding was assessed 
by ITC, however, unexpectedly, the SH3 domain of STAM was shown to binds ubiquitin 
independently, with similar affinity to the UIM.  Building up the ternary complex 
revealed the role of UIM in stimulating AMSH activity in which mutations within the 
UIM and SH3 domains failed to recapitulate this activation phenomenon, suggesting that 
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an intact AMSH-SH3 interaction and a functional UIM is required for AMSH activation. 
These data together suggest a model for how AMSH would work at ESCRT-0 in which 
diubiquitin is held in tandem by both the enzyme and the UIM of STAM, stabilizing the 
chain, thus, stimulating the activity of the enzyme. This model suggests that AMSH has 
the role of promoting cargo shuttling from ESCRT-0 to the subsequent complexes.     
4.2 Materials and Methods 
 
4.2.1 Cloning, Expression, and Purification 
 The DNA encoding the catalytic domain of AMSH was amplified by PCR using a 
plasmid that contained full-length DNA as the template (pGEX-6p1-AMSH, a kind gift 
from Sylvie Urbe, University of Liverpool, UK) and was subcloned into pGEX-6p1 (GE 
Biosciences) by using standard cloning protocols.  The resulting N-terminally fused 
glutathione S-transferase (GST)-tagged protein was expressed in Escherichia coli Rosetta 
cells (Novagen) and purified with a glutathione-Sepharose column (GE Biosciences) 
following manufacturer’s instructions.  After removal of the tag by PreScission protease 
(GE Biosciences), the protein was further purified by size-exclusion chromatography 
(SEC) using Superdex S75 column (GE Biosciences).   
 The series of individual point mutations were introduced into the AMSH catalytic 
domain gene by site-directed mutagenesis using QuikChange Site-Directed Mutagenesis 
Kit (Stratagene) following manufacturer’s protocol.  DNA sequencing confirmed the 
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presence of the mutations.  The resulting proteins were purified using standard GST-
affinity chromatography followed by SEC (Superdex S75 column).  
 The DNA encoding the SH3 and UIM-SH3 domains was amplified by PCR using 
a plasmid that contained the full-length DNA as the template (pGW1Myc2c-STAM2, a 
kind gift from Craig Blackstone, National Institutes of Neurological Disorders and Stroke 
(NINDS) at the National Institutes of Health (NIH)) and was subcloned into pGEX-6p1 
(GE Biosciences) using standard cloning protocols.  The resulting N-terminally fused 
GST-tagged protein was expressed in E. coli Rosetta cells (Novagen) and purified with a 
glutathione-Sepharose column (GE Biosciences) following manufacturer’s instructions.  
After removal of the tag by PreScission protease (GE Biosciences), the protein was 
further purified by size-exclusion chromatography (SEC) using Superdex S75 column 
(GE Biosciences).  
 The A176G mutation was introduced into the UIM-SH3 gene by site-directed 
mutagenesis using QuikChange Site-Directed Mutagenesis Kit (Stratagene) following 
manufacturer’s protocol.  DNA sequencing confirmed the presence of the mutations.  The 
resulting proteins were purified using standard GST-affinity chromatography followed by 
SEC (Superdex S75 column). 
 Human ubiquitin was subcloned into pGEX-6p1 and purified using GST affinity 
chromatography, and the GST tag was removed by PreScission Protease.  The protein 
was further purified using SEC (Superdex S75 column).  Lys63-diubiquitin was 
enzymatically synthesized from ubiquitin using ATP, human E1, and the E2 complex 
(Ubc13 and Uev1a) following previously reported procedures.1  The reaction was 
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incubated at 37C for 2 h and then quenched by dilution with buffer A (50mM sodium 
acetate, pH 4.5).  The quenched reaction mixture was subjected to ion-exchange 
chromatography on a Mono-S column (GE Biosciences) to obtain Lys63-diubiquitin. 
 
4.2.2 DUB Assay 
The initial in vitro DUB assay was carried out by incubating AMSH (residues 
219-424) to a final enzyme concentration of 100 nM with 1 M of the SH3 domain of 
STAM2 or UIM-SH3 gene of STAM2, and 20 M Lys63-diubiquitin in a total reaction 
volume of 20 L.  All reactions were carried out in reaction buffer (50 mM TRIS-HCl 
(pH 7.0), 25 mM KCl, 5 mM MgCl2, and 1 mM DTT) for 5 h at 20C.  The reaction was 
quenched by the addition of 5X SDS-PAGE sample buffer followed by boiling and then 
analyzed by SDS-PAGE.  
The in vitro DUB assay to probe the contribution of the SBM and UIM was 
carried out by incubating AMSH (residues 219-424) to a final enzyme concentration of 1 
M with 5 M of the STAM binding partner, and 20 M Lys63-diubiquitin in a total 
reaction volume of 20 L.  These reactions were carried out in the same reaction buffer 
as before at 37C for 15 minutes.  The reactions were quenched and visualized as above.   
 
4.2.3 Analytical Ultracentrifugation 
 Sedimentation velocity experiments were conducted at 50,000 rpm using the 
Beckman Coulter XLA and XLI (Beckman Coulter, Fullerton, CA, USA).  The samples 
were monitored by both interference and absorbance optics at 254 and 280 nm.  The 
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proteins were dialyzed in 50 mM TRIS-HCl pH 7.6, 50 mM NaCl.  Three concentration 
series for AMSH (residues 219-424) were conducted to evaluate the formation of higher-
order species at 24, 48, and 96 M. The AMSH-SH3 complex was characterized using a 
constant concentration of 23.5 M of AMSH and three concentrations of SH3 at 24, 47, 
and 70 M. The AMSH-UIM-SH3 complex was characterized using a constant 
concentration of 23.5 M of AMSH and three concentrations of 48, 144, and 288 M. 
The AMSH-ubiquitin complex was characterized using a constant concentration of 23.5 
M of AMSH and two concentrations of ubiquitin at 23 and 92M. The AMSH-
diubiquitin complex was characterized using a constant concentration of 23.5 M of 
AMSH and three diubiquitin concentrations at 24, 48, and 96 M. The solvent density 
(1.00170 g.ml-1), viscosity (0.01022 poise), and the partial specific volumes that were 
used for the analyses, 0.73387 ml.g-1 (AMSH219), 0.71870 ml.g-1 (AMSH-SH3), 
0.71701 ml.g-1 (AMSH-UIM-SH3), 0.72934 ml.g-1 (AMSH-diubiquitin), and 0.72479 
ml.g-1 (AMSH-ubiquitin), were calculated by SEDNTERP v. 20120828 BETA 
(http://bitcwiki.sr.unh.edu/index.php/Main_Page).2 The sedimentation coefficients and 
apparent molecular weights were calculated from size distribution analyses [c(s)] using 
SEDFIT v. 14.3e.3; 4 The figures were prepared using GUSSI v. 1.0.7b beta with the 
sedimentation coefficients standardized to s20,w and the data was normalized to the peak 
area of the complexes.   
 Sedimentation equilibrium experiments were conducted at 20C using a 6-channel 
centerpiece in an AN-60 Ti rotor spun at speeds of 13,200, 29,900, and 42,000 rpm for 
the AMSH-ubiquitin complex and 11,600, 21,000, and 36,000 rpm for the AMSH-
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diubiquitin complex. The molar ratios of the AMSH-ubiquitin complex were: 1:2, 1:4, 
and 1:8, and the molar ratios of the AMSH-diubiquitin complex were: 1:2, 1:4, and 1:5, 
to determine the molecular weight of the complexes. Absorbance scans at 280 nm were 
taken every 2 hours for 60 hours. The samples were tested for equilibrium using Sedfit.3; 4   
Calculations of the molecular weights were done by SEDPHAT v. 10.58d 5; 6; 7; 8; 9; 10 
using the Species Analysis and Species Analysis with Mass Conservation Constraints.  
Errors were calculated using 1-dimensional error surface projections. Final figures were 
generated in GUSSI. 
 
4.2.4 Isothermal Titration Calorimetry 
 To determine the KDs of AMSH binding to ubiquitin, ITC experiments were 
conducted using the MicroCal ITC200 (GE Healthcare Life Sciences).  The proteins were 
dialyzed in the same buffer as was used for AUC.  For the AMSH-diubiquitin 
experiment, 10 M AMSH was in the cell and 500 M of diubiquitin was in the syringe.  
The AMSH-ubiquitin titration had 100 M AMSH in the cell, and 1 mM ubiquitin in the 
syringe. The F320A mutant of AMSH with ubiquitin had 100 M of the enzyme in the 
cell, and 1 mM of ubiquitin in the syringe. These experiments were done at 20C, 18 total 
injections of 1.4 L per injection, with 180 seconds in between injections to allow for a 
return to baseline before the subsequent injection.  The data was then baseline corrected 
by NITPIC 11 and loaded into SEDPHAT 5; 6; 7; 8; 9; 10 for global analysis and fitting using 
a 1:1 model.  Figures were prepared using GUSSI.  To determine the KD for the AMSH-
SH3 interaction, 50 M of AMSH was in the cell and 750 M of the SH3 domain was in 
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the syringe.  KD of AMSH-UIM-SH3 interaction was determined using 100 M AMSH 
in the cell and 1 mM UIM-SH3 in the syringe.  AMSHK238T-UIM-SH3 experiment was 
conducted using 50 M of the enzyme in the cell and 1 mM of UIM-SH3 in the syringe. 
Characterization of ubiquitin binding to UIM-SH3 was done using 50 M UIM-SH3 was 
in the cell and 3.1 mM ubiquitin in the syringe.  This data was fit to a two-site model.  
Confirmation of SH3-ubiquitin binding was done with 100 M of SH3 in the cell and 3.0 
mM ubiquitin in the syringe.  The UIM-SH3-Lys63-diubiquitin experiment had 50 M of 




4.3.1 Biophysical Characterization of Ubiquitin Binding to the Catalytic Domain of 
AMSH  
 
Mutational and kinetic analyses from the previous chapter prompted us to seek a 
better understanding of AMSH-ubiquitin complex formation in solution. Using 
isothermal titration calorimetry (ITC), we analyzed the binding of Lys63-linked 
diubiquitin and the catalytic domain of AMSH (AMSH 219-424E280A, an inactive mutant 
to ensure diubiquitin is not hydrolyzed), and obtained an equilibrium dissociation 
constant (KD) of 19  4 M (Figure 4.1b and Table 4.1).  As a control, ubiquitin and the 
catalytic domain of AMSH was analyzed and it was determined that it binds AMSH with 
similar affinity of 19  3 M (Figure 4.1a and Table 4.1). Both sedimentation velocity 
and sedimentation equilibrium experiments using analytical ultracentrifugation (AUC) 
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confirmed the ITC results (Figure 4.2, Figure 4.3, and Table 4.2).  Almost identical 
binding affinities between diubiquitin and ubiquitin to AMSH’s catalytic domain suggest 
that there is only one binding site for ubiquitin.  To probe which ubiquitin binding site is 
used, another ITC experiment was done with AMSHPhe320Ala (Phe320 at the distal site is 
mutated to Ala) and ubiquitin.  We observed a ~4-fold decrease in affinity (KD of 81  15 
M) (Figure 4.1c and Table 4.1), consistent with what was observed from kinetics, 
suggesting that the distal ubiquitin makes the most significant contribution to diubiquitin 
binding, and the single binding site observed in our ITC experiments with ubiquitin 
corresponds to binding at the distal site.  These data suggest that AMSH alone cannot 
discriminate between its polyubiquitin substrate and its ubiquitin product.    
 
4.3.2 The Intact Minimal STAM Construct UIM-SH3 is Necessary for AMSH Activation 
 The I44 patch, a hydrophobic surface centered on the Ile44 residue from 
ubiquitin, is ubiquitously used by proteins that specifically bind to ubiquitin, including 
DUBs. Inspection of our structural model representing AMSH-diubiquitin complex 
reveals that the I44 patch of the distal ubiquitin is satisfied, with the Ile44 residue 
engaged in van der Waals interaction with Phe320; however, Ile44 of the proximal 
ubiquitin is unoccupied (Figure 4.4).  Looking at the domain structure of the ESCRT-0 
member, STAM, one finds a UIM (ubiquitin-interacting motif) N-terminally adjacent to 
its SH3 domain (Figure 4.5).  We sought to understand if the UIM, separated from the 
SH3 domain by a short linker, could act as an adaptor to AMSH by interacting with the 
proximal ubiquitin while AMSH’s engages the distal one.  To probe this, we used a 
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combination of biophysical techniques and biochemical assays to assess three individual 
events: (1) AMSH recruitment to STAM via the SH3 domain and a longer STAM 
segment in which the UIM is fused to the SH3 domain (UIM-SH3), (2) ubiquitin binding 
to UIM-SH3, and finally, (3) the ternary complex of the catalytic domain of AMSH, 
UIM-SH3, and Lys63-linked diubiquitin. 
 
4.3.2.1 AMSH Binds to the SH3 Domain of STAM2 
 To confirm that we have the minimal domains required for the AMSH-STAM 
interaction we carried out ITC and AUC experiments.  We determined that the SH3 
domain of STAM binds the catalytic domain of AMSH (AMSH219E280A) with a KD of 
1.4  0.04 M (Table 4.1 and Figure 4.6).  Using the longer UIM-SH3 construct, we 
obtained an identical KD of 1.9  0.1M (Table 4.1 and Figure 4.6), both of which are 
consistent with a previous ITC study, which showed that a peptide representing the SBM 
from AMSH binds the SH3 domain with 7 M affinity.12 Using an orthogonal and 
complementary technique, we confirmed complex formation by sedimentation velocity 
experiments using AUC and determined that the catalytic domain of AMSH forms a 1:1 
complex. The respective s20,w values of 2.5S and 2.6S for the SH3 domain and UIM-SH3 






4.3.2.2 Both SH3 Domain and UIM of STAM Bind Ubiquitin Independently 
 Secondly, we characterized ubiquitin binding to the UIM of STAM.  Since UIMs 
are only 30-residue domains, much too small for bacterial expression, we used UIM-SH3 
to investigate UIM-ubiquitin binding by ITC.  Somewhat surprisingly, we found that both 
the UIM and SH3 domains bind ubiquitin independently. This observation was based on 
two pieces of evidence. (1) The UIM-SH3 construct binds ubiquitin with a KD of 273  
16 M, in agreement with previous biosensor measurements of a STAM-derived UIM 
peptide binding to ubiquitin that provided a KD of 182 M.13 (2) Interestingly, our 
measurement of SH3-ubiquitin binding by ITC resulted in a KD of 62  7 M (Figure 
4.8b and Table 4.1). It has been shown previously that a subset of SH3 domains bind 
ubiquitin,14; 15 and a recent study using NMR titration experiments showed that the SH3 
domain of STAM does in fact bind ubiquitin, and that this interaction can be competed 
off by USP8 binding to the SH3 domain of STAM.16 Taken together, these data seem to 
indicate that both the SH3 domain and the UIM bind ubiquitin independently, with the 
former having higher affinity than the latter, which would explain the overall KD of 273  
15 M obtained as the binding affinity of the UIM-SH3 construct for ubiquitin. It is 
possible that the two binding events corresponding to the two binding sites on UIM-SH3 
have similar enthalpy of binding, and with binding affinities not drastically different 
between them, the ITC experiment is unable to resolve them distinctly.  
          Alternatively, it is possible that the UIM and SH3 domain fold onto each other 
generating a weaker interface for ubiquitin than either of them alone. This seems unlikely 
since UIM-SH3 binds to Lys63-linked diubiquitin with a KD of 54  20 M (Figure 4.8c 
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and Table 4.1), an affinity higher than that of UIM-SH3 for ubiquitin. These results are 
consistent with the principle of avid binding of polyubiquitin chains at ESCRT-0, thus 
indicating that both the UIM and SH3 domain in UIM-SH3 are accessible for ubiquitin 
binding.    
 
4.3.2.3 UIM and SH3 Domains are Necessary for Stimulating the Activity of AMSH  
 Using the catalytic domain of AMSH, UIM-SH3 and Lys63-linked diubiquitin, 
we attempted to recapitulate AMSH recruitment to ESCRT-0 in vitro.  We carried out a 
Lys63-diubiquitin DUB cleavage assay with the AMSH:UIM-SH3 complex. The initial 
experiment comparing the enzyme’s activity alone and in the presence of the SH3 
domain and then, UIM-SH3, revealed a remarkable difference in DUB activity of AMSH.  
In the presence of UIM-SH3, it turned over nearly all of the Lys63-diubiquitin to 
ubiquitin, whereas, AMSH alone or in the presence of simply the SH3 domain had a 
significant amount of diubiquitin remaining, suggesting a stimulatory role for UIM-SH3 
(Figure 4.9). 
 Diving deeper into the mechanism of activation, a similar in vitro assay was 
performed, this time using two SBM, and one UIM mutant versions of the UIM-SH3 
construct (Figure 4.10). Two individual point mutations within the SBM of AMSH were 
introduced (Lys238Ala and Lys238Thr) to obliterate the SH3-SBM interaction. Lys238 is 
a completely conserved residue in the canonical SBM motif known to bind SH3 domains, 
mutating this to threonine made AMSH look like AMSH-LP in terms of its SBM.  
AMSH-LP has the conserved set of residues within its SBM, except   the critical Lys 
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replaced by Thr.  We confirmed that there was no binding between the AMSH SBM 
mutants and the SH3 domain using ITC (Figure 4.11). Secondly, we introduced a 
mutation within the UIM of UIM-SH3 (Ala176Gly) to interrupt ubiquitin binding (Figure 
4.10). The Ala to Gly mutation has been shown previously to cause significant reduction 
in ubiquitin binding.13 The diubiquitin cleavage reactions were performed at 37C for 15 
minutes using 1 M enzyme, 20 M Lys63-linked diubiquitin as the substrate, and 5 M 
STAM binding partner (SH3, UIMA176GSH3, or UIM-SH3). SDS-PAGE analysis 
revealed that only in the presence of the wild-type enzyme and UIM-SH3 is diubiquitin 
completely hydrolyzed to ubiquitin, hence, an intact SBM-SH3 interaction and a 
functional UIM are necessary for AMSH activation (Figure 4.10). 
 Furthermore, we wanted to understand this activation phenomenon in more detail, 
in terms of kcat and KM. To this end, we carried out another kinetic assay in which the 
catalytic domain of AMSH was pre-incubated in the presence of 20-fold excess UIM-
SH3 to ensure that equilibrium favors the formation of the AMSH-UIM-SH3 complex. 
We saw 6-fold activation in AMSH in the presence of UIM-SH3, contributed by a 
somewhat greater change in kcat than in KM (Table 4.3).  The kcat effect is not entirely 
surprising because the UIM interacts with the proximal ubiquitin, and as we have shown 
in our mutational and kinetic analysis, the proximal site plays a significant role in 
properly aligning the isopeptide bond within AMSH’s active-site, as determined by the 





 We found the minimal domain of STAM that is required to stimulate AMSH’s 
activity.  Previous work has shown that STAM has a role in AMSH activation towards 
Lys63 polymeric chains;12; 17 however, these studies were not able to fully elucidate the 
mechanism of activation.  Our study begins to divulge the mechanism underlying 
activation. This work suggests a simple model invoking simultaneous recognition of two 
ubiquitin groups in a polyubiquitin chain by AMSH and the UIM of STAM could explain 
the catalytic activation of the DUB. The UIM of STAM, separated from the SH3 domain 
by a short linker, could act as an adaptor for AMSH by interacting with the proximal 
ubiquitin, while AMSH engages the distal one. Such an arrangement would create a more 
extensive binding interface for diubiquitin in the AMSH:STAM complex than in the 
enzyme alone, causing catalytic activation. It appears that such activation is necessary 
since, as our ITC data show, AMSH has no preference for binding to Lys63-linked 
diubiquitin, therefore by extrapolation to Lys63-linked polyubiquitin chains over the 
ubiquitin product. 
 Prior to activation, AMSH is in a more latent state, but when it is recruited to 
STAM its full activity is unveiled.  AMSH is known to have diverse subcellular 
localization profiles.  Perhaps the free form of the enzyme needs to be in a less-active 
state so as not to hydrolyze the Lys63 chains that are present in the cytosol other than 
endosomes.  Once it is recruited to the endosomes, its true activity comes alive, as seen 
by the 6-fold enhancement in activity upon binding to the STAM derived UIM-SH3 
construct. A significant implication of this mechanism of activation is that the activation 
will be absent when AMSH is trying to cleave the last ubiquitin attached to the cargo. 
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While efficiently cleaving between two ubiquitin groups in a Lys63-linked polyubiquitin 
chain, AMSH might show a severe impediment in hydrolyzing the last ubiquitin attached 
directly to a cargo, on account of two factors: (1) its high specificity for the Lys63-linked 
chain between two ubiquitins, which in turn would make it a poor enzyme when ubiquitin 
is attached to a non-ubiquitin protein, the cargo; and, (2) the lack of an activation effect 
when cleaving ubiquitin attached to a non-ubiquitin moiety. 
 Finally, bringing all our data together, we can envision a mechanism for 
recruitment and activation for AMSH that will ultimately define a function for the 
enzyme.  ESCRT-0 has the defined function of ubiquitinated cargo clustering, capable of 
harboring up to eight ubiquitin moieties at a time,18; 19 which now, with the addition of 
the SH3 domain could be ten ubiquitins. Our ITC data show that the SH3 domain can 
actually bind ubiquitin tighter than the UIM. Subsequently, AMSH is recruited to STAM.  
The AMSH-SH3 binding affinity is stronger than SH3-ubiquitin, making it possible for 
AMSH to effectively displace ubiquitin from the SH3 domain (the binding interface on 
SH3 domain for the two proteins show substantial overlap) 16 leading to its recruitment to 
ESCRT-0. With the UIM from STAM acting as an adaptor to the enzyme, facilitating 
enzyme activity enhancement, AMSH begins to efficiently disassemble the polyubiquitin 
chain attached to the cargo.  Deubiquitination of the chain will continue until the last 
ubiquitin directly attached to the cargo. Thus, recruitment of AMSH to ESCRT-0 will 
lead to substantial chain trimming but not complete deconjugation of ubiquitin from the 
cargo. As discussed in the next paragraph, this would promote the cargo’s passage from 
ESCRT-0 to ESCRT-I and subsequent complexes.  
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  Our proposed mechanism defines AMSH as the DUB that facilitates cargo 
passage from ESCRT-0 onto the next complex.  This idea is supported by previous data 
that shows that avidly bound ubiquitin chains comprise of a binding affinity of ~20 M 
affinity,20 whereas, ESCRT-I subunit, UBAP1, binds ubiquitin anywhere from 70-140 
M.21 The affinity of ESCRT-0 for ubiquitin needs to be reduced at least 5-10-fold in 
order for cargo destined for lysosomal degradation to be transferred to ESCRT-I. When 
going from Lys63-linked tetra-ubiquitin to diubiquitin, ESCRT-0 has a ~6-fold reduced 
affinity, and a remarkable, 46-fold reduction in affinity for ubiquitin.20 Therefore, we 
presume that because of the specificity and activation of AMSH, this would be the 
enzyme that would be most suited for promoting cargo passage, all in support of an idea 
proposed previously.22 By occupying the binding site on ESCRT-0, AMSH will serve to 
keep USP8 off the initial ESCRT complex. The recruitment of USP8 at ESCRT-0 would 
be detrimental to the passage of cargo to lysosome because USP8 has no hindrance in 
complete deconjugation. We suggest that the role of USP8 is specifically at the ESCRT-
III level where complete deconjugation is desired.  
 In summary, using a combination of biochemical and biophysical studies, guided 
by a structural model, we are able to learn many important aspects of AMSH: (1) The 
T313I mutation underlying the MIC-CAP syndrome leads to a significant loss of catalytic 
activity owing to loss of a hydrogen-bonding interaction with ubiquitin. (2) Recognition 
of proximal ubiquitin contributes significantly to catalysis. (3) Activation of AMSH is 
enabled by facile, simultaneous binding to two ubiquitin groups in a polyubiquitin 
substrate, one by the catalytic domain of the DUB (binding to the distal ubiquitin) and the 
other (the proximal ubiquitin) by the UIM from STAM. (4) Taken together, the above 
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two points strongly indicate that AMSH will suffer a severe loss of catalytic efficiency 
when cleaving the last ubiquitin attached to cargo compared to a Lys63-linked 
polyubiquitin chain substrate. These studies provide biochemical and biophysical 
evidence in support of a hypothesis which postulates that AMSH is recruited to the initial 
ESCRT complex to facilitate transfer of cargo from one ESCRT member to the next, but 
not to completely deubiquitinate.23 AMSH recruitment therefore would facilitate cargo 
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Figure 4.1. Isothermal titration calorimetry (ITC) thermograms of ubiquitin 
binding to the catalytic domain of AMSH.  (a) ITC thermogram of ubiquitin 
binding to the catalytic domain of AMSH revealing a KD of 19  3 M.  (b) ITC 
thermogram of Lys63-linked diubiquitin binding to the catalytic domain of 
AMSH revealing a KD of 19  4 M.  (c) ITC thermogram of a Phe320Ala mutant 


























Figure 4.2. c(s) distributions of (a) AMSH219, (b) AMSH:ubiquitin, and (c) 
AMSH:Lys63-diubiquitin.  Three concentration series were used for AMSH219 and 
AMSH:Lys63-diubiquitin, while two concentrations were used for AMSH:ubiquitin.  It 
was found that AMSH219 sediments at 2.2S, AMSH:ubiquitin complex at 2.4S, and 
AMSH:Lys63-diubiquitin at 2.8S, with excess ubiquitin and diubiquitin at 1.2S and 1.7S 














Figure 4.3. Representative sedimentation equilibrium profiles for (a) 
AMSH:ubiquitin and (b) AMSH:Lys63-diubiquitin to determine the molecular 
















SE= sedimentation equilibrium 












Calculated molecular weight (Da) 
AMSH219 2.2 0.7338 23120 22000 SV 
AMSH-SH3 1.3, 2.5 0.7187 7561 / 30664 8600 / 23000 SV 
AMSH-UIM-
SH3 
1.3, 2.6 0.7170 12588 / 35690 12000 / 34000 SV 
AMSH-Ub 1.2, 2.4 0.7247 8976 / 32079 8000 / 24000 SV 
8900  2900 / 31500  12000 SE 
AMSH-DiUb 1.7, 2.8 0.7293 17935 / 41037 17000 / 34000 SV 
















Figure 4.4. Model of AMSH bound to Lys63-diubiquitin.  Cartoon representation 
of AMSH (pink ribbon) bound to a Lys63-linked diubiquitin, showing Ile44 as 
blue spheres in both the proximal (green ribbon) and distal (cyan ribbon) 

















Figure 4.5. Domain diagram of (a) full-length AMSH and (b) full-length STAM 
indicating the appropriate binding partners associated with each domain.  
Abbreviations are as follows: MIT (microtubule interacting and transport), CBS 
(clathrin binding sequence), SBM (SH3-binding motif), JAMM 
(JAB1/MPN/MOV34), VHS (Vps27, Hrs, STAM), UIM (ubiquitin-interacting 
motif), SH3 (Src homology 3 domain), Hrs (hepatocyte growth factor (HGF)-













Figure. 4.6. ITC thermograms of (a) SH3 and (b) UIM-SH3 binding to the 












Figure 4.7. c(s) distributions of the catalytic domain of AMSH binding to (a) the SH3 
domain of STAM and (b) UIM-SH3.  Three concentration series were used to assess the 
formation of the AMSH:SH3 and AMSH:UIM-SH3 complexes revealing 1:1 complexes 
at 2.5S and 2.6S, respectively. Excess SH3 and UIM-SH3 are present at 1.3S.  The data 
for both c(s) distributions were normalized to the peak area of the complexes.  (C) 
Overlay of AMSH, AMSH:SH3, and AMSH:UIM-SH3 revealing changes in s-value of 
the AMSH:SH3 and AMSH:UIM-SH3 complexes compared to AMSH alone at 2.2S. The 











Figure 4.8. ITC thermograms of ubiquitin binding to UIM-SH3 of STAM.  (a) 
Thermogram of ubiquitin binding to UIM-SH3 revealing a KD of 273  16 M. 
(b) Thermogram of ubiquitin binding to the SH3 domain of STAM revealing a KD 
of 62  7 M.  (c) Thermogram of Lys63-linked diubiquitin binding to UIM-SH3 













Figure 4.9. DUB activity assay by monitoring diubiquitin cleavage.   SDS-PAGE 
gel comparing the activity of the catalytic domain of AMSH alone and in the 
presence of STAM’s SH3 domain and UIM-SH3.  Only the lane with UIM-SH3 












Figure 4.10. Catalytic activation of AMSH in presence of UIM-SH3.  (a) Domain 
diagram of the minimal AMSH and STAM proteins, indicating the locations of the 
introduced mutations. (b) SDS-PAGE investigating the effects of mutants on the catalytic 
activation of AMSH.  Only in the presence of the wild-type enzyme and wild-type UIM-
SH3 is the activity of AMSH enhanced, indicated by complete disappearance of the 








Figure 4.11. Representative ITC thermogram of the titration of UIM-SH3 into the 
































AMSH  1.4  0.1 32  5 
AMSH + UIM-SH3 5  1 19  3 
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CHAPTER 5: STRUCTURAL AND BIOPHYSICAL INSIGHT INTO THE ROLES OF 
ESCRT-DUBS 
5.1 Introduction 
 The endosomal sorting complexes required for transport (ESCRT) is a multi-
subunit machinery that is an essential part of the multivesicular body (MVB) pathway in 
which cargo is sequestered and sorted into endosomal membranes.1; 2 The ESCRT 
complex was initially discovered in yeast as a part of the vacuolar protein-sorting (vps) 
mutants, which were unable to deliver proteins to the vacuole.1 13 of the 46 vps mutants 
(class E) lacked the ability to deliver membrane proteins to the vacuole, giving rise to the 
discovery in 2001 of ESCRT-I (the second ESCRT complex) resulting from biochemical 
characterization of those vps mutants.1; 2 The ESCRT machinery is a ubiquitin-dependent 
process that is involved in several cellular processes including endosomal sorting, 
endosomal trafficking, viral budding, cytokinesis, transcriptional regulation, and 
autophagy.3 As a function of its involvement in several processes throughout the cell, the 
ESCRT machinery is implicated in a wide variety of diseases including cancer, 
neurological diseases, bacterial infections, cardiovascular disease, and retroviral 
infection.4; 5   
 The ESCRT machinery is subdivided into four complexes, ESCRT-0, -I, -II, -III, 
that work in a sequential manner to sort membrane proteins to the lysosome (vacuole in 
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yeast);2 not all cellular process require all four of the complexes to carry out its function.  
A milestone study deciphered the role of each of the complexes by reconstituting and 
visualizing the complexes in giant unilamellar vesicles.6 The study found that ESCRT-0 
clusters ubiquitinated cargo and localizes closely to membrane buds that are formed in 
tandem by ESCRT-I and II, which in turn begin to confine the cargo within the newly 
formed buds. Finally, ESCRT-III is recruited to the neck of the bud by ESCRT-II to 
pinch off the membrane, forming intralumenal vesicles (ILVs) that can go off to the 
lysosome to degrade their contents.6     
 Since the ESCRT machinery works in a ubiquitin-dependent manner, 
deubiquitination and DUBs become an important mechanism of regulation within this 
entire machinery.  The model ESCRT system, Saccharmyces cerevisiae (S. cerevisiae), 
uses the DUB Degradation of alpha 4 (Doa4) to recycle ubiquitin from ubiquitinated 
cargo that has been shuttled through the upstream ESCRT complexes and are committed 
to ILVs.7 Doa4 has also been shown interact directly with ESCRT-III subunit, Snf7, thus 
promoting its localization to the last complex, further supporting its DUB role. However, 
direct deubiquitination of cargo is not required for MVB sorting in yeast.7; 8; 9   
 Similarly, the human ESCRT system requires DUBs. In humans, two DUBs are 
employed to regulate ESCRT-mediated sorting, associated molecule with a Src homology 
3 (SH3) domain of STAM (or STAM-binding protein (STAMBP) or simply AMSH), and 
ubiquitin-specific protease Y (UBPY or ubiquitin-specific protease 8 (USP8)).7; 10; 11; 12; 13 
Both AMSH and UBPY have functional SH3-binding motifs (SBMs) that facilitates 
recruitment to ESCRT-0, more specifically, the SH3 domain of STAM, and functional 
MIT domains that allow for recruitment to various CHMPs of ESCRT-III.7; 12; 14; 15; 16 
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ESCRT-0 SH3 recruitment is carried out using a conserved consensus sequence: 
PX(V/I)(D/N)RXXKP, in which X is any residue.7; 12 Linking the S. cerevisiae and 
human ESCRTs, there are three yeast proteins with similar domain structures to UBPY, 
Doa4, Ubp7, and Ubp5, and of the three, Doa4 has a seemingly redundant role to UBPY 
at ESCRT-III, but interestingly, Ubp7 interacts with Hse1, which mimics UBPY binding 
to ESCRT-0.7 There is no direct AMSH homolog within S. cerevisiae.   
 Both AMSH and UBPY have critical roles in receptor down-regulation and other 
ESCRT functions including cytokinesis, HIV budding, and transcriptional regulation; the 
exact role of DUBs is not well understood.  There is a significant amount of in vivo data 
that have implicated one DUB or the other in the down-regulation of various receptors 
using siRNA, unfortunately, we do not know the mechanism by which these enzymes 
work.  For the most part, the role of DUBs has been glossed over in ESCRT literature, 
just accepting that DUBs deubiquitinate cargo, however, diving deeper into the literature 
suggests that DUBs play a significant regulatory role. More importantly, AMSH and 
UBPY may not have redundant functions even though in humans they have the same 
ESCRT-recognition domains. A very good review of ESCRT-DUBs was written back in 
2006.7 The goal of this literature review is to take a more structural and biophysical 







 AMSH is a 424-amino acid member of the JAMM family of DUBs that binds 
Zn2+ at the active site coordinated by two histidines, an aspartate, and a glutamate bridged 
by the catalytic water molecule; a second Zn2+ is bound ~14Å away from the active-site 
zinc for structural integrity.17; 18 AMSH is involved in the regulation of several receptors 
including: epidermal growth factor (EGFR) receptor, calcium-sensing receptor, -opioid 
receptor, protease-activated receptor (PAR), and the chemokine receptor CXCR4.10; 19; 20; 
21; 22; 23; 24; 25 Not only is AMSH implicated in receptor down-regulation, but also has roles 
within mitosis, cytokinesis, and HIV budding.26; 27; 28; 29 
 The structure of the wild-type catalytic domain of AMSH has been determined to 
2.5Å, and a second structure of the catalytic domain including a Glu280Ala active-site 
mutation to 1.7Å resolution.18 The structure of the catalytic domain of AMSH is nearly 
identical to that of the catalytic domain of the homologous (75% sequence similarity in 
the catalytic domain) AMSH-like protein (AMSH-LP) with a root mean square deviation 
(RMSD) of C atoms of 1.49Å, however, AMSH was found to be thermodynamically 
less stable than AMSH-LP, owing to a structural plasticity.18 This idea of structural 
plasticity is consistent with the ability of AMSH to localize to multiple ESCRT 
complexes, whereas, AMSH-LP is ESCRT-independent.  Also, structural analysis has 
shown the potential for the formation of a disulfide bridge between Cys282 and Cys311 
~7Å away from the active-site Zn2+.18 A detailed kinetic study shows that when Cys282 
is mutated to alanine there is a ~6-fold reduction in kcat, suggesting a role for this residue 
within the enzyme’s catalytic mechanism (Davies, C.W., et. al (2013) Biochemistry 
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accepted). Another study found that N-ethylmalemide (NEM) is an inhibitor of AMSH 
activity due to a possible alkylation of Cys282.10 In accordance with this study, the IC50 
for NEM inhibition was determined to be 16.2  3.1 M.30  
 AMSH has exquisite specificity for Lys63-linked polyubiquitin chains.10 The 
structural basis for the AMSH family of DUBs specificity for Lys63-linked chains has 
been elucidated with the x-ray crystal structure of AMSH-LP bound to a Lys63 ubiquitin 
dimer.31 The structure reveals that specificity arises from the specific recognition of a 
tripeptide sequence (Gln62-Lys63-Glu64) within the proximal ubiquitin by four residues 
within the enzyme (Thr, Phe, Ser, and Phe).31 Structural modeling of AMSH onto 
AMSH-LP bound to diubiquitin reveals that the linkage specificity is completely 
conserved between AMSH and AMSH-LP; however, there is a three-residue difference in 
recognition of the distal ubiquitin, a Asn to Asp, a Thr to Met, and a Glu to Val, going 
from AMSH to AMSH-LP.18 A more detailed mutational and kinetic analysis probing the 
role of these residues individually found that the threonine to alanine mutation showed 
some hyperactivity, however, this was counterbalanced with a loss in KM.  Also, the 
threonine (Thr313) is mutated to isoleucine in children with microcephaly capillary 
malformation (MIC-CAP) syndrome.  Analyzing the MIC-CAP-associated mutant 
revealed a significant reduction in catalytic activity, without much change in its 
thermodynamic stability (Davies, C.W., et. al (2013) Biochemistry accepted). Mutating 
the glutamate to alanine revealed the most significant result in which there was an ~74-
fold reduction in kcat (Davies, C.W., et. al (2013) Biochemistry accepted).     
 AMSH localization to ESCRT-0 is facilitated by the SH3 domain of STAM 
binding to the SBM of AMSH.7 It has been shown that clathrin, not the SH3 domain of 
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STAM, is required for AMSH endosomal localization, suggesting that binding clathrin 
allows AMSH to be in close proximity to bind the SH3 domain of STAM.32 Similarly, 
Hrs-STAM (ESCRT-0) localizes to the endosome because of its interaction with clathrin 
via the C-terminal domain of Hrs.33 Furthermore, the recruitment of AMSH to ESCRT-0 
enhances the enzyme’s activity.  One study showed that in the presence of STAM, 
AMSH processed Lys63 ubiquitin chains better than without STAM, or with mutations 
disrupting the enzyme’s ability to bind STAM.11 Also, it was found that mutations within 
the UIM domain of STAM greatly reduced this enhancement of activity, suggesting a KM 
effect for the UIM.11 Another study showed that when diubiquitin was bound to STAM, 
the enzyme processed the chains better than when not bound to STAM; AMSH mutants 
lacking the SBM showed no activity towards diubiquitin bound STAM.34 Using a 
combination of biophysical and biochemical experiments, this activation mechanism has 
been further elucidated.  It was found that the enzyme has no preference for Lys63-linked 
diubiquitin over simply ubiquitin based on isothermal titration calorimetry (ITC) 
experiments that revealed identical binding affinities (19 M); from this, a role for 
STAM’s UIM was proposed (Davies, C.W., et. al (2013) Biochemistry accepted).  An 
enzymatic assay using the minimal domains of AMSH and STAM along with Lys63-
linked diubiquitin found that the UIM of STAM plays a significant role in stimulating the 
enzyme’s activity by recognizing the proximal ubiquitin, while the enzyme binds the 
distal ubiquitin (Davies, C.W., et. al (2013) Biochemistry accepted).  As a consequence 
of these results, it was proposed that AMSH serves to promote the shuttling of 
ubiquitinated cargo from ESCRT-0 to ESCRT-I and –II by reducing the affinity of 
ESCRT-0 for ubiquitin (Davies, C.W., et. al (2013) Biochemistry accepted). 
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 AMSH recruitment to ESCRT-III is facilitated through interactions with ESCRT-
III members, CHMPs.14; 15; 16 A yeast-two hybrid system found that AMSH interacts with 
several CHMP members: CHMP1A, CHMP1B, CHMP2A, and CHMP3; all of these 
CHMPs did not interact with AMSH-LP, suggesting that the AMSH-CHMP interaction is 
specific.16 A more detailed study of the AMSH-CHMP interaction using a glutathione S-
transferase (GST)-pull down assay suggests that AMSH interacts most prominently with 
CHMP1A, followed by CHMP3 and then, CHMP4C. However, CHMP1A only plays a 
regulatory role, whereas CHMP3 is one of the proteins necessary for capping the 
ESCRT-III polymer in the scission process.14; 35 Further structural and biophysical studies 
have been done on the AMSH-CHMP3 interaction.  Some initial studies using small 
angle x-ray scattering (SAXS) found that CHMP3 existed in multiple conformations 
ranging from a closed conformation in a no-salt buffer to an open conformation in a high 
salt condition.36 This study also determined using ITC that the AMSH-CHMP3 binding 
affinity changes as a function of salt concentration ranging from 5.6 nM in no-salt to 392 
nM in 500 mM NaCl.36   
 More recently, the structural basis of AMSH recruitment by CHMP3 was 
elucidated using x-ray structure determination of a complex between the MIT domain of 
AMSH (residues 1-146) and a C-terminal fragment of CHMP3 (residues 183-22, 
representing its MIT-interacting motif (MIM) domain).37 In great agreement with the 
previous study, the KD of the MIT-MIM interaction was found to be 60 nM using ITC 
and 113 nM using Surface Plasmon Resonance (SPR).37 The extraordinarily tight 
complex is mainly stabilized by polar interactions, which is novel compared to previous 
crystal structures of MIT-MIM interactions, showing the importance of hydrophobic 
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interactions.37 Furthermore, the interaction of AMSH and CHMP1A was analyzed by 
SPR and determined a KD of 1.5 mM, suggesting a different mode of interaction between 
CHMP1A-AMSH and CHMP3-AMSH, since a C-terminal peptide of CHMP3 binds with 
micromolar affinity to AMSH, whereas the full-length protein has low nanomolar 
affinity.36; 37 Since ESCRT-III is necessary for the final scission step in MVB biogenesis, 
it is important to comment on how AMSH relates to the role of Vps4 disassembly.  
Overexpression of Vps4 resulted in weakened affinity of CHMP1B for AMSH, 
suggesting that the MIT domain of Vps4 competes for the same binding spot on 
CHMPs.16 Though Vps4 competed off AMSH from CHMP1B, it is not well understood 
how Vps4 would compete off CHMP3 because of the low nanomolar affinity between 
AMSH-CHMP3, whereas the Vps4-CHMP interaction has a micromolar affinity.37; 38 
Further studies are required to elucidate how AMSH is released from ESCRT-III after 
deubiquitination prior to Vps4-mediated recycling.  
 
5.3 USP8/UBPY 
 UBPY is an 1118 amino acid member of the USP family of cysteine protease 
DUBs.39; 40 The USP family is the largest and the most diverse family of DUBs with 56 
distinct members; USPs are large proteins ranging from 300-3400 amino acids, with a 
~350 amino acid catalytic domain.41 UBPY is implicated in the cell cycle by regulating 
the entry into the S phase.42 UBPY also interacts with and serves multiple other roles in 
the cell including: CDC25Mm, a GDP/GTP exchange factor for Ras, GRAIL, an E3 
ubiquitin ligase involved in energy induction in CD4+ T-cells, and Nrdp1, an E3 enzyme 
that regulates receptor tyrosine kinases (RTKs).43; 44; 45 The more widely known role for 
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UBPY is to regulate the cellular levels of ubiquitin by deubiquitinating ubiquitinated 
proteins, specifically, ubiquitinated receptors targeted for degradation by the lysosome, 
much like Doa4.7 UBPY localizes to early endosomes, regulating the level of protein 
ubiquitination on endosomes, where inactivation of UBPY caused morphological 
aberration of endosomes.46 Also, UBPY activity is necessary for regulating the 
degradation patterns of specific receptors such as epidermal growth factor receptor 
(EGFR), MET receptor, the Ca2+-activated K+ channel (KCa3.1), and the epithelial 
Na+channel.13; 47; 48   
 The structure of UBPY has been solved elucidating the many domains that reside 
within UBPY.  The N-terminal domain of UBPY (residues 1-142) was crystallized and its 
structure was determined up to 2.1Å resolution revealing a helical structure that has a 
coiled-coil region forming a molecular dimer.49 This N-terminal region, which was later 
shown to be a canonical MIT domain,14 has a large cavity lined with basic residues that 
are speculated to facilitate ligand binding by a negatively charged molecule; this 
promotes the N to C-terminal interaction between the basic N-terminal region of UPBY 
and the acidic C-terminal tail of CHMPs.49    
 Separated by a 40-amino acid linker from the MIT domain of UBPY is the 
rhodanese domain that facilitates interaction with the RING-finger containing E3 
ubiquitin ligase, neureglin receptor degradation protein 1 (Nrdp1).45; 49 In vivo studies 
show that UBPY specifically interacts with Nrdp1 since UBPY does not bind to cbl, a 
RING Finger E3 ligase involved in EGFR down-regulation.45 Also, UBPY promotes the 
stability of the ligase in which a catalytically inactive mutation within UBPY destabilized 
endogenous Nrdp1.45 The crystal structure of the rhodanese domain (residues 181-319) in 
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complex with Nrdp1 (residues 193-317) was shown to form a 1:1 complex (each 
migrating as monomeric proteins within size-exclusion chromatography (SEC)) that has a 
buried surface area of 2100Å2, mainly comprised of a peptide loop from UBPY (residues 
237-242) nestled within a pocket from Nrdp1 centered on residue Ile218.49 When 
compared to the unbound proteins, no significant conformational changes were found.49 
It is speculated that the rhodanese domain may contribute to UBPY oligomerization 
because of a predicted coiled-coil region within Nrdp1 that may promote dimerization of 
the ligase, therefore, when UBPY is recruited, the enzyme with oligormerizes.49 
 The C-terminal domain, upstream of the rhodanese domain, is the catalytic 
domain of UBPY, in whose segment comprising of 376-residues was crystallized and 
determined its x-ray structure at 2Å resolution.49 The structure of the catalytic domain 
contains similar domain architecture to other members of the USP family (resembling a 
right hand with a palm, thumb and fingers); however, the structure of the catalytic 
domain of UBPY has several structural features that are not present in other USPs.49 Two 
loops (blocking loop 1 (BL1) and 2 (BL2)) in a closed conformation appear to be 
important for capping the active site and recognition of the P site within the substrate, 
which would ultimately block the peptide bond from being presented to the active site.49 
Also, in accordance with the inhibition of substrate entry, the fingers of UBPY are 9 Å 
closer to the active site, leaving insufficient room for the binding of ubiquitin when 
comparing UBPY to previously solved USP family proteins.49; 50; 51 All the analysis of the 
closed conformation of UBPY has brought about a speculation that this is a hardwired 
structural feature that regulates the activity of UBPY where its goes through a substrate-
induced activation mechanism.49 Another structural feature that UBPY has that is not 
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consistent throughout all USP family members is the presence of a Zn2+-binding motif, 
present at the end of the fingers.49 Four cysteines are in a tetrahedral coordination around 
Zn2+, resembling a Zn2+-ribbon fold.52 The importance of this Zn2+-ribbon motif is not 
well understood, however, it is speculated to be important in binding a second ubiquitin, 
similarly to Zn2+-finger domains, allowing for efficient cleavage of ubiquitin chains.49 
 The role of UBPY within the ESCRT machinery is to regulate the ubiquitination 
events by deubiquitinating cargo, maintaining the ubiquitin pool within the cell.  Unlike 
AMSH, UBPY is a promiscuous enzyme in its ability to cleave Lys48 and Lys63-linked 
ubiquitin chains.13 The original analysis of DUB specificity towards Lys48 and Lys63-
linked ubiquitin chains revealed that AMSH cleaved only Lys63 and UBPY cleaved only 
Lys48, however, the substrate used in this experiment had all the lysines mutated to 
arginine except for the lysine used to make the specific chain.10 When the wild-type 
ubiquitin was used, UBPY processed Lys63-ubiquitin chains to lower units suggesting 
that one of the six other lysines are necessary for recognition and activity towards 
Lys63.13 Furthermore, the activity of UBPY was determined by using the substrate-
mimic, ubiquitin 7-amino-4-methylcoumarin (Ub-AMC), obtaining a kcat of 2.4 s-1 and a 
KM of 10.2  1.4 M.49 The ability of UBPY to hydrolyze Ub-AMC suggests the 
possibility that UBPY can also hydrolyze monoubiquitinated substrates.   
 Just like AMSH, UBPY recruitment to ESCRT-0 is facilitated through SBM-SH3 
domain interactions.  The interaction between the SH3 domain of STAM and UBPY was 
first characterized in 2000 in a study that discovered the nine-amino acid consensus SBM 
sequence (PX(V/I)(D/N)RXXKP), and that UBPY has two SBM motifs within its gene.12 
Using deletion mutants of mouse UBPY, an in vitro binding assay was conducted probing 
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the binding interactions of the UBPY mutants to GST-STAM SH3 revealing one SBM 
motif within residues 378-434 and then, another SBM within residues 666-731.12 Human 
UBPY has its two SBMs within residues 405-413 and 738-746. Comparing the sequences 
of the two human UBPY sequences, we see that position three and four are both changed 
when going from one SBM to the other (3ID4 within the first SBM (residues 405-413) 
and 3VN4 in the second SBM (residues 738-746)).  
 For further insights into the SBM-SH3 domain interactions, alanine-scanning 
mutagenesis was performed.  It was found that mutating the prolines at position one and 
nine, the arginine at position five, or the lysine at position eight resulted in complete 
abolishment of binding, whereas, mutating position three (valine /isoleucine) or four 
(asparagine/aparatic acid) resulted in reduced binding.12 The structural basis for 
understanding these interactions has been determined by co-crystallizing the SH3 domain 
of STAM2 with an 11-mer peptide derived from the sequence of mouse UBPY.53 The 
structure of the peptide binding site within STAM2 SH3 is similar to other SH3 domains 
showing a hydrophobic surface suitable for polyproline type II helix-binding and an 
adjacent acidic region formed by the RT and n-Src loops.53 The peptide binds within the 
predicted site of the SH3 domain, however, the second half of the peptide adopts a novel 
right-handed 310 helical conformation.53 Looking at the interactions, the position four 
residue (asparagine in this structure, but could be substituted by an asparatic acid) 
facilitated two hydrogen-bonding interactions with the main chain nitrogen atoms of 
residues in position five and six.53 The significance of the 310 helix becomes important 
because this conformation allows for a series of electrostatic interactions to take place 
between the arginine at position five and the lysine at position eight.53 Two hydrogen-
 129
bonding interactions are seen between arginine and Glu220, and the lysine residue adopts 
four distinct interactions, van der Waals interaction with Trp239, and three hydrogen 
bonding interactions with three oxygen atoms from Glu217, Glu219, and Glu220.53       
 Using tryptophan fluorescence and a mouse UBPY-derived peptide, it was shown 
that UBPY binds to the SH3 domain of STAM2 with a KD of 27 M,53 similar to the 7 
M affinity that was determined for the AMSH-SH3 interaction 34.  Also, data shows that 
the activity of UBPY is enhanced towards Lys48 and Lys63-linked tetraubiquitin chains 
in the presence of STAM.14 These data suggest that the role of STAM is to recruit and 
stimulate DUB activity towards polyubiquitin chains.   
 UBPY, like AMSH, interacts with ESCRT-III proteins, CHMPs, through an MIT-
MIM type interaction using its N-terminal basic MIT domain binding to the acidic C-
terminal domain of CHMPs.  The same study that probed the AMSH-CHMP interaction, 
assayed the MIT domain of UBPY against 11 CHMPs.  The MIT domain of UBPY 
specifically interacted with CHMP1B, 4C, and 7, and 2A to a lesser extent.14 Unlike the 
ability of STAM to stimulate DUB activity, CHMPs had no stimulatory affect on the 
DUB activity of UBPY.14 
 
5.4 Structural and Biophysical Insights into Understanding Previously Described Cellular 
Data Suggest Roles for AMSH and UBPY 
 
 It is widely accepted that the main function of DUBs is to regulate and maintain 
the cellular pool of ubiquitin since the attachment of ubiquitin to target proteins is an 
ATP-dependent process.  The employment of both AMSH and UBPY within the ESCRT 
machinery could and should adopt this same role, however, its not well understood the 
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‘other’ roles that these enzymes have in regulating ESCRT-mediated degradation.  
Mammalian ESCRTs recruit two DUBs to two complexes (ESCRT-0 and III) with 
redundant localization domains between them.  At first look, this recruitment and 
recognition suggests functionally redundant roles, especially since Doa4 is the main 
regulator of ESCRT-mediated degradation in S. cerevisiae.  Further insight into 
understanding these DUBs reveals the difference in ubiquitin-chain specificity, which 
will be the initial determining factor is showing that AMSH and UBPY are not 
functionally redundant; in fact, each seem to serve an important and distinct role is 
regulation and proper functionality of the ESCRT machinery. 
 
5.4.1 The Role of DUBs at ESCRT-0 
 Two models have been proposed for role of a DUB at ESCRT-0 in which AMSH 
serves to oppose the action of the E3 ligase by completely deubiquitinating a 
ubiquitinated receptor, thus promoting the recycling of that receptor back to the plasma 
membrane. Alternatively, the proposed role of UBPY is to deubiquitinate ESCRT-0 
member, STAM, because its been shown that STAM becomes Lys48 ubiquitinated, 
targeting it for proteasomal degradation.7 Both DUBs could theoretically localize with 
similar affinity to ESCRT-0, however, AMSH is recruited mainly by its clathrin-binding 
domain,32 but also, has its SBM that binds to the SH3 domain of STAM.  Similarly, 
UBPY has two SBMs, one of which has been shown to bind to the SH3 domain of STAM 
with 27 M affinity.53 Both DUBs have two points of ESCRT-0 recruitment, however, 
AMSH maybe more apt to be recruited because of the clathrin binding, but the two SBMs 
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of UBPY may produce avid binding even though there is an ~300 amino acid linker in 
between SBMs.   
 The proposed role of AMSH opposing the activity of the E3 ligase, promoting 
receptor recycling, arose from the observation that small interfering RNA (siRNA) 
knockdown of AMSH lead to increased degradation of ligand-stimulated EGFR.10 A 
recent study has proposed that the decision to recycle receptors back to the plasma 
membrane is made prior to the localization of the ubiquitinated receptor to ESCRT-0 
because they showed that an EGF-stimulated chimera protein of EGFR and ErbB2 and 
TGF-stimulated EGFR showed impaired AMSH deubiquitination.54 Structural 
modeling shows that AMSH and AMSH-LP have the same mode of Lys63-linked 
polyubiquitin chain specificity, therefore, taking these results into account, we speculate 
that AMSH cannot completely deubiquitinate a receptor because of its exquisite chain 
specificity.  The enzyme could cleave a Lys63-linked polymeric chain of ubiquitin, 
leaving the last ubiquitin still attached to the receptor. These data do not line up with the 
hypothesis that AMSH opposes E3 ligase activity at ESCRT-0.   
 Alternatively, we can see how UBPY could be the DUB that opposes the action of 
the E3 ligase by completely deubiquitinating a receptor before it is ‘committed’ to the 
subsequent ESCRTs.  This proposed role of UBPY opposing ligase activity has a caveat: 
if the decision for receptor recycling is made before binding to ESCRT-0, then UBPY 
would not be needed, however, if a receptor is incorrectly ubiquitinated and brought to 
ESCRT-0, UBPY could serve the role to correct this by completely removing ubiquitin.  
UBPY could easily have this role because of its lack of specificity.  UBPY cleaves both 
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Lys48 and Lys63-linked ubiquitin chains,13 but more importantly, UBPY also cleaves 
Ub-AMC,49 serving as a model of a monoubiquitinated receptor.  
 Though structural and biochemical data do not support the idea that AMSH 
completely opposes the E3 ligase, these data do suggest that AMSH could work to 
process Lys63-ubiquitin chains at ESCRT-0 down to the last ubiquitin, which could be 
important in efficiently passing ubiquitinated receptors onto the subsequent complexes. 
SPR experiments show that ubiquitin chains bind avidly to ESCRT-0.55 The binding 
affinity of ESCRT-0 for ubiquitin is 920 M, however, through avid binding, the affinity 
of ESCRT-0 for Lys63-diubiquitin increased ~8-fold to 110 M, and for Lys63-
tetraubiquitin to 18 M, a 51-fold increase in affinity.55 Alternatively, when looking at 
ESCRT-I ubiquitin binding affinity, ubiquitin and Lys63-diubiquitin bind in the range of 
70-140 M.56 These data suggest that a polyubiquitinated receptor at ESCRT-0 would not 
be passed on to ESCRT-I/II because it would have a greater affinity for ESCRT-0 than 
for ESCRT-I/II, unless the ubiquitin chain is trimmed substantially, possibly to the last 
ubiquitin.  Taking all of this into account, we speculate that AMSH could play a role as 
the DUB that facilitates the passage of ubiquitinated cargo from ESCRT-0 to ESCRT-
I/II.  As stated above, the structure suggests that AMSH will process Lys63 chains, 
leaving the last ubiquitin moiety, thus greatly reducing the affinity of ESCRT-0 for the 
monoubiquitinated receptor, allowing for efficient passage onto ESCRT-I/II.  This idea 
has been mentioned previously in which it was stated that both AMSH and UBPY might 
be important for disengaging avidly bound K63-linked ubiquitin chains from ESCRT-0 
for cargo to be handed off to ESCRT-I and –II.57 Based on ubiquitin-chain specificity, 
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both UBPY and AMSH could carry out this role at ESCRT-0 since both are activated at 
ESCRT-0;11; 14 both enzymes cleave Lys63-linked chains,10; 14 however, UBPY is more 
promiscuous, therefore, this enzyme has the potential to completely deubiquitinate the 
receptor, thus releasing the cargo from ESCRT-0.  Of the two, AMSH would best be 
served to promote cargo movement from ESCRT-0 to ESCRT-I/II.  
 The S. cerevisiae STAM ortholog, Hse1, has a SBM that interacts with both an E3 
ligase and a DUB. A GST pull-down assay found the DUB, Ubp7, interacts via the SH3 
domain of Hse1.58 Ubp7 interacting with Hse1 is synonymous to AMSH because deletion 
of Ubp7 resulted in an increase in Cps1 sorting; suggesting that DUB activity here 
regulates ubiquitinated cargo.58 Ubp7 has some significant differences compared to 
AMSH.  The domain structure of Ubp7 resembles UBPY more than AMSH in that Ubp7 
is a 125 kD (1072 amino acids) cysteine protease, however, Ubp7 does have a putative 
SBM; its predicted SBM is not the canonical SBM sequence that reside within both 
AMSH and UBPY.58 Lastly, analysis of Ubp7 activity towards HA-Ub-VME was barely 
detectable, probably due to low levels of the protein being expressed in yeast 59 even after 
Hse1 was added, revealing that Hse1 does not activate Ubp7, unlike human ESCRT-
DUBs.58 These results suggest that yeast uses a DUB to carry out a regulatory role early 
in the endosomal process, similar to mammalian DUBs, alternatively, it is not known 
whether Ubp7 can be considered adopting an identical role to what was proposed for 
AMSH at ESCRT-0 because of its expression levels and lack of enzyme stimulation by 
Hse1.       
 The proposed function of UBPY regulating the ubiquitination status of the 
ESCRT-0 members themselves, specifically STAM arose from a study in which UBPY 
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was knocked out and it was found that >90% of STAM levels were reduced, with only a 
minimal affect on Hrs.13 Similarly, another study investigating the ubiquitination status of 
ESCRT-0 showed that wild-type AMSH and a functional SBM controlled the 
ubiquitination of both Hrs and STAM.19 These studies suggest that ESCRT DUBs not 
only regulate the cargo degradation, but also, the ESCRT-0 members themselves.  It is 
not fully understood why ESCRT-0 becomes ubiquitinated.  Two of the possible reasons 
for ESCRT-0 ubiquitination are: (1) to regulate the steady state levels of both Hrs and 
STAM, therefore, degrade these proteins once their function is complete and (2) to 
regulate cargo entry. Proteasome inhibition coupled with UBPY knockout cells had an 
accumulation of ubiquitinated STAM, suggesting that STAM becomes Lys48-
polyubiquitinated.13 In terms of regulating cargo entry, Hrs does not become 
ubiquitinated when its UIM is mutated, suggesting that this UBD not only binds 
ubiquitinated cargo, but also becomes ubiquitinated itself.60 Looking at the ubiquitination 
status of ESCRT-0 and attempting to assign a role to AMSH or UBPY, structural and 
biophysical data supports the model that UBPY regulates STAM proteasomal targeting 
because of its ability to cleave Lys48-linked ubiquitin chains, a role in which AMSH can 
not fit.7 Furthermore, UBPY could in theory control the ubiquitination status of ESCRT-0 
in terms of regulation of cargo entry because studies show that ESCRT-0 is multi-
ubiquitinated or monoubiquitinated.60 Looking at AMSH and its structural and 
biochemical specificity, it could cleave Lys63-linked polyubiquitinated ESCRT-0,60 but 
again, a single ubiquitin moiety would be left, thus not fully releasing the regulatory 
mechanism that blocks cargo entry.  Ultimately, the data supports UBPY controlling the 
ubiquitination of Hrs/STAM as it pertains to proteasomal degradation and ubiquitination.  
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5.4.2 The Role of DUBs at ESCRT-III 
 DUB role at ESCRT-III seems to be more clearly understood than at ESCRT-0, 
however, dissection of these potential roles for DUBs at ESCRT-III have seemingly 
proven to be more complicated than initially thought.  It is widely understood that the 
ubiquitin has to be removed prior to cargo sequestration into an ILV. The confusing part 
regarding this role within mammalian ESCRTs is the presence of both AMSH and 
UBPY.  Both DUBs have functional MIT domains that allow for proper recruitment to 
ESCRT-III, however, as seen with ESCRT-0, their individual ubiquitin chain specificities 
and a new issue, they specifically interact with different ESCRT-III subunits, may 
separate their individual functions at ESCRT-III.    
 Doa4 is the only DUB in S. cerevisiae required to regulate MVB sorting by 
recycling ubiquitin from ubiquitinated cargo destined for the vacuole.7 Of the two DUBs 
employed by the human ESCRT system, UBPY displays the highest similarity to Doa4; 
therefore, it would be easy to assign UBPY a similar role within the mammalian ESCRT 
system.  Structural and biophysical evidence supports this role for UBPY because of the 
lack of chain specificity between Lys48, Lys63, and monoubiquitin.  More evidence in 
support of UBPY functioning to recycle ubiquitin from receptors prior to confinement to 
ILVs arises from studies that highlight the specific interaction UBPY has with CHMP4, 
particularly, CHMP4C.14 This interaction becomes important because CHMP4 is the 
human homologue to Snf7, which is the most abundant ESCRT-III subunit and is 
absolutely necessary for bud severing,61 suggesting UBPY is recruited in close proximity 
to the severing bud neck.  Also, UBPY-CHMP4 interaction could support the idea of 
UBPY oligomerization since CHMP4 oligomerizes,61 but also, UBPY existing in 
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multiple copies has been suggested from the structure of the N-terminal dimerization 
domain.49 If these data are taken together, then multiple copies of UBPY would be 
present to facilitate deubiquitination.  
 Again, AMSH would not have a redundant role because of its chain specificity.  
Even more interesting about AMSH recruitment to ESCRT-III is that its MIT domain 
interactions do not overlap with the UBPY in terms of the subunits necessary for vesicle 
formation.  Of the subunits speculated to be involved in vesicle formation 
(CHMP6<CHMP4<CHMP3<CHMP2), AMSH only interacts specifically and tightly 
with CHMP3.14; 37 It suggests that AMSH and UBPY could in theory be present at 
ESCRT-III at the same time. Based on reasons discussed above, UBPY would be more 
abundant, however, there is no evidence supporting that both enzymes are present at the 
same time.  The tight AMSH-CHMP3 interaction suggests a role for AMSH in HIV-1 
budding.  The role of AMSH in HIV-1 budding is still poorly understood.  One study 
showed that catalytically inactive AMSH resulted in strong inhibition of virion release, 
however, the same study showed that AMSH is not essential for viral budding, stating 
that the initial finding regarding catalytically inactive AMSH inhibiting viral budding 
could be due to competition or interference with other necessary components.16 Another 
study showed that HIV-1 budding has a minimal requirement for CHMP3 as compared to 
CHMP4B and CHMP2 (A or B).62 Slight opposition to this study in which SPR 
measurements showed that CHMP4B binds ~16-fold more tightly to CHMP3 than to 
CHMP2A, while CHMP2A binds CHMP4B and CHMP3 with similar KDs, suggesting 
that CHMP3 would be recruited to the HIV-1 budding site prior to CHMP2A, after 
CHMP4B (CHMP4B<CHMP3<CHMP2A).35 In accordance with these results, AMSH 
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seems to play some role within HIV-1 budding, whereas UBPY would not because of its 
inability to interact with the necessary ESCRT-III subunits, however, the exact role 
AMSH plays is not very clear.       
 A possible non-catalytic role was proposed for AMSH at ESCRT-III by 
interfering with cargo sorting by competing with Vps4 for CHMP-binding, possibly 
inhibiting luminal vesicle budding.7 Biochemical studies show that Vps4 works to recycle 
ESCRT-III proteins after membrane scission because omission of Vps2 (CHMP2) 
completely inhibited a second round of ILV formation.63 These data suggest that when 
the cargo is committed into an ILV, and completely deubiquitinated, membrane scission 
occurs, possibly concurrently to ESCRT-III recycling by Vps4.  The idea that AMSH 
competes with Vps4 for CHMP binding was shown previously in which over-expression 
of Vps4 resulted in decreased binding of CHMP1B to wild-type and catalytically inactive 
AMSH, the MIT domain of Vps4 was the minimal domain needed to compete with 
AMSH for CHMP1B binding.16 Contrary to these results, AMSH binds to CHMP3 with 
63 nM affinity, ~70-fold tighter than the tightest affinity measurement for Vps4-
CHMP1A interaction, suggesting that AMSH would be too tightly bound for Vps4 to 
displace the enzyme.37; 38 If we take into account that based on sequence homology and 
functional similarities, CHMP1-3 are grouped together into a class, different from 
CHMP4-6, containing three conserved leucines,38 then AMSH’s affinity for CHMP3 
would be similar to its affinity for CHMP1 proteins, meaning that its affinity for CHMPs 
would be much greater than Vps4’s affinity for CHMPs.  Based on these data we cannot 
see how Vps4 would effectively compete off AMSH for CHMP binding.  There must be 
another mechanism for DUB release prior to Vps4 recycling the ESCRT-III subunits.   
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5.5 DUB Interaction with Ubiquitin Ligases  
 Although it is better understood that DUBs oppose E3 ligase action by removing 
ubiquitin, it is less well understood why some DUBs interact and binding directly to an 
E3 ligase.  It is suggested that a direct interaction between a DUB and an E3 ligase is 
because many E3 ligases undergo autoubiquitination and DUBs serve to stabilize the 
ligase by reversing this autoubiquitination, however, in reversing autoubiquitination, this 
may indirectly destabilize proteins targeted by the E3 ligase because they will get 
ubiquitinated 64.  Accordingly, AMSH and UBPY have been shown to interact directly 
with E3 ligases, and we seek to gain understanding as to what role these interactions 
serve in regards to regulating the ESCRT machinery. 
 
5.5.1 AMSH-E3 Ligase Interaction 
 A yeast two-hybrid study followed by an immuno-precipitation experiment found 
that AMSH binds Ring-finger protein 11 (RNF11), a small, ring-finger protein that has a 
RING H2 domain that facilitates protein-protein interactions involved in ubiquitination 
events, in particular, HECT-type E3 ligases.65 RNF11 binds to the HECT-type E3 ligase, 
Smurf2, using its PY motif, which does not overlap with AMSH binding, suggesting that 
RNF11 acts as an adaptor protein, mediating the interaction between AMSH and 
Smurf2.65 In the presence of RNF11, Smurf2 promotes ubiquitination of AMSH, 
correlating directly to the observation that within total cell lysates, the steady state level 
of AMSH was significantly reduced in the presence of both RNF11 and Smurf2.65 These 
data suggest a role not spoken of much in terms of ESCRT-mediated degradation, that the 
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E3 ligase, the direct interaction of Smurf2 with AMSH (via RNF11) is necessary for 
regulating the steady-state levels of AMSH.  This is consistent with Smurf2’s function of 
catalyzing the ubiquitination of target protein substrates destined for proteolysis.65   
 Similarly, RNF11 interacts with another E3 ligase, atrophin-interacting protein 4 
(AIP4), through the WW domain of AIP4 and the PY motif in RNF11.65 AIP4 is a 
member of the Nedd4-family of E3 ligases in which the prototypic member, Nedd4 has a 
350-amino acid HECT domain, a Ca2+-dependent phospholipid binding C2 domain, and 
three or four WW domains.66 AIP4 mediates agonist-dependent ubiquitination and 
degradation of the G-protein couple receptor, CXCR4, which in turn caused the 
ubiquitination of ESCRT-0 member, Hrs.66 Not only does AIP4 interact with Hrs, it has 
been shown that AIP4 specifically binds STAM, mediated through the SH3 domain of 
STAM because deletion of the SH3 domain reduced AIP4 binding by 50%.67 In 
accordance with AIP4 binding to STAM, wild-type AIP4 enhanced the ubiquitination of 
STAM compared to a catalytically inactive mutant of AIP4.67   In light of these data, it is 
suggested that AMSH specifically recruits AIP4 to ubiquitinate STAM, which is 
stabilized by catalytically inactive AMSH.13 Supporting this hypothesis, proper sorting of 
CXCR4 is dependent on AMSH, suggesting a role that AMSH regulates the 
ubiquitination status of ESCRT-0, which in turns affects the fate of CXCR4.19 
Alternatively, AMSH does not mediate agonist-induced degradation of CXCR4.68 
However, a larger role for STAM in CXCR4 sorting has been proposed in which AIP4 
binding to and ubiquitinating STAM mediates CXCR4-induced extracellular signal-
regulated kinases-1/2 (ERK-1/2) activation.67 Just like RNF11, STAM could be an 
adaptor protein for the interaction of AMSH with the E3 ligase, however, in terms of 
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AIP4, it seems that this interaction is more involved in regulating CXCR4 sorting as 
opposed to regulating the enzyme itself.  
 
5.5.2 UBPY-E3 Ligase Interaction 
 An affinity pull-down assay was conducted to isolate proteins that bound to the 
E3 ligase, Nrdp1, and UBPY was discovered as a Nrdp1 binding partner.45 Consistent 
with the discovery that Nrdp1 is intrinsically unstable in cells due to autoubiquitination 
and subsequent proteasomal degradation, catalytic activity of UBPY greatly enhances 
Nrdp1 stability to a similar level as catalytically inactive mutants of Nrdp1.45 This 
interaction between UBPY and Nrdp1 has been mapped to the rhodanese domain within 
UBPY, the structure basis of which was described previously.45; 49 It is suggested that 
UBPY and Nrdp1 exist as a highly specific complex for three reasons: (1) UBPY does 
not bind the E3 ligase that ubiquitinates EGFR, Cbl,  (2) USP2, a ubiquitin specific 
protease family member with the highest sequence homology to UBPY in its catalytic 
domain, cannot stabilize Nrdp1, and lastly, (3) Nrdp1 mediates subcellular relocalization 
of UBPY.45 All these studies have led to the speculation that Nrdp1 regulates steady-state 
levels of itself and UBPY through autoubiquitination and ubiquitination of UBPY, 
whereas the activity of UBPY can reverse both of these processes.      
 Another interesting DUB-E3 ligase interaction that has been described previously 
involves two DUBs, UBPY and OTU family member, otubain 1, and the E3 ligase, 
GRAIL (gene related to anergy in lymphocytes).44 GRAIL is an active RING-type E3 
ubiquitin ligase that is crucial in the induction of CD4 T cell anergy.44 Yeast two-hybrid 
study found that two isoforms of otubain1, the full length and an inactive splice variant 
 141
with the same C-terminal domain as the wild-type protein, shows opposite effects 
regarding GRAIL stability.44 Even though the wild type otubain1 has deubiquitinating 
activity towards polyubiquitin chains, the wild type promotes autoubiquitinated GRAIL, 
whereas, catalytically inactive otubain1 reduces the amount of autoubiquitinated 
GRAIL.44 This result prompted another yeast two-hybrid experiment in which it was 
found that otubain1 binds the catalytic domain of UBPY, and immuno-precipitation 
showed that otubain1, GRAIL, and UBPY formed a ternary complex.44 In an attempt to 
understand the role of UBPY in the ternary complex, studies show that UBPY can 
deubiquitinate GRAIL, and in forming the complete complex, a catalytically inactive 
UBPY leads to increase polyubiquitination of GRAIL, suggesting that otubain1 may 
regulate UBPY DUB activity, leading to GRAIL autoubiquitination, whereas, inactive 
otubain1, enhances UBPY activity, thus stabilizing GRAIL.44   
 
5.6 Conclusions  
 A significant body of work has been dedicated toward investigating the 
mechanism of action for ESCRT-mediated degradation, however, there is still a lot to 
learn.  The ESCRT-DUBs, AMSH and UBPY, have been extensively studied for their 
structural and in vivo functions, in relation to the consequences due to gene knockouts, 
however, there is still a significant amount of work to be done to understand their exact 
function within the ESCRT machinery.  Using structural and biophysical data we have 
dissected the proposed roles of AMSH and UBPY in an attempt to test these hypotheses.  
We see that AMSH is more suited to play a role at ESCRT-0 than at ESCRT-III because 
of its ubiquitin linkage specificity, however, an experiment to show that AMSH is 
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incapable of deubiquitinating a monoubiquitinated substrate is still lacking.  Furthermore, 
AMSH activity at ESCRT-III is still a mystery because of its linkage specificity.  
Interestingly though, AMSH has the highest CHMP binding affinity with CHMP3, which 
leads one to believe that this tight interaction is of significant importance.  Could AMSH 
really be playing a non-catalytic role at ESCRT-III?  It makes sense for UBPY to work 
similarly to Doa4 in yeast, but is there any other roles for UBPY at ESCRT-III?  Finally, 
the DUB-E3 ligase interaction has not been discussed at great length especially in terms 
of its role in regulating the ESCRT machinery.  Does the DUB-E3 ligase interaction 
serve to regulate the cellular concentration of ESCRT-DUBs?  Overall, the role of DUBs 
within the ESCRT machinery should be looked at more closely because some of the 
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 Christopher was born in Bowling Green, KY to Simeon and Frederica Davies on 
October 8th, 1986.  He was the last of three children, the oldest child, Claire, and the 
middle, Conrad.  His parents were both born in Sierra Leone, West Africa, and they came 
to the United States to finish their schooling, in search of a better life and more 
opportunities for their three children.  Both Simeon and Frederica have Master’s degrees 
from Western Kentucky University, Simeon in Chemistry and Frederica in Library 
Science and Education, which would set the tone for Christopher’s academic career.   
 Christopher grew up in Frankfort, KY where he attended elementary, middle, and 
one year of high school.  Towards the end of his freshman year in high school, Simeon 
approached Christopher about the idea of sending him to a private school in Lexington, 
KY, Lexington Catholic High School, in order to raise the level of his educational and 
athletic training.  He was attending public school in Frankfort, however, due to the 
minimal amount of advanced placement courses and Christopher’s desire to excel in 
soccer, the decision was made to enroll him at Lexington Catholic High School.  
Christopher spent his last three years of high school at Lexington Catholic High School 
becoming a member of the National Honor’s Society and a prominent member of the 
school’s soccer team, helping to lead them to two consecutive final four finishes, the 




 After graduating in 2004 from Lexington Catholic High School, Christopher 
maintained a Davies’ family tradition of attending Western Kentucky University.  Every 
member of his immediate family has received their degree from Western Kentucky.  As 
much as Christopher entertained the idea of attending other universities, Western 
Kentucky proved to be the best fit for his academic, athletic, and overall growth.  Much 
of Christopher’s success at Western Kentucky stemmed from the discipline and drive that 
was required of a division I soccer player.  Christopher’s time at Western Kentucky 
would prove to be a very significant four years in his life.  There were some tough times 
early on in his college career, mostly stemming from growing up and establishing who he 
was, but ultimately ended up well.  While playing four years of soccer, he managed to be 
heavily involved in undergraduate research under the direction of Prof. Thandi Buthelezi.  
Ever semester, including the first two summers, he would work at least 10 hours a week 
in the lab.  His undergraduate research project was to investigate a host-guest relationship 
using cyclophane molecules to capture polyaromatic hydrocarbons (PAHs) out of 
solution. As a result of his studies, he regularly attended and presented at national 
conferences including: the American Chemical Society (ACS) Meeting, the Pittsburg 
Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon), and the 
National Organization for the Advancement of Black Chemists and Chemical Engineers 
(NOBCChE) Meeting.  As a result of attending the ACS meeting, Christopher met Dr. 
James Grainger, a group leader at the Centers for Disease Control and Prevention (CDC) 
in Atlanta, GA.  After meeting Dr. Grainger at the ACS meeting, further contact 
continued for up to a year later, leading to Christopher being invited to do a summer-long 




 The summer between his junior and senior years, Christopher at age 20, moved to 
Atlanta, GA as an intern at the CDC.  The experiences and the people he met during his 
internship were remarkable and important in his journey.  His project at the CDC was to 
develop a method for quantifying benzo[a]pyrene adducts to human serum albumin to 
study the effects of PAH accumulation in smokers versus non-smokers.  That summer he 
learned about proteins and protein purification, which would drive his long-term career 
interests away from pure chemistry to biochemistry.  More importantly, Christopher 
worked under Dr. Angela Ragin-Wilson, who would mentor him on his path to obtaining 
his PhD.  Dr. Ragin-Wilson is distinguished alum from the Chemistry Department at 
Purdue University; so naturally, she pushed Christopher towards applying for Purdue.  
After a long search at schools and professors, Christopher settled on applying for only 
two schools, Purdue University and University of North Carolina Chapel Hill.   
 His senior year at Western Kentucky was focused on applying for graduate school 
and playing his last year of college soccer, but he also continued to work in the lab.  After 
having applied to Purdue in early September, Christopher received his acceptance letter 
in November; however, the application deadline for North Carolina was not until January.  
Having been accepted into Purdue’s graduate school, he was set on attending Purdue, 
until the acceptance letter for North Carolina came in the email.  Christopher actually had 
to make a decision on which school to attend, and North Carolina had initially offered 
him a fellowship package.  After visiting and meeting professors at both schools, the 
much-anticipated decision was made to attend Purdue.  
 Prior to his arrival in West Lafayette in the fall of 2008, he was invited back to 




Lafayette with much anticipation of what graduate school was all about.  It was around 
this time, that Christopher received an encouraging word from his brother Conrad that 
would set the foundation for what was to come.  Conrad told him that he would be a 
highly sought out researcher.  As the years past, Christopher’s graduate career began to 
align under that encouraging word.  Christopher was a co-author of a Proceedings of the 
National Academy (PNAS) paper in his second year, and then, went on to publish his 
first-author publication at Purdue in 2011.  Christopher would then go on to publish four 
more papers in 2011, 2012, and 2013.  He anticipates another two if not three more 
publications in the near future from his work at Purdue.  This publication record would 
help pave the way for his future scientific career.  During his 5th year, Christopher has 
traveled to Fortune 500 companies, government institutions, and research hospitals to 
give oral presentations on his work.  These presentations built an extraordinary 
professional network for him that ultimately led to company and post-doc interviews.  
After much consultation from those important to Christopher, his decision came down to 
where his heart led him.  He accepted a post-doc position at UC Berkeley working for the 
former National Institutes of Health (NIH) professor, James Hurley.  He will be joining a 
well established, well-known professor to further is structural and biophysical training in 
hopes to go on to establish his own independent scientific career.      
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Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a Parkinson
disease-associated, putative cysteine protease found abundantly
and selectively expressed in neurons. The crystal structure of apo
UCHL1 showed that the active-site residues are not aligned in a
canonical form, with the nucleophilic cysteine being 7.7 Å from the
general base histidine, an arrangement consistent with an inactive
form of the enzyme. Here we report the crystal structures of the
wild type and two Parkinson disease-associated variants of the en-
zyme, S18Yand I93M, bound to a ubiquitin-based suicide substrate,
ubiquitin vinyl methyl ester. These structures reveal that ubiquitin
vinyl methyl ester binds primarily at two sites on the enzyme, with
its carboxy terminus at the active site and with its amino-terminal
β-hairpin at the distal site—a surface-exposed hydrophobic crevice
17 Å away from the active site. Binding at the distal site initiates
a cascade of side-chain movements in the enzyme that starts at a
highly conserved, surface-exposed phenylalanine and is relayed to
the active site resulting in the reorientation and proximal place-
ment of the general base within 4 Å of the catalytic cysteine, an
arrangement found in productive cysteine proteases. Mutation of
the distal-site, surface-exposed phenylalanine to alanine reduces
ubiquitin binding and severely impairs the catalytic activity of the
enzyme. These results suggest that the activity of UCHL1 may be
regulated by its own substrate.
deubiquitinating enzyme ∣ enzyme suicide substrate complex ∣
neurodegeneration ∣ ubiquitination
UCHL1, a member of the UCH (ubiquitin C-terminal hydro-lase) family of deubiquitinating enzymes (DUBs), is a 223-
amino acid protein found abundantly and selectively expressed
in brain, constituting up to 1–2% of total brain protein (1, 2).
In vivo studies suggest that UCHL1 is involved in regulation of
ubiquitin pool, apoptosis, and learning and memory, and its ab-
sence in mice because of spontaneous intragenic deletions yields
phenotypes with neurological defects (3). Mutations in UCHL1
have been implicated in Parkinson disease (PD). A point muta-
tion near the active site that changes Ile93 to Met (I93M) has
been linked to an increased risk of developing an autosomal-
dominant form of PD (4). Conversely, a common S18Y poly-
morphism reduces susceptibility to PD (5, 6) and Alzheimer’s
disease (7). In addition to its association with neurodegenerative
diseases, abnormal expression of UCHL1 is found in many forms
of cancer, including lung, colorectal, and pancreatic cancers, and
may be related to tumor progression (8, 9). The normal function
of UCHL1, however, is not known. Also unknown are how the
activity of this abundant neuronal enzyme is regulated and what
its true physiological substrates are, although biochemical studies
have indicated that UCHL1 can accept short-peptide (α or
ϵ-amino-linked) or small-molecule C-terminal conjugates of
ubiquitin as substrates, cleaving, as its name suggests, the amide
bond following immediately after the C-terminal glycine (Gly76)
of ubiquitin (10).
Like other members of the UCH family, UCHL1 is a cysteine
protease, with a catalytic triad consisting of a cysteine (Cys90), a
histidine (His161), and an aspartate (Asp176). The overall struc-
ture of UCHL1 is very similar to that of its nearest UCH relative,
UCHL3, which shares 51% of sequence identity with UCHL1.
However, unlike UCHL3, the catalytic triad in UCHL1 is mis-
aligned. Whereas the His161-Asp176 distance (2.7 Å) is very
much within the expected range, the critical Cys90-His161 pair
is separated by 7.7 Å (the Sγ atom of Cys90 from the Nδ1 atom
of His161), a distance far greater than expected of a productive
cysteine protease (11). This observation raises the question as to
how this enzyme would catalyze the hydrolysis of an amide bond
as a cysteine protease and how it would act as a ubiquitin hydro-
lase. To resolve this issue, we sought to determine the three-
dimensional structure of the enzyme bound to a substrate analog.
Here we report the X-ray structures of the wild-type UCHL1
and its two PD-associated variants, S18Yand I93M, hereafter re-
ferred to as UCHL1S18Yand UCHL1I93M, bound to a substrate
mimic, ubiquitin vinyl methyl ester (UbVMe).
Results
Structure Determination. To prepare a stable complex with ubiqui-
tin, UCHL1 and its variants were allowed to react with UbVMe, a
derivative of ubiquitin with a glycyl vinyl methyl ester (GlyVMe)
group substituting for Gly76 of ubiquitin (Fig. 1A). UbVMe acts
as a suicide substrate for cysteine protease DUBs by targeting the
active-site cysteine leading to the formation of a covalently
bonded DUB–UbVMe complex, in which a thioether bond links
the Sγ atom of the active-site cysteine of the DUB to the Cβ atom
of the VMe moiety (Fig. 1A) (12). The thioether linkage mimics
the thioester reaction intermediate proposed to exist during
catalysis of the peptide bond hydrolysis by a cysteine protease.
UCHL1 and its variants reacted with UbVMe nearly quantita-
tively, as judged by a mobility shift on a sodium dodecyl sulfate
polyacrylamide gel of approximately 8 kDa, the expected mole-
cular mass of ubiquitin (molecular mass, 8564.5 Da), allowing
isolation of the complexes by size exclusion chromatography in
milligram quantities suitable for crystallization.
The UCHL1S18Y–UbVMe complex structure was solved at
2.4 Å by molecular replacement using the wild-type UCHL1
and ubiquitin (residues 1–75) as search models (11, 12). Cross-
rotation followed by translation search identified a single copy
of the complex in the asymmetric unit. The electron density
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map generated after rigid-body followed by restrained refinement
of the model, obtained as the solution to molecular replacement,
was interpretable, indicating the success of the molecular re-
placement search. Refinement using Refmac (13) after rounds
of model building in Coot (14) yielded a final model with a crys-
tallographic R factor of 20.9% and an Rfree of 25.6% (Table S1).
The final model contains a complete UCHL1S18Y chain (resi-
dues 1–223), a ubiquitin chain (residues 1–75), the GlyVMe
group (modeled as 4-amino methyl butanoate), and 51 ordered
solvent molecules. More than 98% of nonglycine residues are
placed within the most favorable and additionally allowed regions
of the Ramachandran plot, and less than 0.5% are located in the
disallowed areas, as defined by the program PROCHECK (15).
Structure of apo UCHL1I93M (2.80 Å) was solved by molecular
replacement using the wild-type UCHL1 as the search model
(SI Methods and Table S1). Structures of UCHL1-UbVMe
(2.85 Å) and UCHL1I93M-UbVMe (2.80 Å) were solved by
molecular replacement using the UCHL1S18Y–UbVMe com-
plex as the search model (SI Methods and Table S1). The struc-
tures of UCHL1-UbVMe and UCHL1I93M-UbVMe are very
similar to that of UCHL1S18Y-UbVMe (Fig. S1). We therefore
chose to focus our discussion only on the UCHL1S18Y–UbVMe
complex because it was determined at the highest resolution.
Overall Structure of UCHL1S18Y in the Complex. UCHL1S18Y is
composed of two lobes, one consisting of five α helices (α1,
α3, α4, α5, and α6) and the other consisting of two helices (α2
and α7) and a 6-stranded β-sheet (Fig. 1B). These secondary
structures together form an α-β-α sandwich fold that charac-
terizes most structurally known members of the papain family of
cysteine proteases, including UCHL3 (16) and the yeast ubiquitin
C-terminal hydrolase Yuh1 (17). Between the two lobes lies a re-
latively deep cleft that harbors the active site, which is composed
of three secondary structure elements: a helix (α3), a strand (β3),
and a loop (L9) on which the members of the catalytic triad
Cys90, His161, and Asp176 reside, respectively. Tyr18 is located
on the solvent-exposed face of the first N-terminal helix (α1).
This residue is involved in tight hydrogen-bonding interactions
with Arg27 with a distance of 2.8 Å separating the hydroxyl
oxygen and one of the guanidinium nitrogens. In contrast, the
corresponding residue in the wild-type protein, Ser18, is comple-
tely solvent-exposed and is not engaged in any interaction with
other protein atoms. The overall architecture of UCHL1S18Y
in UbVMe-bound complex is quite similar to that of apo wild-
type UCHL1 (11), with Cα rmsd of 1.50 Å (Fig. S2). The arrange-
ment of active-site residues, however, is quite different than the
apo form, which has the general base His161 at 7.7 Å from the
nucleophile Cys90, consistent with an inactive state of the enzyme
(16, 18, 19). In the complex, the catalytic residues have adopted a
canonical arrangement found in active cysteine proteases with
His161 at 3.9 Å from the catalytic Cys90.
Specific Interactions of UbVMe with UCHL1S18Y. Binding of UbVMe
with UCHL1S18Y is substantial, burying 2; 548 Å2 solvent-
accessible surface area. Complex formation involves binding of
UbVMe primarily at two sites on the enzyme: the active-site cleft
and a solvent-exposed hydrophobic crevice 17 Å away from the
active-site cysteine, hereafter referred to as the distal site
(Fig. 2A). In terms of the buried accessible surface area on
UCHL1S18Y, the UbVMe-binding interface is split almost
evenly between the two sites, with the contributions from the ac-
tive site and the distal site being ∼45% and ∼55%, respectively.
The C-terminal segment of UbVMe (Val70 to GlyVMe76) is
deeply buried in the active-site cleft, accounting for nearly
46% of the total buried accessible surface. With its backbone
in an extended β conformation, this segment of UbVMe is exten-
sively coordinated by hydrogen-bonding and salt-bridge interac-
Fig. 1. Structure of UCHL1S18Y bound to the suicide substrate UbVMe.
(A) Schematic representation of the UCHL1S18Y–UbVMe complex formed
by covalent attack of the catalytic cysteine of UCHL1S18Y at the α,β-unsatu-
rated bond of the VMe moiety. (B) Ribbon representation of the structure of
UCHL1S18Y–UbVMe complex at 2.4 Å resolution. UbVMe is shown in green.
Secondary structures of UCHL1S18Y discussed in the text are labeled.
Fig. 2. Intermolecular contacts between UCHL1S18Y and UbVMe. (A) Mole-
cular surface representation of UCHL1S18Y structure as observed in the
crystal structure of its complex with UbVMe (shown as a green ribbon), illus-
trating the distal- and active-site binding of UbVMe. The active-site cysteine is
indicated in yellow. The cross-over loop of UCHL1S18Y (L8 in Fig. 1B) is shown
as a purple ribbon. The N terminus of UbVMe is indicated. (Inset) An ex-
panded view of the distal binding site on UCHL1S18Y showing the Phe214
side-chain (Orange) compared to its position in apo UCHL1 (Blue). (B) Ac-
tive-site interactions of the C-terminal segment of UbVMe (Green Ribbon)
with the UCHL1S18Y (Gray Ribbon). Backbone and side chains of interacting
residues are shown in stick representation. Oxygen atoms are shown in red,
nitrogen atoms in blue, and carbon atoms of UCHL1S18Y and UbVMe (1–75)
in gray and green, respectively. Carbon atoms of the GlyVMe residue are
shown in yellow. The segment comprising residues 156–159 of UCHL1S18Y
is removed for clarity.
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tions to residues lining the active-site cleft of the enzyme
(Fig. 2B), with the active-site cysteine linked to the VMe moiety
of the suicide substrate via a thioether bond. In addition to these
contacts, intermolecular van derWaals contacts also contribute to
the specific recognition of the C-terminal segment of UbVMe.
The two hydrophobic residues, Leu71 and Leu73, point into
the catalytic cleft by making direct van der Waals contacts to
the corresponding UCHL1S18Y residues (Leu71 of UbVMe with
Val212 and Arg213 of UCHL1S18Y, and Leu73 of UbVMe with
Ile8, Leu52, and Phe160 of UCHL1S18Y). The last two residues
of UbVMe, Gly75 and GlyVMe76, fit in the narrowest region of
the catalytic cleft (Fig. 2A). The space surrounding the backbone
Cα atoms of these Gly and GlyVMe residues is insufficient to
accommodate any other side chain, consistent with the selectivity
displayed by UCH enzymes for cleaving the amide bond imme-
diately following the terminal Gly-Gly motif of ubiquitin. The
UCHL1S18Y-interacting UbVMe residues determined in this
study are mostly in agreement with a previous mutational analysis
delineating the side chains of ubiquitin required for its recogni-
tion by UCHL1 (20). For example, mutation of residues Leu71,
Leu73, and Gly76 to Ala on ubiquitin-tryptophan as the substrate
significantly reduced the kcat∕KM value by approximately 50-,
100-, and 300-fold, respectively (20).
The so-called active-site cross-over loop is an important struc-
tural feature shared uniquely among the members of the UCH
family of DUBs (11, 17). This loop has been proposed to play
a pivotal role in substrate selection by UCH enzymes (17, 21).
The cross-over loop in UCHL1, comprising of residues Gly150
to Lys157 (loop L8, Fig. 1B), connects the helix α6 on one lobe
and the strand β3 on the other and strings across the active-site
cleft (11) forming an arch directly over the catalytic Cys90
(Fig 2A). The position and the dimension of this loop in apo
UCHL1 are similar to that in UCHL1S18Y–UbVMe complex
(Fig S2), with the diameter of the opening enclosed by the loop
(the distance measured between the Cα atoms of Glu7 and
Val154, the pair of atoms with widest separation across the loop)
being approximately 9 and 13 Å in the apo and UbVMe-bound
forms, respectively. In the complex, the loop appears to have
opened up a little to embrace the C terminus of UbVMe. Com-
parison of the apo and UbVMe-bound structures suggests that
the cross-over loop of UCHL1 is relatively rigid, which may serve
the function of a stereochemical gate for selecting substrates;
only those ubiquitin conjugates whose C-terminal extension at
ubiquitin (the P1' portion of the substrate) can thread through
the narrow arch of the loop would be accepted (Fig. 2A). This
inference is consistent with a previous biochemical analysis show-
ing that UCHL1 can preferentially cleave small leaving groups
such as amino acids and polypeptides from the C terminus of
ubiquitin (10). In contrast, UCHL3 possesses a longer (residues
146–167) and more flexible cross-over loop, which can adopt a
wide range of conformational states allowing the enzyme to
accept larger extensions at the C terminus of ubiquitin (12). In
addition to its apparent role as a stereochemical gate for sub-
strate selection, the cross-over loop also contributes key interac-
tions to the specific recognition of the C-terminal segment of
UbVMe. For example, the side chain of Arg74 of UbVMe is en-
gaged in electrostatic interaction with that of Asp155 of the cross-
over loop, and, reciprocally, the side chain of Arg153 of the cross-
over loop is hydrogen-bonded to the backbone carbonyl of Arg72
of UbVMe (Fig. 2B).
Alignment of Active-Site Residues is Induced by Binding of UbVMe.
The distal site on UCHL1S18Y is occupied by the two-
residue turn segment (Leu8-Thr9) of the N-terminal β-hairpin
of ubiquitin, with Leu8 nestled in the surface-exposed hydropho-
bic pocket lined by Val31, Leu34, Leu51, Phe214, and Ala216 of
the enzyme. Comparison of UCHL1S18Y–UbVMe structure
with that of UCHL1 in apo form reveals remarkable differences
in the position of the side-chain rings of three residues: Phe214,
Phe53, and the general base His161 (Fig. 3A). In the apo form of
the enzyme, the aromatic ring of Phe214 is solvent-exposed,
facing away from the inner core of the protein (Fig. 2A Inset).
Binding of ubiquitin pushes this ring, causing it to swing inward
7.1 Å (Cζ-Cζ distance) away from its position in the apo form of
the enzyme. The displaced ring of Phe214, in turn, causes the
aromatic ring of Phe53 to swivel away by 7.8 Å (Cζ-Cζ distance)
relative to its unbound position to avoid steric overlap. The
aromatic ring of Phe53 is now too close to His161, which, in order
to accommodate the Phe53 ring, moves into the free space in
the vicinity of Cys90 reorienting itself such that the Nδ1 atom
of the imidazole ring faces the Sγ atom of Cys90 with a distance
of 3.9 Å between the two. Consequently, the enzyme adopts a
catalytically competent, papain-like arrangement of the catalytic
triad (Fig. 3B). The possibility that the change in the environment
surrounding Cys90, brought about by its reaction with the VMe
group, might have attracted His161 to its proximity causing the
observed rearrangement cannot be ignored. This possibility could
be addressed in the future by cocrystallizing UCHL1 with a short
vinyl methyl ester such as Gly-VMe.
In addition to the UCHL1S18Y–UbVMe complex, we have
also solved the structures of the wild-type UCHL1–UbVMe
Fig. 3. Binding of ubiquitin induces a conformational relay leading to the
alignment of the catalytic triad. (A) Conformational changes of three side-
chain rings of UCHL1S18Y induced by UbVMe binding. Superposition of
apo UCHL1 (Orange) and UCHL1S18Y in UbVMe-bound form (Gray) showing
the relative positions of Phe214, Phe53, His161, and Cys90. Electron density
(contoured at 1.0σ) is shown as blue line. UbVMe is shown in green (without
the VMe portion). For clarity, the following segments were removed: residues
31–39, 54–57, 147–160, and 207–212 of UCHL1S18Yand apo UCHL1. (B) Com-
parison of the active-site triad of UCHL1S18Y in UbVMe-bound form with
that of apo UCHL1. Oxygen atoms are shown in red, nitrogen atoms in blue,
sulfur in yellow, and carbon in gray (UCHL1S18Y bound) and orange (apo
UCHL1).









(2.85 Å) and UCHL1I93M–UbVMe (2.80 Å). Comparison of
structures of these complexes with their respective apo enzymes
reveals that the relative movement of Phe214, Phe53, and His161
upon UbVMe binding is a common feature in all the UCHL1
variants studied (Fig. 4). To corroborate the crystallographic
observations, we sought to carry out mutational analysis by sub-
stituting Phe214 with alanine (the F214A mutant). As shown in
Fig. 5, the activity of the F214A mutant in ubiquitin aminomethyl
coumarin (UbAMC) hydrolysis assay is significantly reduced re-
lative to the wild-type UCHL1. This difference in the catalytic
activity of the F214A mutant relative to the wild-type enzyme
is not because of the difference in structures of these proteins;
the overall three-dimensional structure of the F214A mutant is
nearly identical to that of the wild type as judged by inspection
of the far-UV circular dichroism spectra (Fig. S3).
The loss of activity observed upon mutation of Phe214 could
be attributed to the impairment of the concerted movements of
phenylalanine residues or the disruption of binding at the distal
site. To explore this further, we performed isothermal titration
calorimetry (ITC) to estimate the binding affinity of ubiquitin to-
ward the wild-type UCHL1 and the F214A mutant (Fig. 6 and
Table S2). Analysis of the ITC data showed that UCHL1 binds
ubiquitin with a dissociation constant (Kd) of 385 nM, whereas
the F214A mutant binds with approximately 60-fold less affinity
(Kd ¼ 22 μM). This reduced affinity for ubiquitin displayed by
the F214A mutant suggests that Phe214 is essential for distal-site
substrate binding, and the loss of catalytic activity of the mutant
may reflect its reduced affinity toward the substrate. This obser-
vation corresponds to the previous biochemical analysis by
Luchansky et al. demonstrating that Leu8 of ubiquitin is critically
required for its interaction with UCHL1 (20).
Discussion
UCHL1 is a neuron-specific DUB that has been linked to neu-
rodegenerative diseases and cancer. In particular, the two point
mutations I93M and S18Y have been linked to the early onset of
and protection from PD, respectively (4–6). Yet the normal func-
tion of UCHL1 and how the activity of this cysteine protease is
regulated remain elusive. The crystal structure of UCHL1 in apo
form revealed that the active-site triad is misaligned for catalysis.
In traditional cysteine proteases, the nucleophilicity of the cata-
lytic cysteine is enhanced by the abstraction of the proton from
the thiol group by a proximal histidine, the general base catalytic
residue (22). Such a relationship between the nucleophilic
cysteine and the general base histidine would require them to
be within ∼4 Å of each other, allowing effective hydrogen-bond-
ing interactions (16). In the apo UCHL1 structure, this distance
(between Cys90 and His161) is 7.7 Å, far greater than expected
for any productive interaction. To understand how this enzyme
functions as a cysteine protease, we have crystallized and solved
the structures of the wild-type UCHL1 and its two PD-associated
variants, UCHL1S18Y and UCHL1I93M, bound to the suicide
substrate UbVMe. The structures of these complexes reveal a
previously unanticipated feature of the enzyme, a substrate-
mediated distal-site effect leading to the transition of the active
site of the enzyme from an unproductive to its productive form.
The binding of the suicide substrate reveals two dominant sub-
strate binding sites on the enzyme: the active-site cleft and a distal
site 17 Å away from the active site. Intermolecular interactions at
the active-site cleft ensure that the scissile peptide bond is
positioned appropriately relative to the catalytic cysteine. The
Fig. 4. Concerted movement of Phe214, Phe53, and His161 side chains
relative to the apo form is also observed in the crystal structures of the
wild-type UCHL1 and its PD-associated variant I93M bound to UbVMe. Super-
position of the structures of apo UCHL1 (Orange), UCHL1-UbVMe (Yellow),
apo UCHL1I93M (magenta), and UCHL1I93M-UbVMe (Cyan) are shown in
ribbon representations. UCHL1S18Y-UbVMe is also shown (Gray Ribbon)
for comparison. UbVMe from the UCHL1S18Y complex is shown in green.
For clarity, the following segments were removed from the structures:
residues 54–56, 210–213, and 154–160 and the VMe moiety.
Fig. 5. Comparison of the enzymatic activity of the wild-type UCHL1 and the
F214A and C90S mutants. Reaction progress curves showing AMC released vs.
time for the cleavage of Ub-AMC by UCHL1 (Cyan), UCHL1F214A (Purple), and
the catalytically inactive mutant UCHL1C90S (Red). The substrate and enzyme
concentrations for all reactions were 600 and 3 nM, respectively.
Fig. 6. Binding isotherm of the titration of UCHL1 and UCHL1F214A with
ubiquitin. (A) Binding of ubiquitin (100 μM) to UCHL1 (10 μM). (B) Binding
of ubiquitin (576 μM) to UCHL1F214A (56 μM). The top panel for each figure
shows the raw data, and the lower panel shows the integrated heat data as
enthalpy as a function of molar ratio of ligand to protein. The solid line in the
bottom panel represents the best curve fit to the data by using a one-site
binding model.
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active-site cross-over loop may help select the appropriate sub-
strate—a yet to be identified ubiquitinated species with small-
molecule or short/unfolded polypeptide as the C-terminal exten-
sion of ubiquitin. However, no useful chemistry can occur without
the presence of the general base histidine, properly oriented, in
the proximity of the catalytic thiol and the scissile peptide bond.
The task of aligning the general base relative to the reactive
moieties appears to be left to the interactions at the distal site.
A conformational relay, presumably starting at a surface-exposed
phenylalanine in the distal site, is triggered by the binding of the
N-terminal β-hairpin of ubiquitin resulting in the placement of
the active-site histidine in the correct location.
Ligand-dependent alignment of an active-site Cys-His pair has
been observed previously in the case of two cysteine proteases:
USP7, a DUB in the USP family (18), and μ-calpain, a calcium-
activated cysteine protease (19). USP7 is a much larger protein
with a very different binding site for ubiquitin. Crystal structures
of USP7 in free and ubiquitin-aldehyde (Ubal)-bound form re-
vealed that the C-terminal segment of Ubal induces significant
backbone conformational changes in the vicinity of the active site
leading to alignment of the catalytic triad (18). In μ-calpain, cal-
cium binding changes the relative orientation of the two domains
of the protease leading to the alignment of active-site residues
(19). In contrast, ubiquitin-induced conformational changes in
UCHL1 appear to originate at a distal site and involve swiveling
motion of the side-chain rings of three residues that work in
a concerted manner to avoid steric clash, with relatively little
backbone reorganization, consistent with the observation that
the UCHL1 backbone is extensively knotted (23).
The pair of phenylalanine residues (Phe53 and Phe214) in-
volved in the active-site alignment in UCHL1 is highly conserved
in different vertebrates (Fig. S4) as well as in other UCHs
(Fig. S5). Although the general mode of ubiquitin binding
observed in the UCHL1–UbVMe complex, including the interac-
tions involving ubiquitin’s Leu8-Thr9 at the distal site, is very
similar to that seen in UCHL3–UbVMe (12) and Yuh1–Ubal
complexes (17), the concerted movement of phenylalanines lead-
ing to active-site alignment is observed only in the case of
UCHL1. Comparison of the structures of UCHL3 in apo (16)
and UbVMe-bound form (12) reveals that the orientation and the
position of the side-chain rings of the phenylalanine pair and the
general base histidine are nearly identical in both forms, overlap-
ping with those observed in the UbVMe-bound form of UCHL1
(Fig. S6). This observation suggests that there is no distal-site
conformational relay in UCHL3, consistent with a preorganized
active-site triad in this enzyme (16). Considering that UCHL1
and UCHL3 share a high level of sequence and structural simi-
larity and their ubiquitin-binding interfaces are nearly identical
(this study and ref. 12), the difference in the way they are regu-
lated is remarkable. Although the biological relevance of this is
unclear at the moment, this difference may translate into a dif-
ferent function and could explain their distinct tissue specificity
(unlike UCHL1, UCHL3 is expressed ubiquitously in all tissues)
(3, 24).
Compared to other UCHs such as UCHL3, whose active-site
triad is prearranged in a catalytically productive conformation,
UCHL1’s active site is misaligned. Therefore, ubiquitin-mediated
activation of UCHL1 appears to be necessary for the catalytic
activity of this enzyme. The structural studies presented herein
provide a mechanism to this end. However, whether this confers
an advantage to UCHL1 over the selective mechanism of other
ubiquitin hydrolases needs to be investigated in the future.
UCHL1 is abundantly expressed in neurons and has been
known to undergo several types of posttranslational modification,
such as farnesylation and monoubiqutination, that may regulate
its localization and enzymatic activity (25, 26). Our crystallo-
graphic results suggest that the activity of UCHL1 is intrinsically
regulated by its own substrate and provide a structural basis for
the enzyme’s specificity for ubiquitin. Interestingly, these studies
also indicate that the PD-associated mutants of UCHL1 (I93M
and S18Y), like the wild-type enzyme, can adopt productive cat-
alytic triads when bound to ubiquitin. The biochemical basis of
how these mutations are linked to PD is yet to be elucidated.
By showing that the mutants can have a similar productive triad,
and hence similar catalytic properties as the wild type, this study
raises an intriguing question as to what could then be the differ-
ence between the mutants and the wild-type protein.
The true in vivo function of UCHL1 remains unclear.
Although it was proposed to be a deubiquitinating enzyme,
primarily because of its sequence similarity with UCHL3, a widely
accepted deubiquitinating enzyme, several lines of evidence
suggest that UCHL1 may have other alternative functions. For
example, a dimerization-dependent ligase activity was previously
proposed for UCHL1 (27). More recently, a report suggests that
UCHL1 can inhibit microtubule formation in a ubiquitination-
dependent manner. The authors of this report suggest that
UCHL1 may increase ubiquitination (and hence behave as a
ligase) of microtubule components (28). In light of these studies,
and others that indicate that UCHL1 may have functions inde-
pendent of the ubiquitin-proteasome system (29, 30) and the mis-
aligned active site observed in the structure of the apo form of the
protein, the demonstration that UCHL1 can adopt a productive
conformation as a hydrolase when bound to ubiquitin assumes
particular significance.
Although UCHL1 is normally expressed in the brain, abnormal
overexpression of this enzyme has been found in many forms of
cancer, including lung and colorectal cancer (8, 9). Identification
of high-affinity small-molecule inhibitors as pharmacological
agents is highly desirable to elucidate the pathophysiological
roles of UCHL1. The crystallographic studies along with the
mutational data presented here suggest that the perturbation of
enzyme–substrate interactions at the distal site of UCHL1 could
be detrimental to its enzymatic activity. Targeting the distal site
with small-molecule binders that can perturb these inter-
actions could be envisioned as an attractive strategy for UCHL1
inhibition.
Experimental Procedures
Cloning, Expression, and Purification. UCHL1S18Y was subcloned
from a pcDNA-UCHL1S18Y vector into a pGex-6P-1 vector
(GE Biosciences) by using standard cloning protocols. The result-
ing N-terminally fused glutathione S-transferase (GST)-tagged
UCHL1S18Y protein was expressed in Escherichia coli Rosetta
cells (Novagen) and purified with a glutathione-Sepharose col-
umn (GE Biosciences) following manufacturer’s instructions.
For expression and purification of other variants of UCHL1
described in this paper, please see SI Methods.
The UCHL1S18Y–UbVMe complex was prepared according
to the method described by Misaghi et al. with slight modifica-
tions (12). In brief, 1 M excess of UbVMe solution (pH adjusted
to 8.0 by adding 1 M NaHCO3) was added to the UCHL1S18Y
protein solution (in 50 mM Tris.HCl, 150 mMNaCl, pH 7.4). The
mixture was incubated for 5 h at room temperature. The forma-
tion of the complex was verified by an 8-kDa shift of the UCHL1
protein band in an SDS-PAGE gel. The UCHL1S18Y–UbVMe
complex was purified by size exclusion chromatography with a
Superdex S75 column (GE Biosciences). UbVMe used in the
preparation of the complex was obtained by intein-mediated
semisynthesis using a previously published procedure (31, 32).
Crystallization and Structure Determination. The UCHL1S18Y–
UbVMe complex was concentrated to ∼25 mg∕mL in a solution
of 50 mM Tris.HCl (pH 7.4), 150 mM NaCl, and 10 mM DTT.
Crystals were grown at room temperature by the hanging drop
vapor diffusion method from a solution that contained 2.4 M
ammonium sulfate and 0.1 M bicine (pH 9.0). Crystals grew









over 2 months to a final dimension of approximately 200 × 200×
100 μm. Crystals were briefly soaked in the cryoprotectant solu-
tion (2.9 M sodium malonate, pH 7.5) and plunged into liquid
nitrogen for flash cooling. X-ray diffraction data (up to 2.4 Å)
were collected at 100 K on a Mar300 CCD detector (Mar
USA) at the beam line 23-ID-D at the Advanced Photon Source
of Argonne National Laboratory. The data were processed with
the program HKL2000 (33). The crystals belong to the space
group R32, with unit cell dimensions a ¼ 87.3 Å, b ¼ 87.3 Å,
c ¼ 193.5 Å, α ¼ 90.0°, β ¼ 90.0°, and γ ¼ 120.0°, with one
UCHL1S18Y–UbVMe complex per asymmetric unit.
The structure was determined by molecular replacement
employing Molrep (34) using the wild-type UCHL1 and human
ubiquitin (residues 1–75) as search models. Cross-rotation and
translational searches identified a single copy of the complex
in the asymmetric unit. Rigid-body refinement of this model
followed by restrained refinement brought the crystallographic
R factor to 31.7% and Rfree to 40.5%. The electron density
map at this stage showed clear density corresponding to the side
chain of Tyr at position 18 on UCHL1S18Yand the VMe part of
UbVMe. Subsequent refinement was performed with Refmac
(13) and model building with Coot (14). The final crystallo-
graphic R factor (Rcryst) and Rfree are 20.9% and 25.6%, respec-
tively (Table S1). The model contains the complete 223-residue
UCHL1S18Y chain, 1–75 residues of ubiquitin, the GlyVMe
moiety (modeled as 4-amino methyl butanoate), and 51 ordered
solvent molecules. More than 98% of the nonglycine residues are
placed within the most favorable and additionally allowed areas
of Ramachandran plot, and less than 0.5% are located in the dis-
allowed areas, as defined within the program PROCHECK (15).
The first five N-terminal residues carried over from the GST-
tagged cloning vector were disordered and, therefore, were not
included in the model. Graphical analysis was done with the
program PYMOL (DeLano Scientific).
Enzymatic Activity Assay. Stock solutions of wild-type UCHL1 and
the F214A and C90S mutants were diluted into the reaction
buffer (50 mM Tris.HCl, pH 7.4, 1 mM DTT, and 1 mM EDTA)
in individual wells of a 96-well plate to the final concentration of
3 nM. UbAMC was added to these wells to yield a final concen-
tration of 600 nM to initiate the enzymatic reaction. The rate of
AMC cleavage was monitored at 25 °C by a TECAN Genios
microplate spectrofluorometer with excitation at 380 nm and
emission at 465 nm.
ITC. ITC was carried out by using a VP-ITC Microcal calorimeter
(MicroCal) at 24 °C. Ubiquitin from bovine erythrocytes was
purchased from Sigma-Aldrich. Amino acid sequences between
human and bovine ubiquitin are identical. Samples of UCHL1,
UCHL1F214A, and ubiquitin were extensively dialyzed against
the buffer 50 mM Tris-HCl, pH 7.6 (buffer A) and then degassed
to remove dissolved air. Titrations consisted of 10-μL injections
of ubiquitin into the sample cell containing the protein, at time
intervals of 4 min to ensure each peak returned to baseline. Each
UCHL1 sample was followed by a background titration of an
equal volume of ubiquitin being titrated into a sample cell con-
taining buffer A to account for the heat of dilution, which was
subtracted from the UCHL1–ubiquitin data. All data were
analyzed by using the program Origin, version 7.0, included with
the system. The data were fitted with a one-site binding model
(one molecule of ubiquitin binding to one molecule of UCHL1).
Binding constants and thermodynamic parameters are given in
Table S2.
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AMSH plays a critical role in the ESCRT (endosomal sorting complexes
required for transport) machinery, which facilitates the down-regulation
and degradation of cell-surface receptors. It displays a high level of
specificity toward cleavage of Lys63-linked polyubiquitin chains, the
structural basis of which has been understood recently through the crystal
structure of a highly related, but ESCRT-independent, protein AMSH-LP
(AMSH-like protein). We have determined the X-ray structure of two
constructs representing the catalytic domain of AMSH: AMSH244, the
JAMM (JAB1/MPN/MOV34)-domain-containing polypeptide segment
from residues 244 to 424, and AMSH219E280A, an active-site mutant,
Glu280 to Ala, of the segment from 219 to 424. In addition to confirming the
expected zinc coordination in the protein, the structures reveal that the
catalytic domains of AMSH and AMSH-LP are nearly identical; however,
guanidine-hydrochloride-induced unfolding studies show that the catalytic
domain of AMSH is thermodynamically less stable than that of AMSH-LP,
indicating that the former is perhaps structurally more plastic. Much to our
surprise, in the AMSH219E280A structure, the catalytic zinc was still held in
place, by the compensatory effect of an aspartate from a nearby loop
moving into a position where it could coordinate with the zinc, once again
suggesting the plasticity of AMSH. Additionally, a model of AMSH244
bound to Lys63-linked diubiquitin reveals a type of interface for the distal
ubiquitin significantly different from that seen in AMSH-LP. Altogether, we
believe that our data provide important insight into the structural difference
between the two proteins that may translate into the difference in their
biological function.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
AMSH, associated molecule with the SH3 (Src
homology 3) domain of STAM (signal transducing
adaptor molecule), is a member of the JAMM (JAB1/
MPN/MOV34) family of deubiquitinating enzymes
(DUBs),1 which catalyze the hydrolysis of isopeptide
or peptide bonds between ubiquitin and target
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cdas@purdue.edu.
Abbreviations used: DUB, deubiquitinating enzyme;
EGFR, epidermal growth factor receptor; GdHCl,
guanidine hydrochloride; AUC, analytical
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proteins or between monomers in polymeric chains of
ubiquitin. The JAMM family, one of the five classes of
DUBs, is composed of metalloproteases, the others
being cysteine proteases.2–5 These metalloproteases,
although having very different sequences compared to
the quintessential metalloprotease thermolysin, are
generally thought to share similar features in their
active site and, hence, mechanism with thermolysin.
They have a Zn2+ in their active site coordinated by
two histidines, an aspartate or a glutamate and awater
molecule, which, in addition to themetal ion, is held in
its place by hydrogen bonding with a different
glutamate residue. This water plays two critical roles:
(1) it acts as the nucleophile during the hydrolysis of
the peptide bond, and (2) in addition to the other
coordinating side chains, it stabilizes the bound Zn2+,
which is responsible for polarizing the carbonyl group
of the scissile peptide bond. However, of the 14 JAMM
proteins in the human genome, only 7 contain a
complete set of conserved residues needed for Zn2+
coordination,2 6 of which, AMSH, AMSH-LP (AMSH-
like protein), BRCC36, RPN11 (POH1), MYSM1 and
CSN5, have been shown to exhibit isopeptidase
activity towardubiquitin or ubiquitin-likeproteins.2,6,7
AMSH is one of the two DUBs, the other being the
cysteine protease DUB UBPY (also known as
ubiquitin-specific protease 8),8 known to be in-
volved in receptor down-regulation and turnover
mediated by the ESCRT (endosomal sorting com-
plexes required for transport) machinery.9 The
ESCRT machinery, composed of four distinct
macromolecular assemblies, ESCRT-0, ESCRT-I,
ESCRT-II and ESCRT-III, drives the internalization
of ubiquitinated cell-surface receptors,10 which are
shuttled from one ESCRT member to the next (e.g.,
from ESCRT-0 to ESCRT-I, from ESCRT-I to ESCRT-
II and so on) until they are finally degraded by the
lysosome or recycled back to the membrane.11 The
initial (ESCRT-0) and the final (ESCRT-III) com-
plexes are the two recognition points for both
AMSH and UBPY. ESCRT-0 recruits the DUBs
through the SH3 domain of STAM binding to the
PX(V/I)(D/N)RXXKP (X is any amino acid) motif
present on both DUBs, whereas ESCRT-III recruit-
ment is facilitated by the MIT (microtubule interact-
ing and transport) domain of the DUBs binding to
CHMPs (chromatin modifying proteins) of ESCRT-
III.9 The ability of DUBs to deubiquitinate endocy-
tosed receptors at various points in the process,
either before or after sequestration of the receptors
into multivesicular bodies, may have a role in
altering receptor trafficking, regulating their turn-
over rate.12
The exact function of AMSH within the ESCRT
machinery is still poorly understood. Studies have
shown that AMSH has a role in the regulation of
several receptors including epidermal growth
factor receptor (EGFR), calcium-sensing receptor,
δ-opioid receptor, protease-activated receptor and
the chemokine receptor CXCR4.13–20 Studies have
also shown that AMSH serves to regulate endoso-
mal trafficking by counteracting the ubiquitination
of ESCRT-0 proteins themselves.12 Not only does
AMSH have a role in endocytosis of receptors,
AMSH also plays a role in mitosis and
cytokinesis.21–24 During mitosis, AMSH deubiqui-
tinates v-SNARE and VAMP8 in an ESCRT-
dependent manner while also being present in
the early phases of cytokinesis, both implicating a
potential role of AMSH as a regulator of prolifer-
ation and survival.21–23
Even though AMSH has no clearly defined role to
date, it is well characterized that AMSH has
specificity toward Lys63-linked polymeric chains
of ubiquitin, which have previously been shown to
be the minimal requirement for directing receptors
toward lysosomal degradation (in some cases,
monoubiquitination instead of polyubiquitination
is used as a signal for lysosomal degradation).13 The
structural basis for Lys63-linked polyubiquitin chain
cleavage has been elucidated with the crystal
structure determination of the DUB (JAMM) domain
of AMSH-LP.25 AMSH and AMSH-LP share 54%
identity and 75% sequence similarity in their JAMM
domain.9,25 It is known that both proteins act as
regulators of free ubiquitin in the cell, bind clathrin,
contain a putative nuclear localization signal and an
MIT domain.9,26,27 Although perceived as function-
ally redundant, AMSH-LP lacks several key features
when compared to AMSH. AMSH contains an SH3-
binding motif, which facilitates interaction with
STAM of ESCRT-0, while a functional SH3-binding
motif is lost in AMSH-LP from primates but present
in chicken, cow, dog, frog, mouse and snake.9,26,27
AMSH's MIT domain interacts with specific ESCRT-
III proteins, CHMPs, while it was shown that none
of the CHMP proteins interacted with AMSH-LP,
suggesting a highly specific interaction with
AMSH.28 In addition to these differences, it is
possible that the biological difference between the
two proteins may lie also in their catalytic domain,
presumed to be very similar based on the similarity
of primary structure.
The present study aims at providing a structural
and thermodynamic comparison between the cata-
lytic domains of AMSH and AMSH-LP. We have
determined the X-ray crystal structures of two
constructs representing the catalytic domain of
AMSH: AMSH244-424, the JAMM-domain-contain-
ing polypeptide segment from residues 244 to 424
(hereafter referred to simply as AMSH244), and
AMSH219E280A, an active-site mutant, Glu280 to
Ala, of the segment 219–424, which, in addition to
the JAMM domain, also features the SH3-domain-
binding motif at its N-terminus. We see that while
the overall folds of the two proteins are nearly
identical, as expected, the catalytic domain of AMSH
is thermodynamically less stable than that of AMSH-
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LP under guanidine hydrochloride (GdHCl)-in-
duced unfolding, based on which we propose that
the catalytic domain of AMSH is structurally more
plastic than the latter, a property that may endow
specific advantage toAMSH, enabling it to adapt to a
variety of working environments within the context
of ESCRT machinery.
Results
Structure of the catalytic domain of AMSH
AMSH244 crystallized in the C2 space group, with
seven monomers in the asymmetric unit (Supple-
mentary Fig. 1). The structure was solved by
molecular replacement (MR) with the catalytic
domain of AMSH-LP as the search model.25 The
MR search identified a model with seven subunits in
the asymmetric unit. Rigid body followed by
restrained refinement of this model yielded a
crystallographic R-factor (Rcrys) and a free R-factor
(Rfree) of 25.4% and 34.8%, respectively. Electron
density map at this stage was interpretable and
showed clear density for the two zinc ions where
they should be located, indicating that the MR
search was successful. Refinement using PHENIX29
after rounds of model building yielded a final Rcrys
and Rfree of 19.3% and 22.9%, respectively (Table 1).
The structure of the polypeptide in different sub-
units is nearly identical except for the N-terminal
residues, Asn244 to Asp252, which were ordered to
a different extent in different subunits.
The observation of seven monomers in the
asymmetric unit prompted us to investigate the
oligomeric state of the catalytic domain of AMSH in
solution. AMSH244 was subjected to analytical
ultracentrifugation (AUC) experiments, along with
the catalytic domain of AMSH-LP for comparison.
The AUC data indicate that, in solution, the catalytic
domains of both AMSH and AMSH-LP exist as
predominantly globular, monomeric proteins with
sedimentation coefficient (s20) values of 2.1 and 2.03,
respectively (Fig. 1). However, these data do not rule
out the possibility that the full-length protein can
exist as a multimer in solution, through self-
association of the part missing in our construct.
Like the DUB domain of AMSH-LP, the structure
of AMSH244 consists of the JAMM core with two
characteristic insertions, insertion 1 (Ins-1, residues
302–327) and insertion 2 (Ins-2, residues 381–403).
The JAMM core comprises a mixed β-sheet in the
shape of a partially unfurled β-barrel sandwiched
by two α-helices, one on top (α1) and one on the
bottom (α3) (Fig. 2a), a feature found in other JAMM
domain proteins, such asAfJAMM and Prp8.30–33 As
seen in AMSH-LP, the catalytic site is lined mostly
by residues from the JAMM core, from the loop
between α1 and β2, α3, β6 and the loop following it
(Fig. 2a). Residues from the β-hairpin turn segment
in Ins-1 also contribute to the catalytic site. The
catalytic zinc is coordinated by His335, His337
(located on β6 and immediately following it),
Asp348 (located on α3) and a water molecule that
is hydrogen bonded to Glu280 (located on the loop
following α1) (Fig. 2b). In addition to these zinc-
coordinating residues, the oxyanion-stabilizing side
chain from Ser345 (on α3) completes the set of
catalytic residues required for peptide bond hydro-
lysis by a thermolysin-type, mechanistically speak-
ing, zinc metalloprotease.34,35 We confirmed the
presence of a second zinc ion, 14 Å away from the
active site, by the presence of strong electron density
in the 2Fobs−Fcalc map in the area coordinated by the
residues His350 from the JAMM core and His396,
His398 and Cys390 from Ins-2 (Fig. 2c), the same set
of residues that coordinate the second zinc ion in
AMSH-LP.25
As seen in the structure of the DUB domain of
AMSH-LP, the active site of AMSH is in a closed
configuration, covered by two side chains, those of
an aspartate (Asp309) in Ins-1 and a phenylalanine




Space group C121 P43212
Cell dimensions
a, b, c (Å) 203.5, 67.4, 113.2 53.4, 53.4, 128.8
α, β, γ (°) 90, 112.4, 90 90, 90, 90
Resolution (Å) 50.0–2.50 (2.59–2.50) 50–1.68 (1.71–1.68)
Rsym
a 8.5 (54.3) 7.1 (60.4)
I/σI 12.6 (2.04) 28.3 (3.7)
Unique reflections 48,879 22,375
Completeness (%) 99.5 (97.8) 99.6 (100.0)





Number of atoms 9560 1398
Number of ions 14 2
rmsd
Bond lengths (Å) 0.008 0.006









Numbers in parentheses are for the high-resolution shell.
a Rsym=∑∑|Ihkl− Ihkl(j)|/∑Ihkl, where Ihkl(j) is the observed
intensity and Ihkl is the final average intensity.
b Rcrys=∑||Fobs|−|Fcalc||/∑|Fobs| and Rfree=∑||Fobs|−|
Fcalc||/∑|Fobs|, where Rfree and Rcrys are calculated using a
randomly selected test set of 5% of the data and all reflections
excluding the 5% test data, respectively.
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(Phe395) in Ins-2, with their van der Waals
surfaces touching each other (Fig. 2a). The side
chains of these two residues have to move away
from each other to let the scissile isopeptide bond
on the substrate access the active site, suggesting
that there is considerable flexibility either in these
side chains or in the polypeptide backbone bearing
them. Interestingly, in the structure of AMSH-LP
DUB domain bound to Lys63-linked ubiquitin
dimer, the corresponding residue pair is still seen
in a similar position as the substrate-free form,25
suggesting that these residues close the active site
during catalysis as well, perhaps to help position
the scissile peptide bond or stabilize the transition
state or both. Both these residues are absolutely
conserved in all AMSH sequences analyzed so far
(data not shown) and in AMSH-LP as well,
suggesting a functional role.
Fig. 2. The structure of the catalytic domain of AMSH. (a) Ribbon representation of the X-ray structure of AMSH244.
(b) Expanded view of the active-site zinc coordination. (c) Expanded view of the second zinc coordination site. The
coordinating residues are shown as sticks, with carbon shown in green, oxygen shown in red, nitrogen shown in blue and
sulfur shown in yellow. Zinc is shown as a gray sphere.
Fig. 1. c(s) distribution plots of the DUB domains of AMSH244 and AMSH-LP as determined by AUC. (a) c(s)
distribution plot of AMSH244 using interference optics shows that the majority of discrete species at 2.1 S is a globular,
monomeric protein. The protein concentrations used were 30 μM (large dashes), 60 μM (continuous line) and 120 μM
(small dashes). (b) c(s) distribution plot of AMSH-LP using absorbance at 280 nm shows that the majority of discrete
species at 2.03 S is a globular, monomeric protein. The protein concentrations used were 25 μM (large dashes), 47 μM
(continuous line) and 94 μM (small dashes).
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In our efforts to structurally characterize AMSH's
recruitment to the ESCRT-0 complex, we generated
an N-terminally longer construct of the catalytic
domain that has, in addition to AMSH's DUB
domain, the peptide sequence that AMSH uses to
bind to STAM's SH3 domain.9 An active-site
mutant of this construct, AMSH219E280A, in which
Glu280 is mutated to alanine, crystallized in the
tetragonal space group P43212, with a single
molecule in the asymmetric unit, consistent with
the monomeric state of AMSH244 found in solution.
The structure of this mutant was solved by MR
using the structure of AMSH244 as the search probe
(Table 1). The overall fold of the two structures is
very similar, with a root-mean-square deviation
(rmsd) between Cα atoms of 0.84 Å. The N-terminal
SH3-binding peptide segment was not visualized in
the structure perhaps because of disorder in the
crystal, suggesting that this peptide segment is
flexible and is easily accessible for binding to the
SH3 domain of STAM. The catalytic activities of
AMSH244 and AMSH219 are similar (Supplemen-
tary Fig. 2), suggesting that the SH3-domain-
binding peptide segment does not fold onto the
catalytic domain, at least not in way to influence
diubiquitin binding. We speculate that the flexibil-
ity of this segment may allow it to serve as a part of
a linker that connects the JAMM domain to the N-
terminal portion of the protein. The structure of the
mutant does confirm the presence of the E280A
mutation; however, clear density in the vicinity of
the active-site metal-coordinating residues was still
observed, which was interpreted as the density
corresponding to a Zn2+ (Fig. 3). Thus, despite
having lost the catalytic glutamate and consequent-
ly the water molecule bound to it, the active-site
Zn2+ is still present. Further inspection reveals that
the side chain of a nearby aspartate, Asp309, has
swung by nearly 120° from its position in the wild-
type structure, positioning itself such that one of its
Oδ atoms can coordinate to the zinc, thereby
restoring the tetrahedral coordination around it
(Fig. 3). As expected, the E280A mutant is still
catalytically inactive despite having the zinc in
place (Supplementary Fig. 2).
A potential disulfide bond in the catalytic
domain of AMSH
The overall structure of AMSH244 and
AMSH219E280A is nearly identical; however, further
inspection during model building revealed the
presence of a potential disulfide bond 7.4 Å away
from the catalytic zinc in the latter. Rounds of
refinement showed positive density around Cys282
within which we modeled in three alternate confor-
mations, one of which placed this cysteine side chain
within disulfide-bonding distance from Cys311 (Sγ–
Sγ distance of 2.0 Å) (Supplementary Fig. 3). The
presence of dithiothreitol (DTT) throughout purifi-
cation and in the crystallization buffer presents a
possible reason for the multiple conformations
observed in the crystals, preventing the cysteine
pair from achieving 100% occupancy in its oxidized
form (Supplementary Fig. 3). It is possible that this
disulfide may exist in AMSH244 as well, but its
observation is precluded because of DTT, whose
reducing effect is perhaps more in this construct
than in AMSH219E280A. Interestingly, sequence
alignment analysis shows that these cysteines are
conserved between AMSH and AMSH-LP;25 how-
ever, we do not see the equivalent cysteine pair
within disulfide-bonding distance in AMSH-LP (Sγ–
Sγ distance is 4.2 Å in this case). Cys282 is next to the
Fig. 3. Superposition of the active sites of AMSH244 andAMSH219E280A. AMSH244 is shown in green, andAMSH219E280A,
in pink. The zinc-coordinating residues in AMSH219E280A are outlined in electron density (2Fobs−Fcalc) at 1 σ.
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active site, and in fact, it makes a van der Waals
contact with Leu73 of the distal ubiquitin in the
structure of AMSH-LP DUB domain bound to
Lys63-linked ubiquitin dimer.25 In the disulfide
orientation, however, as seen in the model of
AMSH244 bound to Lys63-linked diubiquitin
(please see below), the contact is lost. To probe if
the oxidation state of Cys282 is important for the
catalytic activity of the enzyme, we created a mutant
that would lack the disulfide bond (the Cys282-to-
Ala mutant) and prepared the mutant and the wild-
type proteins, avoiding DTT all throughout the
purification procedure. The catalytic activity of the
Cys282Ala mutant is close to the activity seen with
the wild-type protein (the mutant retains ∼80% of
the activity seen with the wild type) (Supplementary
Fig. 2).
AMSH diubiquitin recognition
The overall three-dimensional fold of the catalytic
domain of AMSH is very similar to that of the
previously determined DUB domain of AMSH-LP
[Protein Data Bank (PDB) code: 2ZNR25] with an
rmsd of 1.49 Å of Cα atoms as determined by the
superposition program SuperPose.36 The architec-
ture of both the active site and the second zinc-
binding site of both the proteins is nearly identical
(Fig. 4). To gain insight into how AMSH would
recognize Lys63-linked diubiquitin, we generated a
model of AMSH244 bound to Lys63-linked ubiqui-
tin dimer by superimposing AMSH244 onto the
previously determined X-ray structure of the DUB
domain of AMSH-LPE292A bound to Lys63-linked
ubiquitin dimer (PDB code: 2ZNV25) (Fig. 5). The
overall structure of AMSH244 is similar to that of
ubiquitin-bound DUB domain of AMSH-LP with an
rmsd of 0.93 Å of Cα atoms. This level of structural
similarity suggests that the mode of diubiquitin
binding seen in the model would be preserved in the
actual structure of AMSH244 bound to Lys63-linked
diubiquitin.
Proximal ubiquitin recognition
The residues that are involved in proximal
ubiquitin recognition are completely conserved
between AMSH and AMSH-LP (Fig. 6a) (in diubi-
quitin, a lysine residue of one ubiquitin, called the
proximal ubiquitin, is linked by isopeptide bond to
the C-terminal carboxylate group of another ubiqui-
tin, called the distal ubiquitin). Fig. 7 shows the
superposition of AMSH244 with AMSH-LP's DUB
domain, in both its free form and bound to Lys63-
linked diubiquitin. The position and orientation of
the conserved residues in the proximal site, Phe343,
Phe395 and Thr341 of AMSH (Phe355, Phe407 and
Thr353 in AMSH-LP) (Fig. 7), which are known to
Fig. 4. Structural comparison of the catalytic domains of AMSH and AMSH-LP. (a) Backbone superposition of AMSH
(shown in green) and AMSH-LP (shown in cyan). (b) Expanded view of the zinc-coordinating residues in the active site.
(c) Expanded view of the residues coordinating the second zinc. The coordinating residues are shown as sticks, with
carbon shown in green and cyan, oxygen shown in red, nitrogen shown in blue and sulfur shown in yellow. Zinc is shown
as a gray sphere.
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aid in aligning the isopeptide bond and making
specific contacts with the two residues flanking
Lys63 of proximal ubiquitin, Gln62 and Glu64, are
very similar in both the enzymes, consistent with the
Lys63-linkage specificity exhibited by both. The only
difference seen from the modeling is the orientation
of Ser346 (Ser358 in AMSH-LP). The Oγ atom of
AMSH's Ser346 is pointing away from Glu64 of the
proximal ubiquitin (Fig. 7), contrary to the equiva-
lent residue in both free and ubiquitin-bound
AMSH-LP, which are at distances of 2.4 Å and
2.6 Å from proximal ubiquitin's Glu64, respectively.
Distal ubiquitin recognition
Inspection of the model representing AMSH244
bound to Lys63-linked diubiquitin reveals some
significant differences from AMSH-LP in the resi-
dues that are supposed to be used for interactions
with the distal ubiquitin. First, we see that Asp324 of
AMSH-LP, which makes hydrogen-bonding and
electrostatic interactions with Arg74 of the distal
ubiquitin, is replaced by Asn312 in AMSH, which,
though may be able to retain the hydrogen-bonding
interaction, will lack the electrostatic component,
leading probably to weaker binding. While this
change can be considered conservative to some
extent (Fig. 8), the same cannot be said about the
other two substitutions, AMSH's Thr313 and Glu316
in place of the equivalent Met325 and Val328,
respectively, in AMSH-LP (Fig. 6b). Met325 and
Val328 are making a number of important van der
Waals contacts with hydrophobic residues on the C-
terminus of the distal ubiquitin in AMSH-LP,
particularly with residues Leu73, Val70 and Ile44
(Fig. 8). Threonine is significantly more polar than
methionine but can still provide van der Waals
Fig. 5. Amodel of AMSH244 bound to Lys63-linked ubiquitin dimer. Backbone superposition of AMSH244 (green), the
DUB domain of AMSH-LP (cyan) and the DUB domain of AMSH-LP bound to Lys63-linked diubiquitin (gray). The
proximal ubiquitin and distal ubiquitin are shown in magenta and yellow ribbon, respectively.
Fig. 6. Sequence alignment of AMSH from different
species including AMSH-LP and RPN11. (a) Sequence
alignment comparing the residues implicated in the
proximal ubiquitin binding. (b) Sequence alignment
comparing the residues implicated in the distal ubiquitin
binding.
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contact using its CγH3 group. Glutamate, however,
cannot substitute readily for valine. On the other
hand, Glu316 is appropriately positioned for elec-
trostatic and polar interactions with Arg42 and
Gln49 of the distal ubiquitin as seen in our model
(Fig. 8). Crystal structure analysis of E280A mutant
of AMSH244 bound to Lys63-linked diubiquitin
should be sought to verify if such interactions
actually occur.
In order to understand the consequences of these
substitutions on the kinetic properties of AMSH, we
determined the kinetic parameters of AMSH244 and
compared them with those of the DUB domain of
AMSH-LP. AMSH244 is catalytically less efficient
than the DUB domain of AMSH-LP with Lys63-
linked diubiquitin as the substrate, with most of the
difference being contributed by a kcat that is 7-fold
less, but with a slightly better Km (2-fold lower)
(Table 2 and Supplementary Fig. 4). These data
suggest that the substitutions in the distal site of
AMSH may lead to weaker interactions with the
substrate in the transition state of the reaction being
catalyzed, whereas the interactions in the ground-
state enzyme–substrate complex are relatively less
affected.
Comparison of thermodynamic stability of the
catalytic domains of AMSH and AMSH-LP
To explore further the similarity or the lack thereof
between the catalytic domains of AMSH andAMSH-
LP, we wondered if there would be any difference in
thermodynamic stability between the two proteins.
The unfolding of the catalytic constructs of both
AMSH and AMSH-LP was induced by GdHCl and
monitored at 220 nm using circular dichroism (CD)
spectroscopy. Both proteins reveal a loss in second-
ary structure with increasing concentration of
GdHCl (Supplementary Fig. 5); however, it was
observed that AMSH is less stable toward GdHCl
than AMSH-LP, with midpoint of transitions at 2.7
and 3.5 M GdHCl for AMSH and AMSH-LP,
respectively (Table 3). Using the linear extrapolation
Fig. 7. A view of the residues involved in the proximal ubiquitin recognition. Superposition of AMSH244 (green
ribbon), the DUB domain of AMSH-LP (cyan ribbon) and the DUB domain of AMSH-LP bound to Lys63-linked
diubiquitin (gray ribbon). Residues from the proximal ubiquitin making contact at the proximal site are shown in
magenta.






AMSH244 1.4±0.1 32.0±5.3 43.8
AMSH-LP DUB 10.3±0.3 66.2±4.8 155.6
0.860±0.0654a 71.8±6.3a 12.0a
a Kinetic parameters reported by Sato et al.25 Differences in the
values are presumably due to the difference in substrates used in
the activity assay.







AMSH244 3.7 2.7 −1.4
AMSH-LP DUB 4.9 3.5 −1.4
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method described previously,37 we found ΔGH2O of
AMSH244 to be 1.2 kcal mol−1 less than that of the
DUB domain of AMSH-LP, indicating that the
former is thermodynamically less stable than the
latter (Fig. 9 and Table 3). We propose that this
difference in stability implies a difference in flexibil-
ity between the catalytic domains of the two
proteins. A more stable protein is likely to have
better close packing of side chains, making it more
rigid, whereas a less stable protein, presumably
because it has lesser amount of close packing, can
tend to be more plastic, a property that may make
AMSH more suitable for working in the context of a
number of different types of protein–protein com-
plexes, such as ESCRT-0 and ESCRT-III. Whether
this has anything to do with the biological differ-
ences between the two proteins is worth investigat-
ing in the future.
Discussion
AMSH is one of the two DUBs that are employed
to regulate the functionality of the ESCRTmachinery
by counteracting the ubiquitination of cell-surface
receptors that are directed toward degradation by
the lysosome. Studies have clearly indicated that
AMSH is important for receptor turnover and for
maintaining free ubiquitin pool within the cell;
however, a clearly defined role is yet to be assigned.
What is clearly known is that AMSH has specificity
toward the Lys63-linked ubiquitin chains.9,13 DUB
specificity for one linkage over another was not
understood until the structural basis for Lys63-
linked polyubiquitin cleavage was revealed from
the crystal structure of the DUB domain of AMSH-
LP bound to Lys63-linked ubiquitin dimer.25 The
structure shows how both the proximal and the
distal ubiquitins are recognized; however, AMSH-
LP's role in the cell is still unknown. Although it
shares 54% identity and 75% similarity in its JAMM
domainwith AMSH,26 AMSH-LP is not functionally
redundant, based on its inability to bind to the
Fig. 8. A view of the residues involved in the distal ubiquitin recognition. Superposition of AMSH244 (green
ribbon) and the DUB domain of AMSH-LP bound to Lys63-linked diubiquitin (gray ribbon). The distal ubiquitin is
shown in yellow. Hydrogen-bonding interactions are shown as black dashes, and van der Waals interactions are
shown as blue dashes.
Fig. 9. Fraction unfolded curves comparing the stability
of the catalytic domains of AMSH and AMSH-LP with
increasing concentrations of GdHCl followed by CD
spectroscopy at 220 nm. Data for AMSH244 are shown
in filled circles, and those for the DUB domain of AMSH-
LP are shown in open circles.
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ESCRT complex.9,26 The study presented here seeks
to compare the catalytic domains of AMSH and
AMSH-LP structurally and thermodynamically to
provide further insight into AMSH's sole specificity
within the ESCRT machinery.
We have determined the structure of two con-
structs representing the catalytic domain of AMSH,
AMSH244 and AMSH219E280A. The structure of
AMSH244 confirms that AMSH is indeed a zinc
metalloprotease of the JAMM family of DUBs with
two zinc ions, one at active site and the other playing
a structural role in supporting the placement of
ubiquitin-binding residues in Ins-2 in a position
appropriate for isopeptide bond recognition. The
structure of AMSH219E280A provided a surprising
observation. We anticipated the loss of the active-
site zinc due to the E280Amutation because Glu280,
according to the known mechanism of thermolysin-
type zinc-dependent metalloproteases, is responsi-
ble for holding a water molecule, the one that
functions as the nucleophile, at a position such that it
is able to serve as the fourth ligand in the
coordination sphere of the catalytic zinc. Instead,
we see clear density for the zinc. Asp309, on an
adjacent loop (from Ins-1), has moved in place to
become the fourth residue to coordinate the zinc
(Fig. 3). The ability of the enzyme to counteract the
loss of the glutamate by still retaining its zinc
suggests a form of structural plasticity, allowing for
conformational freedom. A similar mutation was
incorporated in AMSH-LP for the purpose of co-
crystallization with diubiquitin, and the authors
stated that they do not see any electron density
corresponding to the active-site zinc.25 Interestingly,
Asp309 and its equivalent residue in AMSH-LP
have to have a certain amount of flexibility;
otherwise, the active site will not be accessible for
the diubiquitin substrate. The question that if the
observation pertaining to Asp309 in AMSH219E280A
is due to more flexibility of Ins-1 in AMSH than in
AMSH-LP cannot be answered from the data
presented here. It is possible that the same rearran-
gement of the equivalent aspartate in AMSH-LP
might have been observed in the structure of
ubiquitin-free AMSH-LPE292A.
Another interesting finding we see from the
structure of AMSH219E280A is the presence of a
potential disulfide bond adjacent to the active site
(Supplementary Fig. 3). It should be noted that a
disulfide bond next to the putative active-site zinc
was also observed in the structure the JAMM-
domain protein AfJAMM, a cytosolic protein from
Archaeoglobus fulgidus.32 The possibility that the
cysteine pair in AMSH is capable of existing in
reduced and oxidized forms, reduced when in
cytosol and oxidized when associated with endo-
somes, cannot be ruled out. This feature may
contribute to or result from the structural plasticity
of the enzyme. However, we cannot say with any
degree of certainty if this reversible disulfide bridge
is unique to AMSH and, if it is, whether it
contributes to the biological difference between
AMSH and AMSH-LP, two very similar proteins.
It is not clear why the DUB domain of AMSH, not
AMSH-LP, should have a disulfide, or is it common
to both of them (DTT was also present in the
crystallization buffer and throughout purification in
the case of the AMSH-LP DUB domain). If it
happens to be unique to AMSH, it could perhaps
be linked to its association with endosomes, which
have been shown to be oxidizing.38
Moving forward, we sought to directly compare
the catalytic domains of AMSH and AMSH-LP
structurally and thermodynamically. It is expected
that homologous proteins that share 75% sequence
similarity have a similar fold and overall architec-
ture. On par with this expectation, the catalytic
domains of AMSH and AMSH-LP have a nearly
identical fold and superimposable zinc coordination
sites (Fig. 4). Furthermore, AUC experiments con-
firmed that both the proteins are globular and
monomeric in solution (Fig. 1). Thus, structurally,
we cannot separate the two proteins from one
another. Thermodynamically, however, we see a
difference between the two. Chaotrope-induced
unfolding with GdHCl indicates that the catalytic
domain of AMSH is thermodynamically less stable
than that of AMSH-LP (Fig. 9). Analysis of primary
sequences of the proteins does reveal some differ-
ences in certain key positions, such as in the
hydrophobic core (residues Val259, Val363 and
Phe376 in AMSH are substituted by residues
Leu271, Ile375 and Ile388 in AMSH-LP, respective-
ly), which could contribute to the difference in
thermodynamic stability; however, this needs to be
investigated in future.
We have sought to obtain structural insight into
AMSH's ability to recognize Lys63-linked diubiqui-
tin through modeling. Only recently was Lys63-
linkage specificity understood from the structural
analysis of the DUB domain of AMSH-LP bound to
Lys63-linked diubiquitin.25 This structure reveals
interactions between the enzyme and both the distal
and the proximal ubiquitins, but the basis for
specificity arises from residues in the proximal site
of the enzyme interacting with the proximal
ubiquitin, despite a more extensive interaction
with the distal ubiquitin (a significantly more
accessible surface area is buried upon interaction
with distal than proximal ubiquitin).25 Overall,
AMSH adopts very similar interactions when
modeled according to the ubiquitin-bound structure
of AMSH-LP. As indicated by our model, the
proximal binding site is highly conserved between
the two proteins (Fig. 6 and 7), consistent with
Lys63-linkage specificity of AMSH as well. The only
noticeable difference is the orientation of a critical
serine residue, Ser346, which we propose will be
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induced to adopt an orientation seen in AMSH-LP
upon binding to ubiquitin in the proximal site,
consistent with the proposed plasticity of the
enzyme.
Seeing that AMSH may have specific interactions
with the proximal ubiquitin means that this enzyme
will be unable to cleave a monoubiquitinated
receptor because the last ubiquitin moiety is directly
attached to the receptor, which is unlikely to have
the same three-residue peptide sequence that occurs
in ubiquitin and in the same conformation. Our
analysis therefore seems to indicate that AMSH
would only be a chain-modifying enzyme, having
the ability to shorten a Lys63-linked polymeric
chain, leaving the last ubiquitin still attached to the
substrate. However, it has been proposed that
AMSH acts to oppose E3-ligase activity on the
receptor through deubiquitination, presumably by
the complete removal of ubiquitin tag, at an early
stage of endosomal sorting process, thereby pro-
moting recycling of the receptor.9 Consistent with
this model, small interfering RNA-mediated knock-
down of AMSH leads to increased rate of EGFR
degradation, presumably due to enhanced targeting
to the lysosomal pathway.13 This implies that
AMSH is able to completely deubiquitinate EGFR,
since monoubiquitinated EGFR can still be targeted
to lysosome.9 This apparent paradox can be
resolved if we allow for a rearrangement of the
active site of the enzyme, aided once again by its
structural plasticity, brought about by its binding
partners on the ESCRT machinery. Further studies
are needed to confirm AMSH's ability to cleave a
monoubiquitinated substrate to provide clarity to
this hypothesis.
Our analysis reveals a difference in the distal-site
residues between the two enzymes. The rather
nonpolar face of the distal site in AMSH-LP is
replaced by a polar one in AMSH (Fig. 8). Consid-
ering the high level of overall similarity between the
two proteins, this difference is striking. Our kinetic
data appear to indicate that the distal-site differences
may translate into a reduced affinity between the
enzyme and the substrate in the transition state of the
reaction rather than in the Michaelis complex,
making the catalytic domain of AMSH less efficient
than that of AMSH-LP. More work needs to be done
in the future to see if the difference in kinetic
properties we are observing here is related to the
biological difference betweenAMSHandAMSH-LP.
It should be noted that AMSH undergoes activation
upon recruitment to the ECSRT complex,9 the
functional significance of which has not been
understood yet. If this activation is important for
its biological function, one may speculate that the
substitution seen in AMSH's distal site is “designed”
to keep the enzyme in a latent state.
In conclusion, we have determined the structure
of the catalytic domain of the endosome-associated
DUB AMSH and found that though structurally
nearly identical with the catalytic domain AMSH-
LP, it possesses significantly less thermodynamical-
ly stability than the latter, an observation we
propose implies greater structural plasticity for the
catalytic domain of AMSH. This property may, in
addition to having a functional SH3-binding motif
and MIT domain, endow the enzyme with ability to
take part in the ESCRT-mediated functions.
Materials and Methods
Cloning, expression and purification
The DNA encoding AMSH244 was amplified by PCR
using a plasmid that contained full-length DNA as the
template (pGEX-6P1-AMSH, a kind gift from Sylvie Urbe,
University of Liverpool, UK) and was subcloned into
pGEX-6P1 (GE Biosciences) by using standard cloning
protocols. The resulting N-terminally fused glutathione S-
transferase (GST)-tagged protein was expressed in Escher-
ichia coli Rosetta cells (Novagen) and purified with a
glutathione-Sepharose column (GE Biosciences) following
the manufacturer's instructions. After removal of the tag
by PreScission protease (GE Biosciences), the protein was
further purified by size-exclusion chromatography (SEC)
using a Superdex S75 column (GE Biosciences).
AMSH219 was subcloned into a pGEX-6P1 expression
vector as described above. The Glu280Ala mutation was
introduced into the gene by site-directed mutagenesis
using QuikChange Site-Directed Mutagenesis Kit (Strata-
gene) following the manufacturer's protocol. DNA se-
quencing confirmed the presence of the mutation.
AMSH219E280A was purified using standard GST affinity
followed by SEC (Superdex S200 column). The DUB
domain of AMSH-LP (a kind gift from Prof. Shuya Fukai,
The University of Tokyo, Japan) was purified as described
in Ref. 25.
Crystallization and structure determination
Crystals of AMSH244 were grown at room temperature
by the sitting-drop vapor diffusion method from a mother
liquor containing 0.2 M sodium malonate (pH 7.0), 20%
polyethylene glycol (PEG) 3350 and 5% PEG 400. Crystals
of AMSH219E280A were grown at room temperature by
the sitting-drop vapor diffusion method from a mother
liquor containing 0.1 M 4-morpholineethanesulfonic acid
(pH 6.5), 15% PEG 6000 and 5% methyl-2,4-pentanediol.
Crystals were briefly soaked in cryoprotectant solution
(20% ethylene glycol) and then plunged into liquid
nitrogen for flash cooling. X-ray diffraction data were
collected at 100 K on aMar300 CCD detector (Mar USA) at
beamline 23-ID-D at the Advanced Photon Source at
Argonne National Laboratory. The data were processed
using HKL2000.
The crystal structure of AMSH244 was solved by MR
using a homology model of the catalytic domain of
AMSH, built based on the crystal structure of the catalytic
domain of AMSH-LP using the SWISS-MODEL homology
modeling server,39 as the search model. Refinement and
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multiple rounds of model building were carried out using
PHENIX29 and Coot,40 respectively, yielding a final model
with a crystallographic R-factor (Rcrys) of 19.3% and a free
R-factor (Rfree) of 22.9%. Residues Thr250 of chain C,
Ile251 of chain D, Pro402 of chain E and Glu314, Asn315
and Glu316 of chain G are within disallowed regions of the
Ramachandran plot. All of these residues were in weak or
no density at 1 σ except Glu314 and Thr250. The structure
of AMSH219E280A was also determined by MR using
AMSH244 structure as the search model. Refinement and
model building were carried out in the same method as
described above, yielding an Rcrys of 18.0% and an Rfree of
20.5% (Table 1). Graphical analysis was carried out using
PyMOL (DeLano Scientific).
Analytical ultracentrifugation
To characterize the oligomeric state of AMSH and
AMSH-LP, we conducted sedimentation velocity experi-
ments at 50,000 rpm using both the Beckman Coulter XLI
and XLA. (Beckman Coulter, Fullerton, CA, USA). The
samples were monitored by both absorbance and inter-
ference optics at 280 and 675 nm, respectively. The
proteins were dialyzed in 50 mM Tris–HCl (pH 7.6),
50 mM NaCl and 1 mM DTT. Three concentration series
were conducted to evaluate the formation of higher-order
species, AMSH244 at 30, 60 and 120 μM and AMSH-LP at
25, 47 and 94 μM. The sedimentation coefficients and
apparent molecular weights were calculated from size
distribution analyses [c(s)] using SEDFIT v. 12.0 41,42. The
solvent density, viscosity and partial specific volume of
the proteins were calculated using SEDNTERP v. 1.09†.
Guanidine melt using CD spectroscopy
The stability of the folded state ofAMSH244 andAMSH-
LP toward GdHCl was determined using 8-M stock
concentrations of GdHCl (Sigma). Varying concentrations
of GdHClwere added to the protein (0. 2mgmL−1) diluted
in 100 mM phosphate buffer, pH 7.4, and allowed to sit at
room temperature overnight to allow for complete
equilibration. Changes in the folded state of the proteins
were monitored using CD by following changes in
ellipticity at 220 nm. CD spectra were recorded in a Jasco
J-810 Spectropolarimeter in the far-UV region (195–
260 nm) in a 0. 1-cm-path-length cuvette. Each spectrum
was averaged over four scans ( 50 nm min−1 scan speed,
with an 8-s time constant) and corrected by subtraction of a
spectrum of the buffer alone. Mean residue molar
ellipticity values were calculated using the following
equation:
h½  = h × 100 × M
C × l × n
where θ is the ellipticity in degrees, l is the optical path in
centimeters, C is the concentration in milligrams per
milliliter, M is the molecular mass and n is in the number
of residues in the protein.
The mean residue molar ellipticity [θ] is given in degree
per centimeter squared per decimole. Unfolding curves
were analyzed using a two-state unfolding model, using
linear extrapolation to obtain the ΔG value in the absence
of GdHCl.37
Determination of kinetic parameters and DUB assay
Human ubiquitin was subcloned into pGEX-6P1 and
purified using GST affinity chromatography, and the
GST tag was removed by PreScission Protease. The
protein was further purified using SEC (Superdex S75
column). Lys63-diubiquitin was enzymatically synthe-
sized from ubiquitin using ATP, human E1 and the E2
complex (Ubc13 and Uev1a) following previously
reported procedures.25 The reaction was incubated at
37° for 4 h and then quenched by dilution with buffer
A (50 mM sodium acetate, pH 4.5). The quenched
reaction mixture was subjected to ion-exchange chro-
matography on a Mono-S column (GE Biosciences) to
obtain Lys63-diubiquitin.
The in vitro DUB assay was carried out by incubating
AMSH244, wild-type AMSH219, wild-type AMSH219
expressed and purified in the absence of DTT
(AMSH219-DTT), AMSH219C282A (expressed and purified
in the absence of DTT) and AMSH219E280A to a final
enzyme concentration of 100 nM with 20 μM Lys63-
diubiquitin in a total reaction volume of 20 μL. All
reactions were carried out in reaction buffer [50 mM Tris–
HCl (pH 7.0), 25 mM KCl, 5 mM MgCl2 and 1 mM DTT]
for 1 h at 20 °C, except AMSH219-DTT and AMSH219C282A,
which were incubated in the same reaction buffer without
DTT. The reaction was quenched by the addition of 5×
SDS-PAGE sample buffer followed by boiling and then
analyzed by SDS-PAGE.
The kinetic parameters were determined by incubat-
ing the enzyme (100 nM AMSH244 and 25 nM DUB
domain of AMSH-LP) with four concentrations of
diubiquitin, ranging from 20 to 100 μM, in reaction
buffer [50 mM Tris–HCl (pH 7.0), 25 mM KCl, 5 mM
MgCl2 and 1 mM DTT]. The reaction was carried out at
20 °C for 15 min for initial velocity measurements.
Reaction tubes were quenched by the addition of 5×
SDS-PAGE sample buffer followed by boiling. The
reaction mixtures were visualized by SDS-PAGE gels
and scanned. Bands corresponding to monoubiquitin
were integrated using ImageJ software‡. Ubiquitin
standards ranging from 4 to 12.3 μg were used to
draw a calibration plot, which was used to quantify the
amount of ubiquitin produced. Kinetic parameters were
calculated by fitting the data in SigmaPlot.
Accession numbers
Coordinates and structure factors have been deposited
in the PDBwith accession numbers 3RZU (AMSH244) and
3RZV (AMSH219E280A).
Supplementary materials related to this article can be




427Catalytic Domain of AMSH and AMSH-LP
171
Acknowledgements
The authors acknowledge Sylvie Urbé (University
of Liverpool) for her generous gift of the AMSH full-
length plasmid from which we were able to carry
out our studies. We thank Prof. Shuya Fukai
(University of Tokyo) for providing GST-fused
AMSH-LP. We thank Pavel Afonine for his helpful
suggestions on refinement and Alex Tuttle for
cloning GST-tagged ubiquitin. We also thank
Venugopalan Nagarajan and Michael Becker at
beamline 23-ID-D of Advanced Photon Source for
assistance with data collection. The General Medi-
cine and Cancer Institutes Collaborative Access
Team has been funded in whole or in part with
Federal funds from the National Cancer Institute
(Y1-CO-1020) and the National Institute of General
Medical Science (Y1-GM-1104). Use of the Ad-
vanced Photon Source was supported by the U.S.
Department of Energy, Basic Energy Sciences, Office
of Science, under Contract DE-AC02-06CH11357.
Financial support from the National Institutes of
Health (1R01RR026273) is gratefully acknowledged.
References
1. Maytal-Kivity, V., Reis, N., Hofmann, K. & Glickman,
M. H. (2002). MPN+, a putative catalytic motif found
in a subset of MPN domain proteins from eukaryotes
and prokaryotes, is critical for Rpn11 function. BMC
Biochem. 3, 28.
2. Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brum-
melkamp, T.R.,Dirac,A.M., Sixma, T.K.&Bernards, R.
(2005). A genomic and functional inventory of deubi-
quitinating enzymes. Cell, 123, 773–786.
3. Komander, D., Clague, M. J. & Urbe, S. (2009).
Breaking the chains: structure and function of the
deubiquitinases. Nat. Rev., Mol. Cell Biol. 10, 550–563.
4. Wilkinson, K. D. (2009). DUBs at a glance. J. Cell Sci.
122, 2325–2329.
5. Komander, D. (2010). Mechanism, specificity and
structure of the deubiquitinases. Subcell. Biochem. 54,
69–87.
6. Zhu, P., Zhou, W., Wang, J., Puc, J., Ohgi, K. A.,
Erdjument-Bromage, H. et al. (2007). A histone H2A
deubiquitinase complex coordinating histone acetyla-
tion and H1 dissociation in transcriptional regulation.
Mol. Cell, 27, 609–621.
7. Sobhian, B., Shao, G., Lilli, D. R., Culhane, A. C.,
Moreau, L. A., Xia, B. et al. (2007). RAP80 targets
BRCA1 to specific ubiquitin structures at DNA
damage sites. Science, 316, 1198–1202.
8. Avvakumov, G. V., Walker, J. R., Xue, S., Finerty, P. J.,
Jr, Mackenzie, F., Newman, E. M. & Dhe-Paganon, S.
(2006). Amino-terminal dimerization, NRDP1–rhoda-
nese interaction, and inhibited catalytic domain
conformation of the ubiquitin-specific protease
8 (USP8). J. Biol. Chem. 281, 38061–38070.
9. Clague, M. J. & Urbe, S. (2006). Endocytosis: the DUB
version. Trends Cell Biol. 16, 551–559.
10. Wollert, T. & Hurley, J. H. (2010). Molecular mecha-
nism of multivesicular body biogenesis by ESCRT
complexes. Nature, 464, 864–869.
11. Saksena, S., Sun, J., Chu, T. & Emr, S. D. (2007).
ESCRTing proteins in the endocytic pathway. Trends
Biochem. Sci. 32, 561–573.
12. Wright, M. H., Berlin, I. & Nash, P. D. (2011).
Regulation of endocytic sorting by ESCRT-DUB-
mediated deubiquitination. Cell Biochem. Biophys. 60,
39–46.
13. McCullough, J., Clague, M. J. & Urbe, S. (2004). AMSH
is an endosome-associated ubiquitin isopeptidase. J.
Cell Biol. 166, 487–492.
14. Sierra, M. I., Wright, M. H. & Nash, P. D. (2010).
AMSH interacts with ESCRT-0 to regulate the stability
and trafficking of CXCR4. J. Biol. Chem. 285,
13990–14004.
15. Kyuuma, M., Kikuchi, K., Kojima, K., Sugawara, Y.,
Sato, M., Mano, N. et al. (2007). AMSH, an ESCRT-III
associated enzyme, deubiquitinates cargo on MVB/
late endosomes. Cell Struct. Funct. 31, 159–172.
16. Ma, Y.M., Boucrot, E., Villen, J., Affar el, B., Gygi, S. P.,
Gottlinger, H. G. & Kirchhausen, T. (2007). Targeting
of AMSH to endosomes is required for epidermal
growth factor receptor degradation. J. Biol. Chem. 282,
9805–9812.
17. Herrera-Vigenor, F., Hernandez-Garcia, R., Valadez-
Sanchez, M., Vazquez-Prado, J. & Reyes-Cruz, G.
(2006). AMSH regulates calcium-sensing receptor
signaling through direct interactions. Biochem. Biophys.
Res. Commun. 347, 924–930.
18. Reyes-Ibarra, A. P., Garcia-Regalado, A., Ramirez-
Rangel, I., Esparza-Silva, A. L., Valadez-Sanchez, M.,
Vazquez-Prado, J. & Reyes-Cruz, G. (2007). Calcium-
sensing receptor endocytosis links extracellular calci-
um signaling to parathyroid hormone-related peptide
secretion via a Rab11a-dependent and AMSH-sensi-
tive mechanism. Mol. Endocrinol. 21, 1394–1407.
19. Hislop, J. N., Henry, A. G., Marchese, A. & von
Zastrow, M. (2009). Ubiquitination regulates proteo-
lytic processing of G protein-coupled receptors after
their sorting to lysosomes. J. Biol. Chem. 284,
19361–19370.
20. Hasdemir, B., Murphy, J. E., Cottrell, G. S. &
Bunnett, N. W. (2009). Endosomal deubiquitinating
enzymes control ubiquitination and down-regulation
of protease-activated receptor 2. J. Biol. Chem. 284,
28453–28466.
21. Carlton, J. G. & Martin-Serrano, J. (2007). Parallels
between cytokinesis and retroviral budding: a role for
the ESCRT machinery. Science, 316, 1908–1912.
22. Morita, E., Sandrin, V., Chung, H. Y., Morham, S. G.,
Gygi, S. P., Rodesch, C. K. & Sundquist, W. I. (2007).
Human ESCRT and ALIX proteins interact with
proteins of the midbody and function in cytokinesis.
EMBO J. 26, 4215–4227.
23. Mukai, A., Mizuno, E., Kobayashi, K., Matsumoto, M.,
Nakayama, K. I., Kitamura, N. & Komada, M. (2008).
Dynamic regulation of ubiquitylation and deubiqui-
tylation at the central spindle during cytokinesis. J. Cell
Sci. 121, 1325–1333.
24. Tanaka, N., Kaneko, K., Asao, H., Kasai, H., Endo, Y.,
Fujita, T. et al. (1999). Possible involvement of a novel
STAM-associated molecule “AMSH” in intracellular
428 Catalytic Domain of AMSH and AMSH-LP
172
signal transduction mediated by cytokines. J. Biol.
Chem. 274, 19129–19135.
25. Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H.,
Yamashita, M., Ookata, K. et al. (2008). Structural basis
for specific cleavage of Lys 63-linked polyubiquitin
chains. Nature, 455, 358–362.
26. Kikuchi, K., Ishii, N., Asao, H. & Sugamura, K. (2003).
Identification of AMSH-LP containing a Jab1/MPN
domain metalloenzyme motif. Biochem. Biophys. Res.
Commun. 306, 637–643.
27. Nakamura, M., Tanaka, N., Kitamura, N. & Komada,
M. (2006). Clathrin anchors deubiquitinating en-
zymes, AMSH and AMSH-like protein, on early
endosomes. Genes Cells, 11, 593–606.
28. Agromayor, M. & Martin-Serrano, J. (2006). Interac-
tion of AMSHwith ESCRT-III and deubiquitination of
endosomal cargo. J. Biol. Chem. 281, 23083–23091.
29. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W.,
Ioerger, T. R., McCoy, A. J., Moriarty, N. W. et al.
(2002). PHENIX: building new software for automat-
ed crystallographic structure determination. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 58, 1948–1954.
30. Pena, V., Liu, S., Bujnicki, J. M., Luhrmann, R. &
Wahl, M. C. (2007). Structure of a multipartite
protein–protein interaction domain in splicing factor
prp8 and its link to retinitis pigmentosa. Mol. Cell,
25, 615–624.
31. Zhang, L., Shen, J., Guarnieri, M. T., Heroux, A.,
Yang, K. & Zhao, R. (2007). Crystal structure of the
C-terminal domain of splicing factor Prp8 carrying
retinitis pigmentosa mutants. Protein Sci. 16,
1024–1031.
32. Ambroggio, X. I., Rees, D. C. & Deshaies, R. J. (2004).
JAMM: a metalloprotease-like zinc site in the protea-
some and signalosome. PLoS Biol. 2, 113–119.
33. Tran, H. J., Allen, M. D., Lowe, J. & Bycroft, M. (2003).
Structure of the Jab1/MPN domain and its implica-
tions for proteasome function. Biochemistry, 42,
11460–11465.
34. Gupta, S. P. (2007). Quantitative structure–activity
relationship studies on zinc-containing metalloprotei-
nase inhibitors. Chem. Rev. 107, 3042–3087.
35. Lipscomb,W. N. & Strater, N. (1996). Recent advances
in zinc enzymology. Chem. Rev. 96, 2375–2434.
36. Maiti, R., Van Domselaar, G. H., Zhang, H. &Wishart,
D. S. (2004). SuperPose: a simple server for sophisti-
cated structural superposition. Nucleic Acids Res. 32,
W590–594.
37. Pace, C. N. (1986). Determination and analysis of urea
and guanidine hydrochloride denaturation curves.
Methods Enzymol. 131, 266–280.
38. Austin, C. D., Wen, X., Gazzard, L., Nelson, C.,
Scheller, R. H. & Scales, S. J. (2005). Oxidizing
potential of endosomes and lysosomes limits intracel-
lular cleavage of disulfide-based antibody–drug con-
jugates. Proc. Natl Acad. Sci. USA, 102, 17987–17992.
39. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. (2006).
The SWISS-MODEL workspace: a web-based envi-
ronment for protein structure homology modelling.
Bioinformatics, 22, 195–201.
40. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K.
(2010). Features and development of Coot. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 66, 486–501.
41. Brown, P. H. & Schuck, P. (2006). Macromolecular size-
and-shape distributions by sedimentation velocity
analytical ultracentrifugation. Biophys. J. 90, 4651–4661.
42. Schuck, P. (2000). Size-distribution analysis of macro-
molecules by sedimentation velocity ultracentrifuga-
tion and lamm equation modeling. Biophys. J. 78,
1606–1619.
429Catalytic Domain of AMSH and AMSH-LP
173
The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1
(UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK)
Christopher W. Davies a, Joseph Chaney a, Gregory Korbel b, Dagmar Ringe c, Gregory A. Petsko c,
Hidde Ploegh b, Chittaranjan Das a,⇑
aDepartment of Chemistry, Purdue University, West Lafayette, IN, USA
bWhitehead Institute for Biomedical Research, Cambridge, MA, USA
cRosenstiel Basic Medical Sciences Research Center, 415 South Street, MS-029, Waltham, MA, USA
a r t i c l e i n f o
Article history:
Received 8 February 2012
Revised 25 April 2012
Accepted 27 April 2012






a b s t r a c t
UCHL1 is a 223 amino acid member of the UCH family of deubiquitinating enzymes (DUBs), found abun-
dantly and exclusively expressed in neurons and the testis in normal tissues. Two naturally occurring
variants of UCHL1 are directly involved in Parkinson’s disease (PD). Not only has UCHL1 been linked to
PD, but it has oncogenic properties, having been found abnormally expressed in lung, pancreatic, and
colorectal cancers. Although inhibitors of UCHL1 have been described previously the co-crystal structure
of the enzyme bound to any inhibitor has not been reported. Herein, we report the X-ray structure of
UCHL1 co-crystallized with a peptide-based fluoromethylketone inhibitor, Z-VAE(OMe)-FMK (VAEFMK)
at 2.35 Å resolution. The co-crystal structure reveals that the inhibitor binds in the active-site cleft, irre-
versibly modifying the active-site cysteine; however, the catalytic histidine is still misaligned as seen in
the native structure, suggesting that the inhibitor binds to an inactive form of the enzyme. Our structure
also reveals that the inhibitor approaches the active-site cleft from the opposite side of the crossover loop
as compared to the direction of approach of ubiquitin’s C-terminal tail, thereby occupying the P10 (leaving
group) site, a binding site perhaps used by the unknown C-terminal extension of ubiquitin in the actual
in vivo substrate(s) of UCHL1. This structure provides a view of molecular contacts at the active-site cleft
between the inhibitor and the enzyme as well as furnishing structural information needed to facilitate
further design of inhibitors targeted to UCHL1 with high selectivity and potency.
 2012 Elsevier Ltd. All rights reserved.
UCHL1, a protein normally expressed exclusively in the brain
and testis, is a member of the ubiquitin carboxy-terminal hydro-
lase (UCH) family of enzymes, a subclass of a larger group of
enzymes collectively called deubiquitinases (DUBs).1,2 DUBs
catalyze the hydrolysis of isopeptide or peptide bonds between
ubiquitin and target proteins, or between monomers in polymeric
chains of ubiquitin.3–6 Although the exact in vivo substrate(s) for
this enzyme is not known, biochemical studies have shown that
UCHL1 is active only towards ubiquitin conjugates with small leav-
ing groups at the C-terminus of ubiquitin.7,8 There are five classes
of DUBs, four of which are cysteine proteases including the UCH
family, the fifth class being zinc metalloproteases.4–6,9 UCHL1, like
its other family members, UCHL3, UCHL5, and BAP1, contains a cat-
alytic triad consisting of a cysteine (Cys90), a histidine (His161),
and an aspartate (Asp176). The X-ray crystal structure of the en-
zyme is known and reveals a misaligned catalytic triad with a
Cys-His distance of 8 Å, much further than a catalytically compe-
tent distance of 4 Å for a cysteine protease.10 However, upon
binding to ubiquitin, as revealed in the co-crystal structure of this
enzyme with the ubiquitin-based suicide substrate, ubiquitin
vinylmethylester (UbVME), the catalytic triad adopts a productive
arrangement as seen in other active cysteine proteases.11
The physiological function of UCHL1 is not known; however,
abnormal expression of UCHL1 is observed in many forms of can-
cers, including colorectal, lung and pancreatic cancers.12–14 UCHL1
transgenic mice are prone to malignancy, primarily lymphomas
and lung tumors,15 and the gad (gracile axonal dystrophy) mouse
exhibits severe neurologic defects.16 UCHL1’s role in disease makes
it a possible target for design of therapeutics in the form of small-
molecule inhibitors. Many other cysteine proteases have been so
targeted, because elevated and uncontrolled levels of protease
0960-894X/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
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activity can result in physiological imbalance, leading to the onset
of several diseases.17,18 One of the most studied cysteine protease
targets for inhibition is the caspase family of cysteine proteases,
the members of which are covalently inactivated by peptide
halomethyl ketones such as Z-VAD-FMK (benzyloxycarbonyl-Val-
Ala-Asp fluoromethylketone).19 FMKs (fluoromethylketones) are
irreversible inhibitors of cysteine proteases by virtue of their
ability to alkylate the active-site thiol, leading to the displacement
of the halide group by the catalytic cysteine to form a thioether
bond between the cysteine and the inhibitor.18,20
Here we report the X-ray co-crystal structure of UCHL1 with a
tripeptide fluoromethylketone, Z-VAE(OMe)-FMK (benzyloxycar-
bonyl-Val-Ala-Glu(c-methoxy) fluoromethylketone),21 at 2.35 Å
resolution. The co-crystal structure reveals that the inhibitor binds
in the active-site cleft, irreversibly modifying the active-site cys-
teine. However, the catalytic histidine is still misaligned as seen
in the native structure,10 suggesting that the inhibitor binds to
an inactive form of the enzyme. Our structure also reveals that
the inhibitor approaches the active-site cleft from the opposite side
of the crossover loop as compared to the direction of approach of
ubiquitin’s C-terminal tail thereby occupying the P10 site, a binding
site perhaps used by the unknown C-terminal extension of ubiqui-
tin in the actual in vivo substrate(s) of UCHL1. Our structure pro-
vides both the first view of molecular contacts at the active-site
cleft between an inhibitor and this enzyme as well as the structural
information needed to facilitate further design of inhibitors toward
UCHL1 with high selectivity and potency.
Z-VAE(OMe)-FMK (hereafter referred to as simply VAEFMK)
was synthesized as described previously.21 We identified VAEFMK
as an inhibitor of UCHL1 during a screen of inhibitors for the viral
DUB, UL36 (of herpes simplex virus type 1). During that screen,
which included several CMK (chloromethyl ketone) and FMK based
putative cysteine protease inhibitors, it was observed that some of
these molecules inhibited UL36 both in lysates and in cell culture
(unpublished data). The assay employed here relied on the ability
of the DUB to react with HA (hemagglutinin)-tagged ubiquitin
vinylmethyl ester (HA-UbVME). Curiously, we found one particular
compound, VAEFMK, effectively inhibited UCHL1’s reaction with
HA-UbVME at the concentration of 100 lM; however, there was
no effect on UCHL3 and UCHL5 at that concentration. On the other
hand, a related compound, Z-VAD-FMK, was unable to inhibit
UCHL1 activity even at 440 lM concentration (Supplementary
Fig. 2). VAEFMK was co-crystallized with wild-type UCHL1 (upon
covalent modification of the enzyme’s thiol, the fluoride group is
lost (see mechanism below), therefore, the fluoride group is not
seen in the structure and the actual adduct we crystallized should
be referred to as UCHL1-VAE thioether). The co-crystal structure
was solved by molecular replacement (MR) using the structure of
UCHL1 (Protein Data Bank (PDB) code: 2ETL) as the search model.
After MR, the electron density map (2FO–FC) was inspected for
presence of positive density that could correspond to bound inhib-
itor. Inspection of the map indeed revealed positive density corre-
sponding to the inhibitor within the active-site cleft. Using
ProDrug Server,22 we generated a model of the inhibitor and placed
the molecule within the positive density and carried out rounds of
restrained refinement combined with rounds of model building,
which resulted in a final free R (Rfree) and a crystallographic R
(Rcrys) of 25.0 and 19.7%, respectively (Table 1). The final refined
model contains the complete 223 amino acids of the wild-type
UCHL1 with a single molecule of bound inhibitor. The pentapetide
fragment carried over from the GST (glutathione S-transferase)
expression tag after cleavage by PreScission Protease (GE Biosci-
ences, USA) was disordered and therefore not modeled. Similarly
to the native UCHL1 crystal, the model contains a dimer in the
asymmetric unit, with each monomer in the asymmetric unit
containing one copy of the inhibitor.
VAEFMK is a peptide-based inhibitor that resembles the well-
known caspase inhibitor Z-VAD-FMK (Fig. 1a). The usual mecha-
nism of FMK inhibitors proceeds via a two-step addition followed
by collapse/migration/displacement mechanism. Fluorine being a
highly electron withdrawing group combined with the inductive
effects of the carbonyl carbon oxygen makes the carbonyl carbon
more electrophilic than the alpha carbon where the substitution
ends up. Covalent modification proceeds by an initial nucleophilic
attack on the carbonyl carbon by the reactive thiol from the en-
zyme, followed by the collapse of the carbonyl, migration of the
thiol to the alpha carbon, and subsequent displacement of the
Table 1




Space group P 4212
Cell dimensions
a, b, c (Å) 110.0, 110.0, 78.7
a, b, c () 90, 90, 90
Resolution (Å) 50.0–2.35 (2.43–2.35)
⁄Rsym 5.1 (49.9)
I/r I 48.5 (2.1)
Unique reflections 19259





Number of atoms 3589
DRG Molecules 2
rmsd
Bond lengths (Å) 0.005
Bond angles () 1.0
Ramachandran plot
Most favored (%) 91.4
Additionally allowed regions (%) 7.3






⁄Rsym = Rj| I(h)j  <I(h)>|/Rj I(h)j , where I(h)j is the scaled observed intensity of the
jth observation of reflection h, and <I(h)>is the mean value of corresponding
symmetry-related reflections.
1Rcrys =R ||Fobs|  |Fcalc ||/R |Fobs| and Rfree = R ||Fobs|  |Fcalc|/R |Fobs|, where Rfree and
Rcrys are calculated using a randomly selected test set of 5% of the data and all
reflections excluding the 5% test data, respectively. Numbers in parentheses are for
the high-resolution shell.
Figure 1. VAEFMK. (a) Structure of Z-VAE(OMe)-FMK (VAEFMK). (b) UCHL1 is
irreversibly modified by VAEFMK.
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fluorine (the overall reaction is shown in Fig. 1b). Inspection of the
electron density map (2FO–FC) immediately after the MR search
showed electron density adjacent to the Cys90 sulfur atom, with
continuous density emanating from Cys90. This allowed us to
model a covalent bond between the cysteine and the carbon atom
of the FMK group, as drawn in Fig. 1. Thus, the co-crystal structure
shows that VAEFMK binds to UCHL1 (the compound-bound struc-
ture is hereafter referred to as UCHL1-VAE thioether or simply as
UCHL1-VAE) via a similar mechanism of action as that known for
other FMK inhibitors that inactivate cysteine proteases, including
caspases. The inhibitor sits within the solvent-exposed active-site
cleft in an extended conformation. The benzyloxycarbonyl group
of the inhibitor is exposed to solvent and is relatively disordered
as indicated by lack of strong density for the benzylic group,
although its position was clearly discernible in our structure
(Fig. 2). The Glu(OMe) end of the inhibitor is located next to a pock-
et adjacent to the catalytic cysteine in the active-site cleft.
Most of the interactions that stabilize the inhibitorwithin the ac-
tive site of both the subunits of UCHL1 are between the groups that
constitute the oxyanion hole of the enzyme with the backbone of
VAEFMK (Fig. 2 and Supplementary Fig. 1). For example, the back-
bone NH groups of Ser89 and Cys90 hydrogen bond with the
backbone carbonyl oxygen atom of the Glu(OMe) residue of the
inhibitor. The carbonyl group of the Ala residue of the inhibitor is
within hydrogen-bonding distance of the backbone NH groups of
Asn88 and the side chain NH2 group of the oxyanion-stabilizing res-
idue, Gln84. Apart from these hydrogen-bonding interactions, van
der Waals interactions also appear to play a role in stabilizing the
bound inhibitor. For example, the Cb atom of the alanine residue
in the inhibitor makes a contact with the side chain of Arg178,
which seems to have turned around relative to its position in the na-
tive structure to accommodate the inhibitor (Figs. 2 and 3). Also, the
hydrophobic side chain of Val of VAEFMK is nestled against the side
chain of Asn159 (Fig. 2). The inhibitor in one of the subunits appears
to be better definedwithin the active site, perhaps due to additional
interactions with two protein-bound water molecules in the active
site. Backbone NH ofMet6 is hydrogen-bonded to awatermolecule,
which in turn, hydrogen bonds with the carbonyl group on the side
chain of Glu(OMe) residue, and the other water molecule is held in
place by hydrogen-bonding with the side chain of Asn159 (Fig. 2).
These water molecules were not visualized in the other subunit.
The overall architecture of inhibitor-bound UCHL1 has re-
mained the same as in the native structure,10 with root mean
square deviation (rmsd) of 0.67 Å2 in Ca atoms of the two struc-
tures, suggesting a minimal conformational rearrangement upon
binding of the inhibitor. The catalytic triad in the inhibitor-bound
structure maintains the orientation seen in the native protein;
His161 is still 8 Å away from Cys90, even though the inhibitor
covalently modifies the catalytic cysteine (Fig. 3). Since the misa-
ligned active site represents an inactive form of the enzyme, nucle-
ophilicity of the catalytic cysteine does not require the presence of
the catalytic histidine in its vicinity (within hydrogen-bonding dis-
tance), somewhat surprising considering the widely-held view that
the nucleophilicity of the catalytic cysteine in cysteine proteases is
due to its existence as an ion-pair with the catalytic histidine (thio-
late-imidazolium ion pair).23
How does VAEFMK bind to UCHL1? We superimposed the
structures of UCHL1-VAE with that of UbVME-bound UCHL1
(UCHL1-UbVME) (PDB code: 3KW5). The crossover loop compris-
ing residues 150–160 can be thought of as a structural feature that
divides the active-site cleft into two halves, on its right-hand side
lies the P1 subsite (the way it is presented in Fig. 4) and on the left,
the P10 subsite. The C-terminal tail of ubiquitin in the UbVME-
bound structure approaches the active-site thiol from the expected
P1 side of the active-site cleft, whereas the inhibitor approaches
from the other side (Fig. 4). This binding mode may occur because
of the bulky nature of the amino acids bearing the FMKmoiety. The
cleft on the P1 site is narrowest next to the catalytic cysteine, a fea-
ture that allows UCHL1 to position the scissile peptide bond right
after the C-terminal Gly–Gly motif with exquisite precision. This
feature, along with the crossover loop, might have prevented
VAEFMK from approaching the catalytic thiol from the P1 side.
Abnormal expression of UCHL1, whose in vivo function remains
to be established, has been associated with various forms of cancer,
making UCHL1 an attractive target for therapeutics development.
Our data may assist future structure-based efforts to design better
inhibitors. The structure of UCHL1-VAE shows that VAEFMK tar-
gets the active site of UCHL1, as expected, resulting in covalent
modification of the catalytic thiol, thereby irreversibly inactivating
the enzyme. Although the inhibitor is tethered to the catalytic cys-
teine covalently, our structure shows additional non-covalent
interactions between the inhibitor and atoms in the active-site
cleft of the enzyme, mainly between the oxyanion hole groups
with the peptide backbone of VAEFMK (Fig. 2).
The co-crystal structure reported here presents a number of
interesting observations. It shows intermolecular contacts be-
tween the inhibitor and the elements of active site structure of
the enzyme. With very little induced fit (except for Arg178), VAE-
FMK binds to the active site with the Cys–His pair still in misa-
ligned arrangement, as seen in the native structure, suggesting
that the catalytic thiol is sufficiently nucleophilic even without
forming an ion-pair with the catalytic histidine. Previous studies
in papain indicated that the reactivity of the catalytic cysteine
is due to formation of an ion-pair with the catalytic histidine,
Figure 2. Interactions stabilizing VAEFMK within UCHL1’s active site. Stereo view of the active-site residues involved in stabilizing VAEFMK within one subunit of UCHL1’s
active site. UCHL1 is shown in green sticks and VAEFMK in white sticks encapsulated by magenta mesh electron density map (2FO–FC) contoured at 0.8r. The black line
represents van der Waals interactions, while blue dotted lines are hydrogen-bonding interactions.
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analogous to the activation of the catalytic serine in the epony-
mous serine proteases by histidine.24 UCHL1 has been thought to
be papain-like in mechanism of action, but our observation sug-
gests that this may not necessarily be the case. The cysteine may
be reactive enough without participation by the histidine, perhaps
due to a lowered pKa. However, inspection of the contacts around
the catalytic thiol reveals only two nearest neighbors, the back-
bone NH group of Phe162 and the side-chain NH2 group of the oxy-
anion-stabilizing residue Gln84, which are at 4.6 and 5.0 Å from
the Sc atom, respectively. It is unclear if these groups, which are lo-
cated significantly farther than hydrogen-bonding distances, could
influence the pKa of the catalytic thiol. Alternatively, the inhibitor
may have been able to exploit proximity to form the covalent bond
with a relatively unreactive thiol. It is also possible that fluoride
being a good leaving group makes the histidine unnecessary for
the reaction to proceed. The fact that the inhibitor seems to bind
to a misaligned active site of UCHL1 may turn out to be advanta-
geous from the point of view of specificity, because—among UCH
members whose crystal structures have been solved—UCHL1 ap-
pears to be unique with its misaligned active-site triad. It may be
that the very high intracellular concentration of UCHL1 makes it
desirable to have the apoenzyme exist in a form that has little or
no activity, and which is only activated by binding of specific
substrates.
The co-crystal structure identifies a number of potential con-
tacts that can be exploited for future inhibitor design. The methoxy
group on the inhibitor is pointing toward a crevice in the active site
that is lined by mostly hydrophobic side chains (Fig. 5). Installation
of a hydrophobic side chain in place of the methoxy group might
yield tighter-binding analogs. The inhibitor side chain carbonyl
group faces a surface that appears to be lined withmostly polar res-
idues. We speculate that installation of a Glu—by removing the
methoxy group—will improve the potency of the inhibitor, since
Arg153 is poised to make a salt-bridge with the carboxylate group
on the inhibitor. Lastly, by superimposing UCHL1-UbVME with
UCHL1-VAE structures, we generated a composite view (Fig. 4) that
shows how UCHL1 might bind to a ubiquitin conjugate with a C-
terminal extension. This composite picture should be viewed as a
model representing how UCHL1 could bind to its yet-to-be-identi-
fied substrate for hydrolysis. The ubiquitin moiety would bind at
the P1 site (as visualized in the UCHL1-UbVME structure). The leav-
ing group attached to it will be threaded through the crossover
loop, with part of it perhaps sitting in a similar position in the P10
site as seen occupied by VAEFMK. With the catalytic histidine in
place, oriented correctly upon ubiquitin binding, hydrolysis of the
ester or amide linkage between ubiquitin and the C-terminal
extension would be executed, leading to the departure of the leav-
ing group from the VAEFMK side of the crossover loop.
Our structural studies have provided the first inhibitor-bound
X-ray structure of the deubiquitinase UCHL1 co-crystallized with
Z-VAE(OMe)-FMK. Although the inhibitor is seen covalently teth-
ered to the catalytic cysteine through reaction with the FMK group,
this group alone is not sufficient. For example, a close structural
analog of this compound, Z-VAD-FMK, a well-known caspase
inhibitor, does not inhibit UCHL1’s activity even at concentrations
as high as 440 lM. This suggests that suitable FMK inhibitors can
be developed with relatively high selectivity toward UCHL1.
Accession number
Coordinates and structure factors have been deposited in the
Protein Data Bank with accession number 4DM9.
Figure 3. Superposition of wild-type UCHL1, UCHL1-UbVME, and UCHL1-VAE. Active site superposition of UCHL1, UCHL1-UbVME, and UCHL1-VAE showing differences in
the spatial arrangement of active-site residues due to UbVME and VAEFMK binding compared to the wild type. Wild-type UCHL1 is shown in green sticks, UCHL1-UbVME in
cyan sticks, and UCHL1-VAE in white sticks. Both UbVME and VAEFMK have been removed for clarity.
Figure 4. VAEFMK and ubiquitin binding sites within UCHL1. Superposition of
UCHL1-UbVME and UCHL1-VAE reveals a novel binding site for VAEFMK, which
approaches the active site from the opposite side of the crossover loop as compared
to the C-terminal tail of ubiquitin. Ubiquitin is shown in magenta ribbon, VAEFMK
in white sticks, and the crossover loop as blue ribbon.
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the extensions showed the opposite
resemblance. The authors concluded
that recognition of the ground state by
M48U1 and M48U7 is more favorable
energetically, contributing to their higher
affinities. More expansive neutralization
studies (180 isolate panel) revealed potent
activity against all except those from
Clade A/E. The presence of His at position
375 of gp120 of these isolates (instead of
the canonical Ser) is interpreted to explain
this resistance, because the His partially
fills the Phe43 pocket, thereby hindering
access of the extensions (but not CD4 or
the mimetics lacking the extensions).
This is consistent with previous findings
that resistance to M48U1 involves the
substitution of Ser375 with more bulky
residues. The results are discussed in
terms of a new mechanism of action of
CD4 binding site ligands beyond the pre-
viously described avidity (multivalent
forms) and avoidance of conformational
change (e.g., mAb VRC01), namely opti-
mization of the fitting of the hydrophobic
extensions within the interfacial Phe43
cavity.
These new agents and the structural
elucidation of the mechanisms underlying
their enhanced anti-HIV potencies prom-
ise to guide further design of novel
neutralizing agents based on optimal
fitting of extensions into the Phe43 cavity.
The recent ex vivo and nonhuman primate
studies with M48U1 as a vaginal microbi-
cide to prevent HIV-1 sexual transmission
(Dereuddre-Bosquet et al., 2012) are
highly promising for the potential antiviral
use of these miniproteins. Structure-
guided design and analysis thus continue
to pave the way for the development of
new CD4 mimetics that not only cap the
Phe43 cavity, but also fit energetically
favorable extensions deep within its
boundaries.
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E3 ubiquitin ligases are the last of an enzyme trio that covalently modifies proteins with ubiquitin, facilitating
various cellular functions. In this issue of Structure, Duda and colleagues provide the structural basis for the
autoinhibited Ariadne-family of E3-ubiquitin ligases.
Ubiquitination, a covalent attachment of
the 76-amino-acid polypeptide ubiquitin
(Ub) to lysine residues of target proteins,
is an important post-translational modi-
fication that controls a wide range of
cellular processes. Three enzymatic sys-
tems facilitate covalent modification of
proteins by Ub: E1 activating enzymes,
E2 conjugating enzymes, and E3 Ub
ligases. First, Ub is activated via adeny-
lation by E1 and is linked subsequently
to a cysteine residue on the enzyme as a
thioester complex. Ub is then transferred
to the catalytic cysteine on an E2 via
transthiolation. The final step of the ubiq-
uitination cascade involves the transfer
of Ub from the thioester-linked E2 enzyme
(E2Ub) to a Lys residue of the substrate
mediated by an E3 ligase. Two distinct
mechanisms exist for ligation of Ub to
substrates. A homologous to the E6AP





type E3 ligase, so named
because of the presence of a
C-terminally located HECT
domain, transfers Ub from
the active-site cysteine of an
E2Ub complex to the cata-
lytic cysteine within the
HECT domain, forming an
E3Ub thioester intermediate
prior to depositing Ub onto a
Lys residue of the substrate.
The overwhelming majority
of E3 ligases in the human
genome, however, are RING
E3 ligases, which employ a
different mechanism. RING
E3s contain a RING domain
that coordinates a pair of
Zn2+ ions, which is used to re-
cruit E2Ub (Deshaies and
Joazeiro, 2009). Contrary to
HECT E3s, RING E3s do not
have a catalytic residue.
Instead, acting solely as a
scaffold, they bring the
E2Ub complex and sub-
strate together, thereby allowing the
direct transfer of Ub from the catalytic
cysteine of E2s to Lys residues of the
substrate.
In the past, eukaryotic E3s have been
classified as HECT or RING ligases, with
distinct mechanistic features, according
to their structure. But recently, in a sig-
nificant work, Wenzel et al. (2011) pro-
vided first evidence in support of a
RING-HECT hybrid mechanism used by
the novel RING1-in-between-ring (IBR)-
RING2 (RBR) ligase human homolog of
Ariadne (HHARI), the founding member
of a group of conserved eukaryotic
ligases. The well-known members of this
group now include the Parkinson’s dis-
ease (PD)-associated protein Parkin,
which is linked to autosomal recessive ju-
venile PD, and linear Ub chain assembly
complex (LUBAC), which functions in
NF-kB signaling. RBR E3s can be charac-
terized by a canonical RING1 domain,
typical of those found in RING E3s, and
the presence of additional IBR domain fol-
lowed by the RING2 domain, which de-
fines them as a unique group of ligases.
Like the RING domain of RING E3s, the
RING1 domain is known to recruit
E2Ub, with the proposed HECT type of
mechanism arising due to the presence
of an invariant cysteine in the RING2
domain, which is thought to form a thio-
ester intermediate with Ub taken from
the active-site cysteine of the E2 before
ultimately transferring it to a Lys residue
on the substrate. Although biochemical
evidence supported the RING-HECT
hybrid mechanism (Wenzel et al., 2011),
structural understanding of this unique
class of ligases remained elusive. Struc-
tures of RING1, IBR, and RING2 domains
from different RBRs have been character-
ized before, but not together in a full-
length construct. Previous biochemical
studies with RBRs showed that the full-
length proteins are incapable of catalytic
activity, but constructs encompassing
the RBR core are capable of autoubiquiti-
nation, a biochemical read-out of their
enzymatic activity. This suggests that
full-length RBRs are autoinhibited, but
the structural basis of this was not known.
In this issue of Structure, Duda et al.
(2013) provide the first X-ray crystal struc-
ture of full-length HHARI, an Ariadne
family of RBR E3 Ub ligases. Like Parkin
and HOIP (one of the RBRs of the hetero-
dimeric LUBAC E3), the full-length HHARI
remains in an inactive state, but unlike
Parkin, HHARI is still capable of binding
to E2, suggesting that the protein is in a
conformation that prevents its E3 ligase
activity. HHARI is an extended 90 A˚-long
assembly of multiple do-
mains: a UBA-like domain
comprised of a three-helix
bundle, RING1, a two-helix
RING1-to-IBR linker, the
IBR, RING2, and the Ariadne
domain. The IBR and RING1




has a novel Zn2+-binding fold
containing eight cysteines,
seven of which are involved
in Zn2+ coordination, with the
lone unliganded cysteine,
Cys357, required for autoubi-
quitination of HHARI.
The structural basis for
HHARI autoinhibition arises
from the C-terminal Ariadne
domain effectively capping
RING2, thus masking the cat-
alytic cysteine, rendering it
unable to be ubiquitinated.
The Ariadne domain buries
1,000 A˚2 of total surface on
top of RING2, forming 122 contacts.
When the Ariadne domain was deleted
from HHARI, a reversal of the autoinhi-
bited state was seen, and a complemen-
tary experiment showed that an isolated
Ariadne domain also inhibits Ub transfer
when added in trans to a construct of
HHARI lacking the Ariadne domain, sug-
gesting that the release of the Ariadne
domain promotes E2-E3 Ub transfer.
The X-ray structure of HHARI reported
here by Duda et al. (2013) provides un-
ambiguous evidence showing that the
inherent lack of HHARI’s E3 ligase activity
is hardwired in its structure. A similar
mechanism of autoinhibition is perhaps
used by other members of the Ariadne
family of RBRs aswell, although it remains
to be demonstrated. Almost coinciding
with this report, the X-ray structure of
full-length Parkin is also being reported
(Trempe et al., 2013). The structure of
Parkin reveals one more example of an
autoinhibited RBR E3. In Parkin, both the
E2 binding site on RING1 and the catalytic
site on RING2 are blocked by close pack-
ing against other domains unique to this
protein (Trempe et al., 2013). Together,
these structural studies strongly indicate
that autoinhibition may be a common
property of RBR E3s, perhaps to avoid
autoubiquitination that may render these
Figure 1. A Cartoon Representation of the Autoinhibited and Active
State of the RBR E3 Ligase, HHARI
The C-terminal Ariadne domain of HHARI folds back onto RING2, capping the
catalytic cysteine (Cys357), resulting in autoinhibition of ligase activity even
when RING1 is bound to UbE2. Ligase activity is presumed to commence
upon displacement of Ariadne, likely resulting from either posttranslational
modification (PTM) or binding of an unknown Ariadne binding protein (ABP),
leaving the catalytic cysteine exposed for Ub transfer.




enzymes susceptible to rapid, untimely
degradation by proteasome, as specu-
lated by Duda et al. (2013).
This full-length HHARI structure, like
Parkin, drives the field into pondering the
mechanism for activation. Parkin un-
dergoes PINK1-dependent phosphoryla-
tion to turn into an active form; however,
the mechanism is not fully understood
(Trempe et al., 2013). Similarly, the
Ariadne domain needs to be removed
from RING2 to undergo thioester bond
formation and subsequent Ub ligase ac-
tivity, which, as the authors suggest,
could be facilitated either by a post-
translational modification or an Ariadne
binding partner (Figure 1). Future studies
will show us the mechanism of catalytic
activation of these intriguing ligases. The
structures of HHARI and Parkin lay the
foundation of an exciting array of further
structural work that will reveal mecha-
nistic details of RING-HECT hybrid catal-
ysis of Ub transfer.
ACKNOWLEDGMENTS
Financial support from the American Heart Associ-
ation Predoctoral fellowship (12PRE12060249) to
C.W.D. is gratefully acknowledged, and financial
support from the National Institutes of Health
(1R01RR026273) is gratefully acknowledged.
REFERENCES
Deshaies, R.J., and Joazeiro, C.A. (2009). Annu.
Rev. Biochem. 78, 399–434.
Duda, D.M., Olszewski, J.L., Schuermann, J.P.,
Kurinov, I., Miller, D.J., Nourse, A., Alpi, A.F., and
Schulman, B.A. (2013). Structure 21, this issue,
1030–1041.
Trempe, J.F., Sauve, V., Grenier, K., Seirafi, M.,
Tang, M.Y., Menade, M., Al-Abdul-Wahid, S.,
Krett, J., Wong, K., Kozlov, G., et al. (2013). Sci-
ence. Published online May 9, 2013. http://dx.doi.
org/10.1126/science.1237908.
Wenzel, D.M., Lissounov, A., Brzovic, P.S., and
Klevit, R.E. (2011). Nature 474, 105–108.




High-throughput compatible fluorescence resonance energy
transfer-based assay to identify small molecule inhibitors
of AMSH deubiquitinase activity
Jamie L. Arnst a, Christopher W. Davies b, Srikumar M. Raja a, Chittaranjan Das b, Amarnath Natarajan a,c,d,⇑
a Eppley Institute for Cancer Research and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
bBrown Laboratory of Chemistry, Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
cDepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA
dDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
a r t i c l e i n f o
Article history:
Received 25 October 2012
Received in revised form 17 May 2013
Accepted 23 May 2013






a b s t r a c t
Deubiquitinases (DUBs) play an important role in regulating the ubiquitin landscape of proteins. The DUB
AMSH (associated molecule with the SH3 domain of STAM) has been shown to be involved in regulating
the ubiquitin-dependent down-regulation of activated cell surface receptors via the endolysosomal deg-
radative pathway. Therefore, small molecule AMSH inhibitors will be useful chemical probes to study the
effect of AMSH DUB activity on cell surface receptor degradation. Currently, there are no known selective
inhibitors of AMSH or high-throughput compatible assays for their identification. We report the develop-
ment and optimization of a novel fluorescence resonance energy transfer (FRET)-based add-and-read
AMSH DUB assay in a 384-well format. In this format, the optimal temperature for a high-throughput
screen (HTS) was determined to be 30 C, the assay tolerates 5% dimethyl sulfoxide (DMSO), and it has
a Z-score of 0.71, indicating HTS compatibility. The assay was used to show that AMSH selectively cleaves
Lys63-linked diubiquitin over Lys48- and Lys11-linked diubiquitin. The IC50 value of the nonspecific
small molecule DUB inhibitor N-ethylmaleimide was 16.2 ± 3.2 lM and can be used as a qualitative posi-
tive control for the screen. We conclude that this assay is high-throughput compatible and can be used to
identify novel small molecule inhibitors of AMSH.
 2013 Elsevier Inc. All rights reserved.
Ubiquitination of proteins has been implicated in numerous
biological pathways, including (but not limited to) cell cycle regu-
lation, DNA damage, and endocytosis [1–4]. Ubiquitin molecules
are ligated to their target proteins as both mono- and polyubiquitin
chains. The diversity in the linkages (eight different linkages) in the
polyubiquitin chains facilitates the relay of a variety of signals
[4,5]. Deubiquitinases (DUBs)1 cleave the isopeptide bond in the
polyubiquitin chain or the protein–ubiquitin linkage to further reg-
ulate ubiquitin-mediated signaling [4,6]. DUBs are part of multipro-
tein complexes and have both enzymatic and scaffolding functions.
Their knockdown not only eliminates the enzymatic function but
also disrupts the scaffolding functions, resulting in the dysfunction
of the entire complex. DUB activity-specific small molecule inhibi-
tors will provide the precision to specifically study the role of
enzymatic functions within these multiprotein complexes. Recent
studies have also implicated DUBs in several diseases, particularly
cancer, and targeting DUBs for therapeutic intervention is an emerg-
ing theme [7,8].
AMSH (associated molecule with the SH3 domain of STAM)
plays a key role in regulating receptor sorting at the endosome
through its function as a DUB [9–11]. AMSH belongs to the JAMM
(JAB1/MPN/MOV34) DUB family and specifically cleaves Lys63-
linked polyubiquitin [12,13]. Through interactions at multiple
points in endocytic cargo sorting, AMSH plays a critical regulatory
role in cell surface receptor down-regulation [14,15]. Down-regu-
lation is accomplished through the recognition of specific ubiquiti-
nation patterns on internalized receptors, specifically
multi-monoubiquitination and Lys63 polyubiquitination [3,11].
Spatial and temporal dysregulation of AMSH-mediated deubiquiti-
nation of internalized ubiquitinated cell surface receptors affects
their sorting to the lysosome. Consistently, knockdown of endoge-
nous AMSH or overexpression of catalytically inactive AMSH mu-
tants has been shown to promote the lysosomal degradation of
epidermal growth factor receptor (EGFR) as well as other cell sur-
face receptors [16–22]. Small molecule inhibitors of AMSH will be
valuable chemical probes for dissecting endocytic cargo sorting.
0003-2697/$ - see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ab.2013.05.017
⇑ Corresponding author at: Eppley Institute for Cancer Research and Allied
Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA. Fax: +1
402 559 8270.
E-mail address: anatarajan@unmc.edu (A. Natarajan).
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Currently, there are no known inhibitors of AMSH and no report of
a high-throughput compatible assay for the identification of poten-
tial inhibitors.
AMSH alone has been shown to have DUB activity in cell-free
assays, making it suitable for high-throughput screens (HTSs)
[13,23–25]. There are many assay types used in high-throughput
formats to identify inhibitors of enzymes such as proteases
[26,27]. The ease of execution and cost per well has made fluores-
cence-based assays a popular choice in the HTS community. Our
laboratory previously reported the development of fluorescence
polarization assays and HTSs to identify inhibitors of protein–pro-
tein interactions [28–30]. Because it is known that AMSH cleaves
Lys63 ubiquitin chains, we chose to explore a fluorescence reso-
nance energy transfer (FRET)-based system [13,23–25]. In a typical
FRET assay, the donor and acceptor/quencher are spaced by a suit-
able linker that, when cleaved, results in the loss of FRET/gain in
fluorescence. The catalytic domain of AMSH and a Lys63-linked
diubiquitin probe labeled with a donor and a quencher on different
ubiquitins was used in this study. The development and optimiza-
tion of a FRET-based high-throughput compatible AMSH assay is
reported. Importantly, this assay can be easily modified for other
DUBs that demonstrate linkage-specific cleavage, which might
not readily cleave other commercially available ubiquitin probes.
Materials and methods
General reagents
All FRET-labeled diubiquitin probes were purchased from Bos-
tonBioChem (R&D) and were stored in 50 mM Hepes (pH 7.5),
150 mM NaCl, and 2 mM dithiothreitol (DTT). The catalytic domain
of AMSH (residues 219–424) was expressed and purified as de-
scribed previously and stored in 50 mM Tris (pH 7.4), 50 mM NaCl,
and 1 mM DTT [24]. All concentrations shown in parentheses are
final assay concentrations. Anti-ubiquitin antibody (P4D1) was ob-
tained from Cell Signaling.
DUB assay
All measurements were made on 384-well, low-volume, black,
round-bottom polystyrene NBS microplates (Corning) using a
SpectraMax M5 plate reader (MDS). All reactions were done in
reaction buffer (50 mM Hepes [pH 7.0], 25 mM KCl, 5 mM MgCl2,
and 1 mM DTT) in a final volume of 20 ll [24]. Measurements were
taken at an excitation wavelength of 544 nm and an emission
wavelength of 572 nm, and the cutoff was set at 570 nm. The re-
ported fluorescence values (relative fluorescence units, RFU) are a
ratio of total fluorescent signal to the background obtained from
the probe alone. All experiments were performed at least twice
and each time as duplicates.
Dose–response and time-dependent studies of AMSH and K63POS1
probe
AMSH was titrated (15.6–250 nM) into a constant concentra-
tion of K63POS1 probe (500 nM), and the DUB reaction was moni-
tored over time at 15-min intervals for 2 h at 30 C. The optimal
probe concentration was determined by titrating K63POS1 probe
(200–600 nM) while holding the concentration of AMSH constant
at 125 nM. The plate was read following a 90-min incubation.
The relationship between product formation and fluorescence
was determined by incubating 10 lM K63POS1 probe with 5 lM
AMSH overnight at room temperature. Cleaved probe was then di-
luted 2-fold in reaction buffer followed by fluorescent
measurements.
DMSO tolerance
Increasing concentrations of dimethyl sulfoxide (DMSO, 0.5–
25% of the assay volume, 20 ll) was added to AMSH (125 nM),
and the mixture was incubated for 30 min. K63POS1 probe
(500 nM) was then added to the reaction mixture and incubated
for an additional 90 min at 30 C, and measurements were made.
Statistics were performed using a Student’s t test.
NEM inhibition assay
Increasing concentrations of N-ethylmaleimide (NEM, 0.8–
500 lM) were added to AMSH (125 nM) with a 1:9 ratio of vol-
umes and incubated at room temperature for 30 min. Then 10 ll
of K63POS1 probe (500 nM) was added to bring the assay volume
to 20 ll. Fluorescence measurements were made after a 90-min
incubation at 30 C. The data were fitted and the IC50 values were
derived using nonlinear least squares fit to a single site-binding
model (SigmaPlot 11.0). NEM time-dependent inhibition was per-
formed by incubating AMSH (125 nM) with 15 or 30 lM NEM for
1 h, 45 min, 30 min, or 15 min at room temperature. The
K63POS1 probe was then added and incubated for 90 min at 30 C.
The effect of NEM on the K63POS1 probe fluorescence was
determined by incubating cleaved or uncleaved probe with NEM
(0–500 lM) for 90 min at 30 C. Cleaved probe for this study was
generated as described in the ‘‘Dose–response and time-dependent
studies of AMSH and K63POS1 probe’’ section above.
Z-Score
AMSH (125 nM) was incubated for 30 min with or without
25 lM NEM at room temperature. K63POS1 probe (500 nM) was
then added to AMSH, AMSH + NEM, and buffer-only wells for
90 min at 30 C before taking fluorescence measurements. Plates
were then sealed and incubated at 4 C overnight for the 24-h mea-
surement. Data from the 384-well plates were collected on sepa-
rate days, with 48 data points for each condition per day. The Z-
score was calculated using AMSH + K63POS1 probe as the negative
control and K63POS1 probe alone as the positive control.
Results and discussion
Selective cleavage of Lys63-linked diubiquitin probe by AMSH
Several DUBs have been shown to possess linkage-specific
cleavage, including members of the JAMM family [5]. AMSH has
been shown to selectively cleave Lys63-linked polyubiquitin
chains [13,23–25]. The catalytic domain of AMSH and a diubiquitin
FRET probe in which the donor and quencher are placed on differ-
ent ubiquitins linked by the Lys63 isopeptide bond was used to
establish the AMSH assay. To identify a suitable probe and demon-
strate AMSH’s cleavage selectivity, the catalytic domain of AMSH
was incubated with five different diubiquitin probes (K11POS4,
K48POS1, K48POS3, K63POS1, and K63POS3) that have three dif-
ferent linkages (Lys11, Lys48, and Lys63) (Fig. 1A–C, respectively).
Fig. 1 shows the distance between the closest and farthest Lys res-
idues on adjacent ubiquitins. Cleavage of the probes was assessed
by the change in fluorescence following a 1-h incubation with
AMSH (Fig. 2). The cleavage was also confirmed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE; see Fig. S1
in Supplementary material). No change was observed in the
fluorescence reading in the presence of AMSH (Fig. 2, gray bars)
with K11POS4, K48POS1, and K48POS3 probes compared with
probe alone (Fig. 2, black bars), indicating that AMSH did not cleave
the Lys11- or Lys48-linked probes. Approximately 4- and 3-fold
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increases in the fluorescence were observed with the K63POS1 and
K63POS3 probes, respectively. This increase in fluorescence dem-
onstrates that Lys63-linked diubiquitin is cleaved by AMSH. The
difference in the fold change between the two Lys63 probes is
likely due to the different positions of the donor/quencher pair,
where POS3 may interfere with cleavage by AMSH (Fig. 1C).
K63POS1 probe had the larger signal window and, therefore, was
used as the probe for all subsequent studies. The selectivity of sub-
strate from the FRET study was consistent with the observed cleav-
age by Western blot analysis and previously reported studies
showing that AMSH preferentially cleaves Lys63-linked polyubiqu-
itin chains over Lys48-linked polyubiquitin chains [13–15,23–25].
AMSH FRET assay optimization
Next, to optimize the concentration of reagents and time of
incubation to be used for a screen, we conducted dose–response
and time-dependent studies. A dose-dependent increase in the
fluorescence was observed with increasing concentrations of
AMSH (0–250 nM), with the signal beginning to saturate at
250 nM (Fig. 3). For subsequent studies, we selected 125 nM AMSH
because this provided a reasonable signal window while minimiz-
ing reagents. The time-dependent increase in the cleavage of the
K63POS1 probe was monitored over 2 h (Fig. 4). The fluorescent
signal was linear up to 90 min, after which it began to plateau
due to complete consumption of K63POS1 probe. Therefore, for
the above concentrations of enzyme and substrate, we concluded
that an incubation time of 90 min will yield the largest signal win-
dow while still in the linear range. Next, we performed a dose-
dependent study with the K63POS1 probe. We observed increased
signal with increasing K63POS1 probe concentrations, which
plateaued at 500 nM at 90 min (Fig. 5A, gray bars). To determine
whether this saturation was an artifact of the detection system,
the K63POS1 probe was incubated with AMSH overnight to gener-
ate cleaved ubiquitin, which was then titrated in reaction buffer,
Fig.1. Diubiquitin structures. Shown are structures of K11 diubiquitin (A), K48 diubiquitin (B), and K63 diubiquitin (C), with the lysine residues (red) and the isopeptide bond
(cyan) shown as sticks. The largest and smallest distances between lysine residues on the proximal and distal ubiquitins are shown. (For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.)
Fig.2. AMSH probe selection. Diubiquitin probes of different linkages (final
concentration of 500 nM) were incubated with (gray bars) or without (black bars)
250 nM AMSH for 30 min at 30 C (n = 2).
Fig.3. The fluorescence signal is dose dependent. AMSH was titrated (0–125 nM)
into 500 nM K63POS1 probe and incubated for 2 h at 30 C (n = 2).
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and fluorescence was measured. We observed a linear relationship
between probe concentration and fluorescence (Fig. 5B), suggest-
ing that the saturation observed in Fig. 5A is not an artifact of
the detection system. In this study, we also observed a smaller
dose-dependent increase in the noise with increasing K63POS1
probe concentrations (Fig. 5A, black bars). Although the best signal
to noise (4) was observed at both 200 and 500 nM of the
K63POS1 probe, for subsequent studies we selected the 500-nM
concentration because it provided a larger screening window (9
vs. 3).
Temperature dependence
Screening large libraries takes several days to complete, and
there are always fluctuations despite the best climate-controlled
environment; therefore, we next assessed the effect of temperature
on the stability of this assay. This was accomplished by incubating
the K63POS1 probe with and without AMSH at five different tem-
peratures (25–45 C) for 90 min (Fig. 6). With increasing tempera-
tures, we observed a significant increase in the variability of the
AMSH + K63POS1 fluorescent signal, particularly at temperatures
above 40 C, but little change in probe alone. This indicates that
temperatures should not exceed 40 C during an HTS. In addition,
we observed variation in the signal window, with the largest win-
dow seen at 30 C. Although at 25 C we observed less fluctuation
in the signal with AMSH, we conclude that 30 C is optimal because
it results in a larger screening window in this assay format.
DMSO tolerance
DMSO is a widely used solvent for small molecules, and com-
mercially available chemical libraries used in screening campaigns
are commonly shipped as DMSO solutions. Thus, the effect of
DMSO on the assay was assessed. Increasing concentrations of
DMSO were titrated into a constant concentration of AMSH and
incubated for 30 min. The K63POS1 probe was then added, and
the resulting mixture was incubated for an additional 90 min
(Fig. 7). We observed a small but significant increase in the back-
ground at 5% DMSO, with much larger effects at higher DMSO con-
centrations (Fig. 7, black bars). In addition, a significant decrease in
the signal at 10% DMSO (Fig. 7, gray bars) was observed. This sug-
gests that DMSO has a significant effect on the assay, particularly
as it relates to the screening window. Based on these observations,
Fig.4. The fluorescence signal is time dependent. AMSH (125 nM) was incubated
with 500 nM K63POS1 probe at 30 C. The signal was monitored over 2 h (n = 2).
Fig.5. (A) Optimization of K63POS1 probe concentration. AMSH concentration was held constant at 125 nM, and K63POS1 probe was titrated in and incubated at 30 C for
90 min (n = 2). (B) Linear relationship between monoubiquitin formation and fluorescence. K63POS1 probe (10 lM) was incubated with or without 10 lM AMSH overnight.
Cleaved probe was then titrated in buffer (2.5–2.5 lM) (n = 2).
Fig.6. Temperature dependence of AMSH DUB activity. K63POS1 probe (500 nM)
was incubated either with or without AMSH (125 nM) for each temperature. For
each temperature, measurements were taken following a 90-min incubation of
AMSH and probe (n = 2).
74 FRET-based AMSH deubiquitinase assay / J.L. Arnst et al. / Anal. Biochem. 440 (2013) 71–77
185
we conclude that the assay does not tolerate DMSO above 5% and
that during an HTS DMSO concentrations should be kept to a min-
imum and should not exceed 5%.
Inhibition studies
Currently, there are no known selective inhibitors of AMSH;
however, a positive control is desirable for a high-throughput
screening campaign. A previous study showed that the nonselec-
tive Michael acceptor, NEM, inhibits AMSH, possibly by reacting
with Cys282 near the active site [13]. Therefore, to demonstrate
that small molecules can inhibit AMSH in this FRET-based assay
format, we determined the effects of NEM in the AMSH FRET assay
(Fig. 8). AMSH was incubated with different concentrations of NEM
(5-fold dilutions) for 30 min at room temperature. The K63POS1
probe was then added, and the mixture was incubated for an addi-
tional 90 min at 30 C. Fluorescence measurements revealed a
dose-dependent decrease with increasing concentrations of NEM,
indicating inhibition of AMSH (Fig. 8). The IC50 value
(16.2 ± 3.1 lM) for NEM was determined by curve fitting the data.
We also observed a time-dependent effect of AMSH inhibition by
NEM at 15 lM (IC50) and 30 lM (2  IC50) (Fig. 9). Increasing
inhibition by NEM was observed up to 45 min of incubation with
AMSH, after which saturation was observed. This is likely due to
all available NEM having reacted with AMSH at these concentra-
tions. In addition, to confirm that NEM was not affecting the FRET
signal of the K63POS1 probe, we incubated increasing concentra-
tions of NEM (0–500 lM) with cleaved or uncleaved K63POS1
probe (Fig. 10). We observed no significant effects on the fluores-
cent signal in the presence of NEM. Because AMSH belongs to the
JAMM family of DUBs that are Zn metalloproteases, the chelation
agents phenanthroline and 2,20-bipyridine were also tested in this
assay (data not shown). To our surprise, we observed inhibition of
AMSH only at very high concentrations (>1 mM) of the com-
pounds. Based on these findings, we suggest NEM as a qualitative
positive control for high-throughput screening campaigns to iden-
tify reversible inhibitors. To identify hits from a high-throughput
screening campaign, fluorescence values that are 3 standard devi-
ations (99% confidence) from the mean of the negative control
(DMSO) should be used and validated in subsequent dose–re-
sponse studies.
Fig.7. Assay stability in the presence of increasing DMSO concentrations. Increasing
concentrations of DMSO were added to AMSH (125 nM) and incubated for 30 min
before the addition of K63POS1 probe (500 nM). After a 90-min incubation with
K63POS1 probe, fluorescence measurements were taken. ⁄P 6 0.035; ⁄⁄P 6 0.008
(n = 2).
Fig.8. Inhibition by NEM. Fivefold dilutions of NEM were incubated with AMSH
(125 nM) for 30 min at room temperature, followed by the addition of K63POS1
probe (500 nM). The plate was then read following a 90-min incubation at 30 C.
IC50 = 16.2 ± 3.1 lM (n = 2).
Fig.9. Time-dependent inhibition by NEM. AMSH (125 nM) was incubated with
either 15 or 30 lMNEM for 1 h, 45 min, 30 min, or 15 min, followed by the addition
of K63POS1 probe (500 nM). Fluorescent measurements were taken following a 90-
min incubation at 30 C (n = 2).
Fig.10. Effect of NEM on K63POS1 probe fluorescence. Increasing concentrations of
NEM (0–500 lM) were incubated for 90 min at 30 C with cleaved or uncleaved
K63POS1 probe before fluorescent measurements were taken (n = 2).
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Z-Score
The suitability of an assay for high-throughput screening is
established by the non-unit statistical parameter Z-score [31]. It
is generally accepted that the Z-score reflects reproducibility,
robustness, and reliability of an assay for high-throughput screen-
ing. The Z-score for a given assay ranges from 0 to 1, with 1 being
ideal and a score P0.5 generally considered as suitable for high-
throughput screening. To determine the Z-score and inter- and in-
tra-plate variability for this assay, measurements were made with
K63POS1 probe only, AMSH + K63POS1 probe, and AMSH + K63-
POS1 probe treated with 25 lM NEM for 120 min (Fig. 11) on sep-
arate days in different 384-well plates. The average Z-score was
0.71, indicating that the assay is reproducible, robust, and reliable
and thus is high-throughput compatible. In addition, following a
24-h incubation at 4 C, the plates were reread (data not shown).
There was no significant difference in the overall Z-score of the
plates; however, there were increases in the fluorescence of
AMSH + K63POS1 probe and AMSH + K63POS1 probe treated with
NEM wells by approximately 9% and 30%, respectively. These in-
creases in fluorescence are likely due to the cleavage of K63POS1
probe by AMSH over time even in the presence of inhibitor. Due
to the potential variability in incubation times of plates during
an HTS, internal plate controls should be used to normalize for
AMSH activity.
In summary, using a FRET-based system, we showed that AMSH
selectively cleaves Lys63-linked diubiquitin over Lys48- and
Lys11-linked diubiquitin. The FRET AMSH assay was miniaturized
to a 384-well format, with the optimal temperature for the screen
determined to be 30 C, and the maximum DMSO concentration
tolerated was determined to be 5%. Furthermore, the Z-score for
this assay was 0.71, which indicates high-throughput compatibil-
ity. Lastly, the reagents for this assay can be readily generated
for an HTS, with the major expense being the linkage-specific FRET
probe.
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ABSTRACT  
AMSH, a deubiquitinating enzyme (DUB) with exquisite specificity for Lys63-linked 
polyubiquitin chains, is an endosome-associated DUB that regulates sorting of activated cell-
surface signaling receptors to lysosome, a process mediated by the members of the endosomal 
sorting complexes required for transport (ESCRT) machinery.  Whole-exome sequencing of 
DNA samples from children with microcephaly capillary malformation (MIC-CAP) syndrome 
identified recessive mutations encoded in the AMSH gene causatively linked to the disease. 
Herein, we report a number of important observations that significantly advance our 
understanding of AMSH within the context of the ESCRT machinery. First, we performed 
mutational and kinetic analysis of the putative residues involved in diubiquitin recognition and 
catalysis with a view to better understanding the catalytic mechanism of AMSH. Our mutational 
and kinetic analysis reveals that recognition of the proximal ubiquitin is imperative for the  
linkage specificity and catalytic efficiency of the enzyme. The MIC-CAP disease mutation, 
Thr313Ile, shows a substantial loss of catalytic activity without any significant change in 
thermodynamic stability of the protein, indicating that its perturbed catalytic activity is the basis 
of the disease. The catalytic activity of AMSH is stimulated upon binding to the ESCRT-0 
member STAM, however, the precise mechanism and its significance are not known. Based on a 
number of biochemical and biophysical analysis, we are able to propose a model for activation 
according to which activation of AMSH is enabled by facile, simultaneous binding to two 
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ubiquitin groups in a polyubiquitin substrate, one by the catalytic domain of the DUB (binding to 
the distal ubiquitin) and the other (the proximal ubiquitin) by the ubiquitin interacting motif 
(UIM) from STAM. Such a mode of binding would stabilize the ubiquitin chain in a productive 
orientation, resulting in an enhancement of the activity of the enzyme. These data together 
provide a mechanism for understanding the recruitment and activation of AMSH at ESCRT-0, 
providing biochemical and biophysical evidence in support of a role for AMSH when it is 
recruited to the initial ESCRT complex: it functions to facilitate transfer of ubiquitinated 
receptors (cargo) from one ESCRT member to the next by disassembling the polyubiquitin chain 
while leaving some ubiquitin groups still attached to the cargo.  
 
 AMSH (associated molecule with a Src homology 3 domain of signal transducing adaptor 
molecule, STAM) is a member of the JAMM (JAB1/MPN/MOV34) family of deubiquitinating 
enzymes (DUBs) (1), which regulates  ubiquitin  signaling by catalyzing the hydrolysis of 
isopeptide (or peptide) bonds between ubiquitin and target proteins or within polymeric chains of 
ubiquitin.  The JAMM family, being one of the five families of mammalian DUBs, are 
metalloproteases, whereas the others, UCHs, USPs, OTUs, and MJDs) are cysteine proteases (2-
4). Members of the JAMM family show substantial variation in their overall amino-acid 
sequence, but share, as the name suggests, a conserved JAMM motif as the catalytic domain. 
Mechanistically, they share distinct similarities to the extensively studied metalloprotease, 
thermolysin.  Like thermolysin, theses enzymes have a Zn2+ in their active site, which is involved 
in their mechanism of catalysis. The Zn2+ ion is coordinated within the active site usually by two 
histidines, an acidic residue (aspartic acid or glutamic acid), and a water molecule that eventually 
is used as the nucleophile for attacking the scissile peptide bond.  This catalytic water is held in 
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place by Zn2+ and another acidic residue (glutamic acid in AMSH), which provides a hydrogen 
bond stabilizing the water.  Sequence analysis of the members of the JAMM family reveals that 
only 7 of 14 proteins have the conserved zinc binding capabilities (5), while only 6 of those 7 
exhibit isopeptidase activity toward ubiquitin and ubiquitin-like proteins, AMSH, AMSH-LP 
(AMSH like protein), BRCC36, RPN11 (POH1), MYSM1, and CSN5 (5-7). 
 AMSH is one of the two DUBs, the other being UBPY (also known as ubiquitin specific 
protease 8, USP8) (8) known to be important regulators of the ESCRT (endosomal sorting 
complexes required for transport) complexes (9). The ESCRT machinery consist of four protein-
protein complexes (ESCRT-0, -I, -II, -III) and the AAA ATPase Vps4 (10, 11) that serve several 
important functions within the cell: endosomal sorting, trafficking, viral budding, cytokinesis, 
transcriptional regulation, and autophagy (12). The ESCRTs were initially discovered in yeast in 
the context of their role in endosomal sorting and trafficking of cell-surface receptors to 
lysosome for degradation, as a means for down-regulating their signals (11). These receptors are 
first ubiquitinated, and then, shuttled through the ESCRT machinery, until their internalization 
within endosomes, which then can fuse with the lysosome delivering the receptors for proteolysis 
(11).   
 Of the four complexes, only ESCRT-0 and ESCRT-III can specifically recognize DUBs 
(9). The ESCRT-0 recognition is carried out through the binding of the SH3 binding motif 
(SBM) of DUBs to the SH3 domain of the ESCRT-0 member STAM (13), while the ESCRT-III 
recognition is via the MIT (microtubule interacting and transport) domain of DUBs binding to 
the C-terminal MIT interacting motifs (MIMs of charged multivesicular body proteins (CHMPs) 
(9). Previous studies have shown that once AMSH binds to STAM, its activity is enhanced (13, 
14), however, the precise mechanism is not known (13). The x-ray crystal structure of the MIT 
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domain of AMSH bound to the C-terminal MIM fragment of the ESCRT-III member CHMP3 
has been determined (15). The structure reveals that the AMSH-CHMP3 complex is stabilized 
mainly by polar interactions, manifesting into tight binding between the two proteins, with a 
dissociation constant (KD) of 60 nM, the highest reported KD for an ESCRT-III MIM -MIT 
interaction (15).   
 A clear role for AMSH has not been identified yet, however, whole-exome sequencing 
analysis has shown that recessive mutations in AMSH leads to microcephaly-capillary 
malformation (MIC-CAP) syndrome (16). MIC-CAP is discovered at or shortly after birth in 
which children diagnosed with the disease have severe microcephaly with progressive cortical 
atrophy, intractable epilepsy, profound developmental delay and multiple small capillary 
malformations on the skin (16-19). The microcephaly phenotype is attributed to the 
accumulation of ubiquitinated proteins, suggesting a lost of enzymatic function as was seen in 
knock-out mice studies (20).   Out of the ten patients that were screened, six had missense 
mutations, two had nonsense mutations, two translational frameshift mutations, and three 
intronic mutations (16). Interestingly, five out of the six missense mutations were found within 
the MIT domain of AMSH, and the sixth, Thr313Ile, found within the JAMM domain (16).  
 Although the exact in vivo function of AMSH is not well understood, its exquisite 
specificity for Lys63-linked polyubiquitin chains, the same type of chain used for endosomal-
lysosomal targeting, is well characterized (21). The structural basis for this recognition was 
elucidated with the homologous protein, AMSH-LP, bound to Lys63-linked dimer of ubiquitin 
(22). This structure reveals that the specificity arises from a tri-peptide sequence within the 
proximal ubiquitin (Gln62, Lys63, and Glu64) interacting directly with a threonine, two 
phenylalanines, and a serine residue (22) on the proximal binding site of the enzyme (in a 
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diubiquitin motif, the proximal ubiquitin is defined as the one that contributes a Lys residue to be 
linked to Gly76 of the other ubiquitin, defined as the distal ubiquitin).  AMSH and AMSH-LP 
share 54% identity and 73% sequence similarity, however, AMSH-LP does not have a functional 
SBM (9, 23) nor MIT domain (24), therefore, not having the ability to bind to the members of 
the ESCRT machinery.  We recently determined the x-ray crystal structure of the catalytic 
domain of AMSH, and found that the catalytic domains of AMSH and AMSH-LP are 
structurally very similar, however, much to our surprise, AMSH is thermodynamically less stable 
than AMSH-LP, which was attributed to structural plasticity of the former (25). This idea of 
structural plasticity is supported by the second x-ray crystal structure of the catalytic domain of 
AMSH bearing the active-site glutamate to alanine mutation, which was expected to cause the 
release of the active-site Zn2+. The structure, however, shows that the tetrahedral coordination 
around the active-site Zn2+ in this mutant is still maintained by a nearby aspartate residue moving 
in to provide the fourth ligand for the metal in place of the lost water (25). Though AMSH and 
AMSH-LP are able to localize to the endosomes in a similar manner through their ability to bind 
to clathrin (13, 26), the differences between them arising out of AMSH-LP’s inability to bind to 
any of the ESCRT complexes suggests that AMSH and AMSH-LP are not functionally 
redundant. Moreover, the active-site cleft of AMSH features three substitutions relative to 
AMSH-LP, substitutions of residues that are predicted to be used for ubiquitin binding. One of 
them, Thr313, which in AMSH-LP corresponds to Met325, is also the site of a MIC-CAP 
mutation.  
 In the present study, we aim to further establish a role for AMSH as an important 
regulator of the ESCRT machinery.  We have carried out extensive mutational and kinetic 
analysis of residues within the catalytic domain of AMSH to understand their role in ubiquitin 
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binding to better understand the enzyme’s catalytic mechanism.  Also, we have studied the effect 
of the Thr313Ile mutation found in children with the MIC-CAP syndrome on the activity and 
thermodynamic stability of AMSH with hopes of understanding the molecular basis of the 
disease. Our results confirmed that residues within the proximal ubiquitin recognition site of 
AMSH are the basis of specificity for Lys63-linked polyubiquitin chain. Furthermore, we found 
that of the three residue differences between AMSH and AMSH-LP in the distal ubiquitin-
binding site, Thr313 and Glu316 had the most significant effects on AMSH activity. Finally, 
using the minimal domains required for AMSH activation, we have shed light on the mechanism 
of AMSH recruitment and activation at ESCRT-0; we found that AMSH is activated due to an 
intact SBM-SH3 interaction and an intact UIM from STAM.  Based on our results, we have 
proposed a mechanism and role for AMSH in the context of ESCRT-0. 
 
Materials and Methods 
Cloning, Expression, and Purification 
 The DNA encoding the catalytic domain of AMSH was amplified by PCR using a 
plasmid that contained full-length DNA as the template (pGEX-6p1-AMSH, a kind gift from 
Sylvie Urbé, University of Liverpool, UK) and was subcloned into pGEX-6p1 (GE Biosciences) 
by using standard cloning protocols.  The resulting N-terminally fused glutathione S-transferase 
(GST)-tagged protein was expressed in Escherichia coli Rosetta cells (Novagen) and purified 
with a glutathione-Sepharose column (GE Biosciences) following manufacturer’s instructions.  
After removal of the tag by PreScission protease (GE Biosciences), the protein was further 
purified by size-exclusion chromatography (SEC) using Superdex S75 column (GE Biosciences).   
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 The series of individual point mutations were introduced into the AMSH catalytic domain 
gene by site-directed mutagenesis using QuikChange Site-Directed Mutagenesis Kit (Stratagene) 
following manufacturer’s protocol.  DNA sequencing confirmed the presence of the mutations.  
The resulting proteins were purified using standard GST-affinity chromatography followed by 
SEC (Superdex S75 column).  
 The DNA encoding the SH3 and UIM-SH3 domains was amplified by PCR using a 
plasmid that contained the full-length DNA as the template (pGW1Myc2c-STAM2, a kind gift 
from Craig Blackstone, National Institutes of Neurological Disorders and Stroke (NINDS) at the 
National Institutes of Health (NIH)) and was subcloned into pGEX-6p1 (GE Biosciences) using 
standard cloning protocols.  The resulting N-terminally fused GST-tagged protein was expressed 
in E. coli Rosetta cells (Novagen) and purified with a glutathione-Sepharose column (GE 
Biosciences) following manufacturer’s instructions.  After removal of the tag by PreScission 
protease (GE Biosciences), the protein was further purified by size-exclusion chromatography 
(SEC) using Superdex S75 column (GE Biosciences).  
 The A176G mutation was introduced into the UIM-SH3 gene by site-directed 
mutagenesis using QuikChange Site-Directed Mutagenesis Kit (Stratagene) following 
manufacturer’s protocol.  DNA sequencing confirmed the presence of the mutations.  The 
resulting proteins were purified using standard GST-affinity chromatography followed by SEC 
(Superdex S75 column). 
Human ubiquitin was subcloned into pGEX-6p1 and purified using GST affinity 
chromatography, and the GST tag was removed by PreScission Protease.  The protein was 
further purified using SEC (Superdex S75 column).  Lys63-diubiquitin was enzymatically 
synthesized from ubiquitin using ATP, human E1, and the E2 complex (Ubc13 and Uev1a) 
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following previously reported procedures (22). The reaction was incubated at 37°C for 2 h and 
then quenched by dilution with buffer A (50mM sodium acetate, pH 4.5).  The quenched reaction 
mixture was subjected to ion-exchange chromatography on a Mono-S column (GE Biosciences) 
to obtain Lys63-diubiquitin. 
Determination of kinetic parameters and DUB assay 
 The kinetic parameters were determined by incubating the enzymes (25 nM T313A, 100 
nM C282A, N312A, E317A, and F320A, 2 µM E316A and F395A, 3 µM T341A and S346A, 
and 10 µM F343A and S345A) with four concentrations of diubiquitin, ranging from 20 to 177 
µM, in reaction buffer (50 mM TRIS-HCl (pH 7.0), 20 mM KCl, 5 mM MgCl2 and 1 mM DTT).  
The reaction was carried out at 20°C for 10-75 min depending on activity for initial velocity 
measurements.  Reaction tubes were quenched by the addition of 5X SDS-PAGE sample buffer 
followed by boiling.  The reaction mixtures were visualized by SDS-PAGE gels and scanned.  
Bands corresponding to monoubiquitin were integrated using Image J software 
(http://rsb.info.nih.gov/ij/).  Ubiquitin standards ranging from 4 to 12.3 µg were used to draw 
calibration plots, which were used to quantify the amount of ubiquitin produced.  Kinetic 
parameters were calculated by fitting the data in SigmaPlot (Systat Software, San Jose, CA).   
 The in vitro DUB assay was carried out by incubating AMSH (residues 219-424) to a 
final enzyme concentration of 100 nM with 1µM of the SH3 domain of STAM2 or UIM-SH3 
gene of STAM2, and 20 µM Lys63-diubiquitin in a total reaction volume of 20 µL.  All 
reactions were carried out in reaction buffer (50 mM TRIS-HCl (pH 7.0), 25 mM KCl, 5 mM 
MgCl2, and 1 mM DTT) for 5 h at 20°C.  The reaction was quenched by the addition of 5X SDS-




 Sedimentation velocity experiments were conducted at 50,000 rpm using the Beckman 
Coulter XLA and XLI (Beckman Coulter, Fullerton, CA, USA).  The samples were monitored by 
both interference and absorbance optics at 254 and 280 nm.  The proteins were dialyzed in 50 
mM TRIS-HCl pH 7.6, 50 mM NaCl.  Three concentration series for AMSH (residues 219-424) 
were conducted to evaluate the formation of higher-order species at 24, 48, and 96 µM. The 
AMSH-SH3 complex was characterized using a constant concentration of 23.5 µM of AMSH 
and three concentrations of SH3 at 24, 47, and 70 µM. The AMSH-UIM-SH3 complex was 
characterized using a constant concentration of 23.5 µM of AMSH and three concentrations of 
48, 144, and 288µM. The AMSH-ubiquitin complex was characterized using a constant 
concentration of 23.5 µM of AMSH and two concentrations of ubiquitin at 23 and 92 µM. The 
AMSH-diubiquitin complex was characterized using a constant concentration of 23.5 µM of 
AMSH and three diubiquitin concentrations at 24, 48, and 96 µM. The solvent density (1.00170 
g.ml-1), viscosity (0.01022 poise), and the partial specific volumes that were used for the 
analyses, 0.73387 ml.g-1 (AMSH219), 0.71870 ml.g-1 (AMSH-SH3), 0.71701 ml.g-1 (AMSH-
UIM-SH3), 0.72934 ml.g-1 (AMSH-diubiquitin), and 0.72479 ml.g-1 (AMSH-ubiquitin), were 
calculated by SEDNTERP v. 20120828 BETA (http://bitcwiki.sr.unh.edu/index.php/Main_Page) 
(27). The sedimentation coefficients and apparent molecular weights were calculated from size 
distribution analyses [c(s)] using SEDFIT v. 14.3e (28, 29). The figures were prepared using 
GUSSI v. 1.0.7b beta with the sedimentation coefficients standardized to s20,w and the data was 
normalized to the peak area of the complexes.   
 Sedimentation equilibrium experiments were conducted at 20°C using a 6-channel 
centerpiece in an AN-60 Ti rotor spun at speeds of 13,200, 29,900, and 42,000 rpm for the 
AMSH-ubiquitin complex and 11,600, 21,000, and 36,000 rpm for the AMSH-diubiquitin 
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complex. The molar ratios of the AMSH-ubiquitin complex were: 1:2, 1:4, and 1:8, and the 
molar ratios of the AMSH-diubiquitin complex were: 1:2, 1:4, and 1:5, to determine the 
molecular weight of the complexes. Absorbance scans at 280 nm were taken every 2 hours for 60 
hours. The samples were tested for equilibrium using Sedfit (28, 29).   Calculations of the 
molecular weights were done by SEDPHAT v. 10.58d (30-35) using the Species Analysis and 
Species Analysis with Mass Conservation Constraints.  Errors were calculated using 1-
dimensional error surface projections. Final figures were generated in GUSSI. 
Isothermal Titration Calorimetry 
 To determine the KDs of AMSH binding to ubiquitin, ITC experiments were conducted 
using the MicroCal ITC200 (GE Healthcare Life Sciences).  The proteins were dialyzed in the 
same buffer as was used for AUC.  For the AMSH-diubiquitin experiment, 10 µM AMSH was in 
the cell and 500 µM of diubiquitin was in the syringe.  The AMSH-ubiquitin titration had 100 
µM AMSH in the cell, and 1 mM ubiquitin in the syringe. The F320A mutant of AMSH with 
ubiquitin had 100 µM of the enzyme in the cell, and 1 mM of ubiquitin in the syringe. These 
experiments were done at 20°C, 18 total injections of 1.4 µL per injection, with 180 seconds in 
between injections to allow for a return to baseline before the subsequent injection.  The data 
was then baseline corrected by NITPIC (36) and loaded into SEDPHAT (30-35) for global 
analysis and fitting using a 1:1 model.  Figures were prepared using GUSSI.  To determine the 
KD for the AMSH-SH3 interaction, 50 µM of AMSH was in the cell and 750 µM of the SH3 
domain was in the syringe.  KD of AMSH-UIM-SH3 interaction was determined using 100 µM 
AMSH in the cell and 1 mM UIM-SH3 in the syringe.  AMSHK238T-UIM-SH3 experiment was 
conducted using 50 µM of the enzyme in the cell and 1 mM of UIM-SH3 in the syringe. 
Characterization of ubiquitin binding to UIM-SH3 was done using 50 µM UIM-SH3 was in the 
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cell and 3.1 mM ubiquitin in the syringe.  This data was fit to a two-site model.  Confirmation of 
SH3-ubiquitin binding was done with 100 µM of SH3 in the cell and 3.0 mM ubiquitin in the 
syringe.  The UIM-SH3-Lys63-diubiquitin experiment had 50 µM of UIM-SH3 in the cell and 
750 µM diubiquitin in the syringe. 
Guanidine Melt using circular dichroism spectroscopy 
 The stability of the folded state of AMSH244 and AMSH-LP towards GdHCl was 
determined using 8M stock concentrations of GdHCl (Sigma).  Varying concentrations of 
GdHCl were added to the protein (0.2 mg.mL-1) diluted in 100 mM phosphate buffer pH 7.4 and 
allowed to sit at room temperature overnight to allow for complete equilibration. Changes in the 
folded state of the proteins were monitored using circular dichroism by following changes in 
ellipticity at 220 nm. CD spectra were recorded in a Jasco J-810 Spectropolarimeter in the far 
UV region (195-260 nm) in a 0.1 cm path length cuvette.  Each spectrum was averaged over 4 
scans (50 nm.min-1 scan speed, with a 8 second time constant) and corrected by subtraction of a 
spectrum of the buffer alone.  Mean residue molar ellipticity values were calculated using the 
following equation: 
[θ] = θ ∗ 100 ∗ M 
C ∗ l ∗ n 
Where θ is the ellipticity in degrees, l is the optical path in cm, C is the concentration in mg/ml, 
M is the molecular mass and n is in the number of residues in the protein. 
The mean residue molar ellipticity [θ] is given in deg.cm2.dmol-1.  Unfolding curves were 
analyzed using a two-state unfolding model, using linear extrapolation to obtain the ΔG value in 





Mutational and kinetic analysis of the catalytic domain of AMSH  
 Previous modeling studies investigating the differences between the ability of AMSH and 
AMSH-LP to bind and cleave Lys63-linked diubiquitin revealed some interesting results.  The 
active site and proximal ubiquitin binding residues were identical between the two proteins; 
however, in the distal ubiquitin-binding site, AMSH has three residue differences compared to 
AMSH-LP.  Based on this analysis, we sought to carry out an extensive mutational and kinetic 
analysis of the putative residues in AMSH that might be involved in diubiquitin cleavage.   
Active site  
 The  active site of AMSH consists of a Zn2+ ion, coordinated directly by three residues 
(Asp348, His 335, and His337) and a water molecule that is hydrogen bonded to Glu280, and a 
putative oxy-anion stabilizing residue (Ser345) (Figure 1). In order to probe the roles of Asp348 
and Glu280, we generated two aspartate mutants (D348A and D348N) and a glutamate mutant 
(E280A) and, as expected, found that there was no detectable activity in these mutants (Table 1), 
most likely due to the loss of Zn2+ for the aspartate mutations and the loss of the water molecule 
in the glutamate mutation.  
 Next, we probed the function of the putative oxy-anion hole-stabilizing residue, Ser345. 
Mutating serine to alanine resulted in a significantly impaired enzyme with a 1000-fold reduction 
in kcat (Table 1). As described with other families of hydrolases, the oxy-anion hole-stabilizing 
residue plays a critical role in donating a hydrogen bond to the negatively charged tetrahedral 
intermediate formed after the initial nucleophilic attack. Substantial reduction of kcat alone upon 
mutation to alanine, with KM remaining nearly the same, is consistent with Ser345 playing the 
role as the oxy-anion stabilizing residue in AMSH.  
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 In our previous structural analysis, we noted a potential disulfide bridge between Cys282 
and Cys311, 7.4Å away from the active-site Zn2+ (25). Previous studies have shown that N-
ethylmaleimide (NEM) inhibits AMSH activity (IC50 of 16.2± 3.2 µM) (21, 38), presumably by 
modifying one of these two cysteines, perhaps Cys282 because it is proximal to the active-site 
cleft. Its modification might introduce some steric hindrance for substrate binding thus 
explaining the inhibitory effect. We sought to determine if Cys282 has any role in the enzyme’s 
catalytic activity.  Previously, when Cys282 was mutated to alanine, we noticed a loss of activity 
(25), however, a more detailed kinetic analysis of this mutant revealed a more significant 
reduction in activity, a 6-fold loss in kcat (Table 1), which would suggest that Cys282 does indeed 
have a role in catalysis. Cys282 is seen making a van der Waals contact with Leu73 of the distal 
ubiquitin, which may explain the reduction in activity observed here.  
Proximal ubiquitin site 
 Modeling of the catalytic domain of AMSH onto the structure of AMSH-LP bound to 
Lys63-linked diubiquitin revealed four residues within AMSH (Thr341, Phe343, Ser346, and 
Phe395) that could determine its specificity for Lys63-linked polyubiquitin chains by 
recognizing the tri-peptide sequence motif Gln62-Lys63-Glu64 within the proximal ubiquitin, 
which encompasses the acceptor Lys63 and its two immediate flanking residues.  Individual 
point mutants (to alanine) were generated and kinetic analysis was performed to probe the 
functional significance of these residues. Overall, the four resides within AMSH showed a 
drastic reduction in kcat with similar KM values compared to the wild-type enzyme, confirming 
their utmost importance to the enzyme’s catalytic mechanism (Figure 2 and Table 1), especially 
during the rate-determining step of isopeptide bond hydrolysis.   
Distal ubiquitin site 
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 The distal site is where AMSH significantly differs from AMSH-LP in diubiquitin 
recognition. Three substitutions are found going from AMSH-LP to AMSH: an aspartate to 
asparagine, a methionine to a threonine, and a valine to glutamate.  Two other important residues 
within the distal site are completely conserved between AMSH and AMSH-LP, a phenylalanine 
(Phe320, AMSH numbering) and a glutamate (Glu317) (Figure 3).  The conserved Phe320 when 
mutated to alanine exhibited a 4-fold reduction in kcat and 3-fold increase in KM, whereas, the 
Glu317Ala mutant exhibits somewhat similar activity to the wild type, with only a modest 2-fold 
reduction in kcat (Table 1).   
 Moving forward, individual point mutations of the three substitutions between AMSH 
and AMSH-LP revealed some interesting results.  Mutating Asn312 to alanine yielded only an 
approximate 3-fold reduction in kcat (Table 1).  Surprisingly, a qualitative diubiquitin cleavage 
assay revealed that Thr313Ala was apparently more active than the wild type (unpublished data), 
however, detailed kinetic analysis showed simply an approximate 2-fold increase in kcat, with a 
~3-fold loss in KM (Table 1).   
 Mutating the Glu316 to alanine proved to cause the most significant change in enzymatic 
activity amongst the distal site residues. Glu316Ala showed a substantial 74-fold reduction in kcat 
(Table 1).  This kcat effect differs strikingly from the distal site residues of AMSH-LP whose 
mutation to Ala showed a loss primarily in KM (22). The effect of the glutamate mutation in 
AMSH mirrors that of residues from the proximal site.  Inspection of the AMSH-diubiquitin 
model reveals that Glu316 is within hydrogen-bonding distance from two distal ubiquitin 
residues: Arg42 is within 3.1Å (εN of Arg42 and εO of Glu316), and Gln49 is within 2.8Å, if the 
side chain is flipped by 180° (Figure 3).  A significant loss in kcat but not in KM is consistent with 
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these hydrogen-bonding interactions contributing to the stabilization of the transition state, 
perhaps by playing a role in orienting the scissile peptide bond for nucleophilic attack.   
 
Kinetic and thermodynamic characterization of the effect of the MIC-CAP-associated 
mutation, Thr313Ile 
 To better understand the molecular basis of the MIC-CAP syndrome, the Thr313Ile 
(T313I) mutant was generated and analyzed both for its catalytic activity towards Lys63-
diubiquitin and its thermodynamic stability. In the absence of a structure, a modeled AMSH-
diubiquitin structure suggests that the side-chain hydroxyl from threonine is hydrogen bonded to 
the backbone NH group of Leu73 in the distal ubiquitin  (Fig. S1). The T313I mutant was found 
to suffer a 6-fold reduction in kcat, with a comparable KM (Table 1).  In terms of its 
thermodynamic stability, T313I was somewhat less stable than the wild type with a ΔGH20 of 2.9 
kcal.mol-1 compared to 3.6 kcal.mol-1 for the wild type (Fig. S2 and Supplementary Table 1).  
This result indicates that the reduced catalytic activity of the mutant could lead to a loss of 
function of AMSH translating into the disease state.  
Biophysical characterization of ubiquitin binding to the catalytic domain of AMSH  
 Mutational and kinetic analyses prompted us to seek a better understanding of AMSH-
ubiquitin complex formation in solution. Using isothermal titration calorimetry (ITC), we 
analyzed the binding of Lys63-linked diubiquitin and the catalytic domain of AMSH (AMSH 
219-424E280A, an inactive mutant to ensure diubiquitin is not hydrolyzed), and obtained an 
equilibrium dissociation constant (KD) of 19 ± 4 µM (Figure 4b and Table 2).  As a control, 
ubiquitin and the catalytic domain of AMSH was analyzed and it was determined that it binds 
AMSH with similar affinity of 19 ± 3 µM (Figure 4a and Table 2). Both sedimentation velocity 
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and sedimentation equilibrium experiments using analytical ultracentrifugation (AUC) confirmed 
the ITC results (Fig. S3, Fig. S4, and Supplementary Table 2).  Almost identical binding 
affinities between diubiquitin and ubiquitin to the catalytic domain of AMSH suggest that there 
is only one binding site for ubiquitin.  To probe which ubiquitin binding site is used, another ITC 
experiment was done with AMSHPhe320Ala (Phe320 at the distal site is mutated to Ala) and 
ubiquitin.  We observed a ~4-fold decrease in affinity (KD of 81 ± 15 µM) (Figure 4c and Table 
2), consistent with what was observed from kinetics, suggesting that the distal ubiquitin makes 
the most significant contribution to diubiquitin binding, and the single binding site observed in 
our ITC experiments with ubiquitin corresponds to binding at the distal site.  These data suggest 
that AMSH alone cannot discriminate between its polyubiquitin substrate and its ubiquitin 
product.    
The intact minimal STAM construct UIM-SH3 is necessary for AMSH activation 
 The I44 patch, a hydrophobic surface centered on the Ile44 residue in ubiquitin, is 
ubiquitously used by proteins that specifically bind to ubiquitin, including DUBs. Inspection of 
our structural model representing AMSH-diubiquitin complex reveals that the I44 patch of the 
distal ubiquitin is satisfied, with the Ile44 residue engaged in van der Waals interaction with 
Phe320; however, Ile44 of the proximal ubiquitin is unoccupied (Fig. S5).  Looking at the 
domain structure of the ESCRT-0 member, STAM, one finds a UIM (ubiquitin-interacting motif) 
N-terminally adjacent to its SH3 domain (Fig. S6).  We sought to understand if the UIM, 
separated from the SH3 domain by a short linker, could act as an adaptor to AMSH by 
interacting with the proximal ubiquitin while AMSH engages the distal one.  To probe this, we 
used a combination of biophysical techniques and biochemical assays to assess three individual 
events: (1) AMSH recruitment to STAM via the SH3 domain and a longer STAM segment in 
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which the UIM is fused to the SH3 domain (UIM-SH3), (2) ubiquitin binding to UIM-SH3, and 
finally, (3) the ternary complex of the catalytic domain of AMSH, UIM-SH3, and Lys63-linked 
diubiquitin.  
AMSH binds to the SH3 domain of STAM2 
 To confirm that we have the minimal domains required for the AMSH-STAM interaction 
we carried out ITC and AUC experiments.  We determined that the SH3 domain of STAM binds 
the catalytic domain of AMSH (AMSH219E280A) with a KD of 1.4 ± 0.04 µM (Table 2 and Fig. 
S7).  Using the longer UIM-SH3 construct, we obtained an identical KD of 1.9 ± 0.1 µM (Table 2 
and Fig. S7), both of which are consistent with a previous ITC study, which showed that a 
peptide representing the SBM of AMSH binds the SH3 domain with 7 µM affinity (14). Using 
an orthogonal and complementary technique, we confirmed complex formation by sedimentation 
velocity experiments using AUC and determined that the catalytic domain of AMSH forms a 1:1 
complex. The respective s20,w values of 2.5S and 2.6S for the SH3 domain and UIM-SH3 (Figure 
5a and b) suggest that the UIM has no role in AMSH recruitment to STAM, as expected.    
Both SH3 domain and UIM of STAM bind ubiquitin independently 
 Secondly, we characterized ubiquitin binding to the UIM of STAM.  Since UIMs are only 
30-residue domains, much too small for bacterial expression, we used UIM-SH3 to investigate 
UIM-ubiquitin binding by ITC.  Somewhat surprisingly, we found that both the UIM and SH3 
domains bind ubiquitin independently. This observation was based on two pieces of evidence. 
(1) The UIM-SH3 construct binds ubiquitin with a KD of 273 ± 16 µM, in agreement with 
previous biosensor measurements of a STAM-derived UIM peptide binding to ubiquitin that 
provided a KD of 182 µM (39). (2) Interestingly, our measurement of SH3-ubiquitin binding by 
ITC resulted in a KD of 62 ± 7 µM (Figure 6b and Table 2). It has been shown previously that a 
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subset of SH3 domains bind ubiquitin (40, 41), and a recent study using NMR titration 
experiments showed that the SH3 domain of STAM does in fact bind ubiquitin, and that this 
interaction can be competed off by USP8 binding to the SH3 domain of STAM (42).  Taken 
together, these data seem to indicate that both the SH3 domain and the UIM bind ubiquitin 
independently, with the former having higher affinity than the latter, which would explain the 
overall KD of 273 ± 15 µM obtained as the binding affinity of the UIM-SH3 construct for 
ubiquitin. It is possible that the two binding events corresponding to the two binding sites on 
UIM-SH3 have similar enthalpy of binding, and with binding affinities not drastically different 
between them, the ITC experiment is unable to resolve them distinctly.  
          Alternatively, it is possible that the UIM and SH3 domain fold onto each other generating 
a weaker interface for ubiquitin than either of them alone. This seems unlikely since UIM-SH3 
binds to Lys63-linked diubiquitin with a KD of 54 ± 20 µM (Figure 6c and Table 2), an affinity 
higher than that of UIM-SH3 for ubiquitin. These results are consistent with the principle of avid 
binding of polyubiquitin chains at ESCRT-0, thus indicating that both the UIM and SH3 domain 
in UIM-SH3 are accessible for ubiquitin binding.    
UIM and SH3 domains are necessary for stimulating the activity of AMSH 
 Using the catalytic domain of AMSH, UIM-SH3 and Lys63-linked diubiquitin, we 
attempted to recapitulate AMSH recruitment to ESCRT-0 in vitro.  We carried out a Lys63-
diubiquitin DUB cleavage assay with the AMSH:UIM-SH3 complex. The initial experiment 
comparing the enzyme’s activity alone and in the presence of the SH3 domain and then, UIM-
SH3, revealed a remarkable difference in DUB activity of AMSH.  In the presence of UIM-SH3, 
it turned over nearly all of the Lys63-diubiquitin to ubiquitin, whereas, AMSH alone or in the 
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presence of simply the SH3 domain had a significant amount of diubiquitin remaining, 
suggesting a stimulatory role for UIM-SH3 (Figure 7). 
 Diving deeper into the mechanism of activation, a similar in vitro assay was performed, 
this time using two SBM, and one UIM mutant versions of the UIM-SH3 construct (Figure 8). 
Two individual point mutations within the SBM of AMSH were introduced (Lys238Ala and 
Lys238Thr) to obliterate the SH3-SBM interaction. Lys238 is a completely conserved residue in 
the canonical SBM motif known to bind SH3 domains, mutating this to threonine made AMSH 
look like AMSH-LP in terms of its SBM.  AMSH-LP has the conserved set of residues within its 
SBM, except   the critical Lys replaced by Thr.  We confirmed that there was no binding between 
the AMSH SBM mutants and the SH3 domain using ITC (Fig. S8). Secondly, we introduced a 
mutation within the UIM of UIM-SH3 (Ala176Gly) to interrupt ubiquitin binding (Figure 8). The 
Ala to Gly mutation has been shown previously to cause significant reduction in ubiquitin 
binding (39).  The diubiquitin cleavage reactions were performed at 37°C for 15 minutes using 1 
µM enzyme, 20 µM Lys63-linked diubiquitin as the substrate, and 5µM STAM binding partner 
(SH3, UIMA176GSH3, or UIM-SH3). SDS-PAGE analysis revealed that only in the presence of the 
wild-type enzyme and UIM-SH3 is diubiquitin completely hydrolyzed to ubiquitin, hence, an 
intact SBM-SH3 interaction and a functional UIM are necessary for AMSH activation (Figure 8). 
 Furthermore, we wanted to understand this activation phenomenon in more detail, in 
terms of kcat and KM. To this end, we carried out another kinetic assay in which the catalytic 
domain of AMSH was pre-incubated in the presence of 20-fold excess UIM-SH3 to ensure that 
equilibrium favors the formation of the AMSH-UIM-SH3 complex. We saw 6-fold activation in 
AMSH in the presence of UIM-SH3, contributed by a somewhat greater change in kcat than in KM 
(Supplementary Table 3).  The kcat effect is not entirely surprising because the UIM interacts with 
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the proximal ubiquitin, and as we have shown in our mutational and kinetic analysis, the 
proximal site plays a significant role in properly aligning the isopeptide bond within the active 
site of AMSH, as determined by the significant loss in kcat upon mutating the residues involved in 
binding.    
 
DISCUSSION 
AMSH is one of the two DUBs recruited to the human ESCRT machinery to regulate the 
endosomal-lysosomal degradation pathway (9). It is a JAMM family DUB,(1) having exquisite 
specificity for recognizing and cleaving Lys63-linked polyubiquitin chains (9), which serve as 
signals for ESCRT-mediated sorting to lysosome.  However, a clearly defined role for AMSH 
has yet to be elucidated.  A homologous protein, AMSH-LP, sharing 54% identity and 73% 
sequence similarity (9, 23), of the same family of DUBs, has the same ubiquitin linkage 
specificity, and from our previous work, is structurally almost identical in its catalytic domain to 
AMSH (25). Even though the catalytic domains of AMSH and AMSH-LP are structurally nearly 
identical, we showed that AMSH is significantly less stable than AMSH-LP, and consequently 
perhaps conformationally more plastic, and the enzymes differ in their ubiquitin recognition (25).  
As a result of these differences, we sought to further investigate AMSH kinetically and 
biophysically to advance our understanding of the enzyme with a view to understanding its role 
in the context of the ESCRT machinery.   
 Our kinetic analysis using site-directed mutagenesis of conserved residues in the 
proximal ubiquitin binding site has shown that the specificity of AMSH for Lys63-linked 
polyubiquitin chains arises from its recognition of the proximal ubiquitin, similar to the case of 
AMSH-LP (22). Lys63-linked chain specificity for AMSH plays a significant role in 
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understanding its function as an ESCRT-DUB.  Since Lys63-linked polyubiquitin chains are 
targeting signals for ESCRT-mediated degradation, the specific DUB activity of AMSH may 
play a central role in the persistent functionality of the ESCRT machinery. Mutation of the 
proximal ubiquitin binding residues causes drastic reduction in kcat, suggesting that recognition of 
the tri-peptide sequence motif Gln62-Lys63-Glu64 within the proximal ubiquitin plays a 
significant role in the ability of AMSH to cleave Lys63-linked polyubiquitin chains.   
Recognition of Lys63 isopeptide bond and its two flanking residues in the proximal ubiquitin 
would mean that AMSH could only efficiently hydrolyze bonds between successive ubiquitins in 
a polymeric chain, and not the last ubiquitin directly attached to a protein receptor (the cargo).  
This impediment toward completely deubiquitinating a ubiquitinated receptor could have 
multiple functional implications (discussed below). At the outset, it calls into question the 
functional role of AMSH when it is recruited to ESCRT-III, where complete deconjugation of a 
ubiquitinated cargo is the absolute desire, since ubiquitin will otherwise end up in intra-luminal 
vesicles (ILVs) attached to the cargo and will be subsequently degraded in the lysosome. It 
seems unlikely that AMSH can have a significant catalytic role with respect to hydrolyzing the 
last ubiquitin attached to the cargo, yet, AMSH binds to ESCRT-III component CHMP3 with 
relatively high affinity.  
 Our data on mutational analysis of the distal ubiquitin binding residues offer some 
interesting insights. Of the three residues different between AMSH and AMSH-LP, two of them, 
Glu316 and Thr313, contribute significantly to catalysis playing different roles than the 
corresponding residues in AMSH-LP. The AMSH residue Glu316 contributes to stabilization of 
the transition state as indicated by the largely kcat effect when it is mutated to Ala, in contrast to 
mostly a KM effect observed when the corresponding residues Val in AMSH-LP mutated to Ala 
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(22). Thr313 in our AMSH-diubiquitin model is seen making a hydrogen bonding contact with 
the backbone NH group of Leu73 of the distal ubiquitin using its side-chain hydroxyl group and 
its methyl group is engaged in van der Waals contact with the aliphatic side groups of Leu73 of 
ubiquitin. Its substitution with Ile as seen in children with the MIC-CAP syndrome is expected to 
preserve the van der Waals contact but loose the hydrogen bond. Our data show that the 
substitution of the Thr to an Ile has minimal effect on protein folding and stability, but results in 
a significantly reduced catalytic efficiency. Going from AMSH to AMSH-LP, the Thr residue is 
replaced by Met, which could contribute only van der Waals interaction with the substrate. Thus, 
it appears that the hydrogen-bonding interaction of Thr in AMSH has a unique role whose loss 
leads to a dramatic effect resulting in a loss of function substantial enough to cause the disease. 
Overall, these results indicate that subtle differences between very similar enzymes can have 
profound functional effects.  
 We found the minimal domain of STAM that is required to stimulate the activity of 
AMSH.  Previous work has shown that STAM has a role in AMSH activation towards Lys63 
polymeric chains (13, 14); however, these studies were not able to fully elucidate the mechanism 
of activation.  Our study begins to divulge the mechanism underlying activation. This work 
suggests a simple model invoking simultaneous recognition of two ubiquitin groups in a 
polyubiquitin chain by AMSH and the UIM of STAM could explain the catalytic activation of 
the DUB. The UIM of STAM, separated from the SH3 domain by a short linker, could act as an 
adaptor for AMSH by interacting with the proximal ubiquitin, while AMSH engages the distal 
one. Such an arrangement would create a more extensive binding interface for diubiquitin in the 
AMSH:STAM complex than in the enzyme alone, causing catalytic activation. It appears that 
such activation is necessary since, as our ITC data show, AMSH has no preference for binding to 
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Lys63-linked diubiquitin, therefore by extrapolation to Lys63-linked polyubiquitin chains over 
the ubiquitin product. 
 Prior to activation, AMSH is in a more latent state, but when it is recruited to STAM its 
full activity is unveiled.  AMSH is known to have diverse subcellular localization profiles.  
Perhaps the free form of the enzyme needs to be in a less-active state so as not to hydrolyze the 
Lys63 chains that are present in the cytosol other than endosomes.  Once it is recruited to the 
endosomes, its true activity comes alive, as seen by the 6-fold enhancement in activity upon 
binding to the STAM derived UIM-SH3 construct. A significant implication of this mechanism 
of activation is that the activation will be absent when AMSH is trying to cleave the last 
ubiquitin attached to the cargo. While efficiently cleaving between two ubiquitin groups in a 
Lys63-linked polyubiquitin chain, AMSH might show a severe impediment in hydrolyzing the 
last ubiquitin attached directly to a cargo, on account of two factors: (1) its high specificity for 
the Lys63-linked chain between two ubiquitins, which in turn would make it a poor enzyme 
when ubiquitin is attached to a non-ubiquitin protein, the cargo; and, (2) the lack of an activation 
effect when cleaving ubiquitin attached to a non-ubiquitin moiety. 
 Finally, bringing all our data together, we can envision a mechanism for recruitment and 
activation for AMSH that will ultimately define a function for the enzyme.  ESCRT-0 has the 
defined function of ubiquitinated cargo clustering, capable of harboring up to eight ubiquitin 
moieties at a time (43, 44), which now, with the addition of the SH3 domain could be ten 
ubiquitins. Our ITC data show that the SH3 domain can actually bind ubiquitin tighter than the 
UIM. Subsequently, AMSH is recruited to STAM.  The AMSH-SH3 binding affinity is stronger 
than SH3-ubiquitin, making it possible for AMSH to effectively displace ubiquitin from the SH3 
domain (the binding interface on SH3 domain for the two proteins show substantial overlap) (42) 
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leading to its recruitment to ESCRT-0. With the UIM from STAM acting as an adaptor to the 
enzyme, facilitating enzyme activity enhancement, AMSH begins to efficiently disassemble the 
polyubiquitin chain attached to the cargo.  Deubiquitination of the chain will continue until the 
last ubiquitin directly attached to the cargo. Thus, the recruitment of AMSH at ESCRT-0 will 
lead to substantial chain trimming but not complete deconjugation of ubiquitin from the cargo. 
As discussed in the next paragraph, this would promote the cargo’s passage from ESCRT-0 to 
ESCRT-I and subsequent complexes.  
  Our proposed mechanism defines AMSH as the DUB that facilitates cargo passage from 
ESCRT-0 onto the next complex.  This idea is supported by previous data that shows that avidly 
bound ubiquitin chains comprise of a binding affinity of ~20 µM affinity (45), whereas, ESCRT-
I subunit, UBAP1, binds ubiquitin anywhere from 70-140 µM (46). The binding affinity of 
ubiquitin at ESCRT-0 needs to be reduced at least 5-10-fold in order for cargo destined for 
lysosomal degradation to be transferred to ESCRT-I. When going from Lys63-linked tetra-
ubiquitin to diubiquitin, ESCRT-0 has a ~6-fold reduced affinity, and a remarkable, 46-fold 
reduction in affinity for ubiquitin (45). Therefore, we presume that because of the specificity and 
activation of AMSH, this would be the enzyme that would be most suited for promoting cargo 
passage, all in support of an idea proposed previously (47). By occupying the binding site on 
ESCRT-0, AMSH will serve to keep USP8 off the initial ESCRT complex. The recruitment of 
USP8 at ESCRT-0 would be detrimental to cargo’s passage to lysosome because USP8 has no 
hindrance in complete deconjugation. We suggest that USP8’s role is specifically at the ESCRT-
III level where complete deconjugation is desired.  
  The main conclusion from our study implies that loss of function mutations in AMSH 
would lead to impairment of ubiquitin-dependent sorting to lysosome via the ESCRT pathway. 
213
 26 
One possible outcome of this impairment is accumulation of ubiquitinated proteins (cargo). 
Indeed, patient cell lines with AMSH mutation show accumulation of aggregated ubiquitin-
protein conjugates (16). Furthermore, impairment of ESCRT-mediated endocytic sorting to 
lysosome is expected to cause hyperactivation of signaling across lipid bilayer. As suggested by 
the authors of the paper describing MIC-CAP mutations, the capillary abnormalities associated 
with the syndrome could be a consequence of hyperactive RAS-MAPK signaling induced in 
humans by impaired AMSH function (16). However, because AMSH has several roles within the 
cell it would be difficult to assign loss of function in one pathway as the exclusive molecular 
basis of MIC-CAP syndrome.  
 In summary, using a combination of biochemical and biophysical studies, guided by a 
structural model, we are able to learn many important aspects of AMSH: (1) The T313I mutation 
underlying the MIC-CAP syndrome leads to a significant loss of catalytic activity owing to loss 
of a hydrogen-bonding interaction with ubiquitin. (2) Recognition of proximal ubiquitin 
contributes significantly to catalysis. (3) Activation of AMSH is enabled by facile, simultaneous 
binding to two ubiquitin groups in a polyubiquitin substrate, one by the catalytic domain of the 
DUB (binding to the distal ubiquitin) and the other (the proximal ubiquitin) by the UIM from 
STAM. (4) Taken together, the above two points strongly indicate that AMSH will suffer a 
severe loss of catalytic efficiency when cleaving the last ubiquitin attached to cargo compared to 
a Lys63-linked polyubiquitin chain substrate. These studies provide biochemical and biophysical 
evidence in support of a hypothesis which postulates that AMSH is recruited to the initial 
ESCRT complex to facilitate transfer of cargo from one ESCRT member to the next, but not to 
completely deubiquitinate it (9). Its recruitment therefore would facilitate cargo shuttling rather 
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Table 1. Kinetic Parameters of AMSH Mutants 























Site Protein kcat x 10-3 (s-1) KM (µM) 
 Wild type 1400 ± 100 32 ± 5 
Active site    
 Glu280Ala NAa NAa 
 Cys282Ala 230 ± 140 45 ± 7 
 Ser345Ala 1.4 ± 0.1 38 ± 15 
 Asp348Ala NAa NAa 
 Asp348Asn NAa NAa 
Proximal     
 Thr341Ala 24 ± 1 15 ± 3 
 Phe343Ala 5 ± 3 21 ± 4 
 Ser346Ala 13 ± 3 23 ± 8 
 Phe395Ala 22 ± 8 18 ± 9 
Distal     
 Asn312Ala 430 ± 60 19 ± 2 
 Thr313Ala 2600 ± 600 82 ± 5 
 Glu316Ala 19 ± 4 31 ± 9 
 Glu317Ala 750 ± 200 19 ± 7 
 Phe320Ala 370 ± 20 98 ± 15 
MIC-CAP    











Table 2. Thermodynamic Parameters Deduced from ITC Data 






Protein Titrant KD (µM) ΔH (kcal.mol-1) ΔS (cal.mol-1.K-1) N 
AMSH Ub 19 ± 3 19.3 ± 7.8 86.4 1 
AMSH DiUb 19 ± 4 13.7 ± 1.8 67.7 1 
AMSHF320A Ub 81 ± 15 2.6 ± 0.4 27.5 1 
AMSH SH3 1.4 ± 0.04 -15.1 ± 0.1 -23.7 1 
AMSH UIM-SH3 1.9 ± 0.1 -15.8 ± 0.1 -26.9 1 
AMSHK238A SH3 NAa NAa NAa NAa 
AMSHK238T SH3 NAa NAa NAa NAa 
SH3 Ub 62 ± 7 -4.1 ± 0.2 5.3 1 
UIM-SH3 Ub 273 ± 16 -18.2 ± 1.0 -44.7 2 







Figure 1. The DUB domain of AMSH. (a) Ribbon diagram of the crystal structure of the 
catalytic domain of AMSH (PDB ID: 3RZU).  The active site is highlighted by the black square. 
(b) An expanded view of the active-site residues of AMSH.  The black spheres represent Zn2+, 
and the red sphere the active-site water molecule. 
Figure 2. Residues involved in proximal ubiquitin recognition within the catalytic domain of 
AMSH.  AMSH residues are shown as pink sticks, proximal ubiquitin residues as green sticks, 
and the distal ubiquitin residues as cyan sticks. 
Figure 3. Residues involved in distal ubiquitin recognition within the catalytic domain of 
AMSH. AMSH residues are shown as pink sticks, proximal ubiquitin residues as green sticks, 
and the distal ubiquitin residues as cyan sticks. 
Figure 4. Isothermal titration calorimetry (ITC) thermograms of ubiquitin binding to the 
catalytic domain of AMSH.  (a) ITC thermogram of ubiquitin binding to the catalytic domain of 
AMSH revealing a KD of 19 ± 3 µM.  (b) ITC thermogram of Lys63-linked diubiquitin binding 
to the catalytic domain of AMSH revealing a KD of 19 ± 4 µM.  (c) ITC thermogram of a 
Phe320Ala mutant of the catalytic domain of AMSH binding to ubiquitin revealing a KD of 81 ± 
15 µM. 
Figure 5. c(s) distributions of the catalytic domain of AMSH binding to (a) the SH3 domain of 
STAM and (b) UIM-SH3.  Three concentration series were used to assess the formation of the 
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AMSH:SH3 and AMSH:UIM-SH3 complexes revealing 1:1 complexes at 2.5S and 2.6S, 
respectively. Excess SH3 and UIM-SH3 are present at 1.3S.  The data for both c(s) distributions 
were normalized to the peak area of the complexes.  (C) Overlay of AMSH, AMSH:SH3, and 
AMSH:UIM-SH3 revealing changes in s-value of the AMSH:SH3 and AMSH:UIM-SH3 
complexes compared to AMSH alone at 2.2S. The c(s) distributions were normalized to the peak 
area of the complexes. 
Figure 6. ITC thermograms of ubiquitin binding to UIM-SH3 of STAM.  (a) Thermogram of 
ubiquitin binding to UIM-SH3 revealing a KD of 273 ± 16 µM. (b) Thermogram of ubiquitin 
binding to the SH3 domain of STAM revealing a KD of 62 ± 7 µM.  (c) Thermogram of Lys63-
linked diubiquitin binding to UIM-SH3 revealing a KD of 54 ± 21 µM.  
Figure 7. DUB activity assay by monitoring diubiquitin cleavage.   SDS-PAGE gel comparing 
the activity of the catalytic domain of AMSH alone and in the presence of the SH3 domain and 
UIM-SH3 of STAM.  Only the lane with UIM-SH3 reveals activation. The asterisk indicates 
ubiquitin contamination in the diubiquitin purification. 
Figure 8. Catalytic activation of AMSH in presence of UIM-SH3.  (a) Domain diagram of the 
minimal AMSH and STAM proteins, indicating the locations of the introduced mutations. (b) 
SDS-PAGE investigating the effects of mutants on the catalytic activation of AMSH.  Only in 
the presence of the wild-type enzyme and wild-type UIM-SH3 is the activity of AMSH 
enhanced, indicated by complete disappearance of the diubiquitin substrate (black arrow). All 
lanes have Lys63-linked diubiquitin. 
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